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ABSTRACT

This dissertation is built upon the fundamental idea that the pre-B cell receptor (pre-BCR)
is important to leukemia cell survival and a logical therapeutic target in B cell precursor
acute lymphoblastic leukemia (BCP-ALL). The pre-BCR is expressed early at a specific
stage during B cell development where it plays a central role in survival of healthy B
lymphocytes. This receptor is composed of the membrane heavy chain (mIgµ) associated
with surrogate light chain components, 5 and VpreB. Through the use of advanced
imaging modalities, in particular two-color single particle tracking (SPT), we showed that
pre-BCRs formed transient, homotypic interactions. These receptors displayed correlated
motion at short separation distances that is consistent with the formation of dimers. These
encounters were sufficient to generate an autonomous signal that helped to maintain
leukemia blast survival. Incubation of the BCP-ALL cells with galectin-1, which can bind
both 5 and glycans, led to aggregate formation that drastically slowed down the diffusion
of pre-BCRs. This correlated to a downregulation of pre-BCR signaling through proximal
Syk activation. Blocking galectin-1’s lectin-binding capability with saturating
concentrations of -lactose partially restored diffusion to “tonic” levels. The introduction
of this sugar also impacted the downstream signaling profile. Due to these differential
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diffusion and signaling profiles observed in experimental procedures we turned
computational biology to gain additional structural insight. Molecular dynamics (MD)
simulations supported the idea that the pre-BCR can allosterically control galectin-1’s
binding capacity at its distal carbohydrate-binding site (CBS). We generated a monovalent
Fab against the dimer interface of the pre-BCR using phage display technologies and
showed that it not only could disrupt dimerization but also disrupted downstream signaling.
Due to recent clinical advances in chimeric antigen receptor (CAR) T cell therapy, we
reformatted our Fab into a scFv, the binding region of the CAR, using genetic cloning
techniques. Through the use of computer-aided design we successfully generated a scFv
with high affinity to the VpreB target. This antibody binding fragment was cloned into a
lentiviral vector containing the CD28 co-stimulatory domain and immunoreceptor
tyrosine-based activation motif (ITAM)-containing TCR-CD3. After efficient
transduction of primary CD8+ T cells, we have shown efficient in vitro efficacy against
BCP-ALL cells.
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CHAPTER 1: INTRODUCTION

Model system: B cell precursor acute lymphoblastic leukemia
Acute lymphoblastic leukemia is the most common cancer in children (1) and an aggressive
neoplasm in adolescents and adults (2). While conventional chemotherapy has improved
the overall long-term survival rate, there are still concerns with existing treatment options
(3). In children, early administration of harsh chemotherapeutic agents has been shown to
severely hinder long-term development (4). In addition, relapse-free survival rates of
patients with high-risk leukemia have plateaued with conventional therapy options (5).
Over 20% of patients treated in the relapse setting and 5% of newly diagnosed patients
treated with chemotherapy died due to complications associated with immune suppression
(6, 7). These factors alone motivate a push for better diagnostic procedures and targeted
therapy that can lead to more individualized care. Appropriate patient stratification based
upon cytogenetics (8) and protein expression profiles (9) can be used to administer a more
personalized approach to treatment. Further, the number of targeted drug options continues
to increase, which includes tyrosine kinase inhibitors (TKIs) (10, 11) and antibody-based
therapies (12, 13). Together, better diagnostics and therapy options will allow oncologists
to optimize the therapeutic window by maximizing drug efficacy and minimizing off-target
effects. This continued push to characterize the diverse signaling capacity of leukemia and
the incorporation of novel therapies will be essential if we hope to improve upon the longterm success that extends beyond relapse-free survival.

Acute lymphocytic leukemia arises from both early B and T lymphocyte lineages, with
precursor B ALL (BCP-ALL) accounting for approximately 70% of cases. This
dissertation reports significant strides in the characterization of a novel target in BCP-ALL.
Through the use of advanced imaging modalities and computational biology, we have
identified mechanistic evidence to support targeting the pre-B cell receptor (pre-BCR) in
this B cell malignancy. We show that the pre-BCR is not only essential to the survival of
leukemic B cells but also has unique features that make it a highly desirable target. This
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evidence led us to the development of a novel chimeric antigen receptor (CAR) T cell
therapy against the pre-BCR that is currently being tested for preclinical efficacy. We
propose that pre-BCR targeting offers potential advantages over current anti-CD19
targeted CAR T therapies (14, 15), by avoiding the loss of mature B cells and maintaining
existing adaptive immunity against common pathogens. The high risk of opportunistic
infections has hindered the treatment success in BCP-ALL (6, 7).

The dissertation contains three principal aims, each based around the central premise that
the pre-BCR is a contributor to leukemia cell survival and a legitimate therapeutic target
in BCP-ALL. The first aim set out to experimentally identify the key initiating mechanism
of the pre-BCR in context of leukemia and its role in supporting leukemia blast survival.
The second aim applied current computational approaches to examine the dynamic
behavior of pre-BCR interactions with galectin, a lectin and pre-BCR ligand abundant in
the bone marrow microenvironment that has been implicated in BCP-ALL resistance to
therapy. The third aim focused on the preclinical development of a targeted therapy against
the pre-BCR, as a proof-of-principal for use in human trials.

The pre-BCR checkpoint in B cell development
Early in B cell development, there
is an important transition from proB cells to pre-B cells (16). This
requires a shift in the dependence
from the IL-7/IL-7R pathway to
pre-B cell receptor (pre-BCR)
signaling

pathway

(17)

and

bypassing a series of important
checkpoint controls

(Figure 1 –

adapted from review by (18)). To
initiate this switch, a functionally
rearranged Ig heavy chain (µHC)

Figure 1. Early
checkpoints

B

cell

development
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must

associate

with

surrogate

light

chain

components

(VpreB/CD179a

and

5/CD179b)(19) (Figure 2). This complex must be expressed on the membrane surface of
the B cell, where it triggers a weak signal through the pre-BCR’s signaling subunits
(Ig/CD79a and Ig/CD79b)(20-22). The pre-BCR signaling pathway is initiated by Lynmediated phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs)
on the cytoplasmic tails of both Ig and Ig (22). Phosphorylated ITAMs generate a
binding site for dual SH2-domains of spleen tyrosine kinase (Syk) leading to activation of
its direct binding partners including phospholipase C (PLC), phosphoinositide 3-kinase
(PI3K), and SH2 domain-containing SLP65 (BLNK) (23). Activation through this pathway
leads to several different cell-fate decisions including cell cycle exit (24, 25), chromatin
remodeling (26), gene transcription (27, 28), and production of factors associated with the
control of central B cell tolerance (29-31). In Chapter 2, we show that these autonomous
(aka “tonic”) signals are mediated through homotypic interactions through the pre-BCR
and are essential for the survival of leukemic B cells (20).

Tens of millions of pre-B cells are produced in a healthy individual daily and eradicated
via this essential pre-BCR checkpoint (32, 33). In its role as a contributor to early B cell
malignancies, autonomous signaling by the pre-BCR is finely-tuned and is disrupted by
either cell-permeable inhibitors of the positive signaling axis or negative regulators that tip
the balance towards hyper-activation (34). Constitutive activation of the pre-BCR signaling
pathway has recently been used to stratify pre-BCR+ versus pre-BCR- BCP-ALL
populations (9). Patients with defining genetic lesions such as t(1;19)(q23;p13) exhibited
enhanced pre-BCR signaling profiles that correlated with decreased relapse-free survival
(9). This pre-BCR+ subset, not only exhibited constitutive activation of pre-BCR signaling
but also showed a consistent upregulation of the transcriptional activator, BCL6. BCL6 has
been described as a classical proto-oncogene (35) and serves as an activator of key
signaling components of the pre-BCR pathway (IGLL1, VPREB1, BLK, BANK1, SYK) (9).
The expression of the pre-BCR and BCL6 were undetectable in a predominant number of
cases (85%) including MLLr, BCR-ABL1, ETV6-RUNX1 and hyperdiploid ALL (9).
Interestingly, treatment of this pre-BCR- subset (i.e. Ph+ leukemia) with small molecule
TKI therapy induced strong upregulation of BCL6 (36). In contrast, targeted TKI therapy
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against the pre-BCR signaling components, such as Syk and BTK, in the pre-BCR+ subset
led to a significant reduction in BCL6 expression (9). It was shown that a “retro-inverso”
BCL6 peptide inhibitor induced cell cycle arrest, impaired colony formation and sensitized
the pre-BCR+ ALL blasts to chemotherapy (9).

Hyperactivation of the pre-BCR signaling pathway
also lead to the induction of apoptosis (20, 37).
Further, it was shown that malignant transformation of
leukemic B cells tolerate this increased signaling by
the concurrent upregulation of negative regulatory
molecules including SPRY2, DUSP6, ETV5 (38).
These data suggest that, similar to healthy B cells
which tolerate only delicately tuned balance of
Figure 2. The preBCR

negative and positive signals, leukemic B cells are also
regulated by a similar process. Thus, in addition to the

more common therapeutic strategy of inhibiting oncogenic addiction (37, 39, 40), placing
the pre-BCR in overdrive may also trigger cell death and represent new opportunities for
leukemia therapy. In Chapter 2, we set out to understand the biophysical mechanisms that
tune the autonomous signaling threshold in live leukemic B cells. We also explore the
possibility for combination therapy, where pre-BCR targeting may lower the required dose
of chemotherapy.

Several different initiating mechanisms have been proposed to drive pre-BCR signaling.
These include self-association between µHC or surrogate light chain (SLC) components
(21, 41, 42) and crosslinking by stromal-bound galectin-1 (43). We were particularly
interested in addressing questions such as: how do serial engagement and duration of preBCR homo-interactions tune the strength of the pre-BCR signaling in leukemic B cells? Is
there a difference in the receptor dynamics when galectin-1 is introduced to the system to
aggregate pre-BCR? How do these distinct mechanisms of engaging the pre-BCR impact
the downstream signaling profile in leukemic B cells?
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Technical Approach I: Single Particle Tracking
Many techniques have been employed to measure the lateral diffusion of particles on the
membrane surface. Common approaches that have been used include fluorescence
recovery after photobleaching (FRAP) and fluorescence correlation spectroscopy
(FCS)(44-47). Though effective in determining ensemble averages of fluorescently-tagged
molecules, these methods are limited in their ability to detect small-scale heterogeneities
or short-lived molecular interaction (48). To gain a better spatiotemporal resolution, single
particle tracking (SPT) approaches have been employed. SPT can capture trajectories of
individual particles at relatively fast (millisecond) time-scales (48, 49). This is achieved by
particle localization of individual proteins labeled with advanced fluorescent markers that
can bring the localization accuracies down to single-digit nanometer scale, as described in
this section.

SPT has seen a major revolution since early studies back in the 1980s, which used gold
nanoparticles to visualize surface properties and later moving receptors on live cells (50,
51). A major advantage in the use of gold, latex, or silica particles, which ranged in size
from 200-1000nm, was inherent in their physical and optical properties such as a large
scattering cross-section that enabled optimal spatial localization down to 1nm and
enhanced photostability, which substantially reduced photobleaching. These factors
allowed for longer sequence acquisitions (up to minutes) at relatively fast frame rates (48,
52). However, though the large cross-sections were beneficial to optical properties of these
particles, these bulky probes posed a problem in that they could putatively interfere with
the protein’s local environment (53). It had been shown that these particles could induce
cross-linking, alter the diffusion profile, and sterically hinder the protein’s interaction
network (53, 54). These experimental artifacts led many groups to develop probes with
more optimal phyico-chemical (smaller size) and optical properties (limited
photobleaching).

Small molecule fluorescent dyes with diameters several orders of magnitude smaller than
gold nanoparticles (1-2nm) would ensure little/no impact on the proteins environment.
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Major advances in the use of fluorescent molecules occurred in the early 1990s when
researchers showed that single molecules dyes coupled to molecular targets could be
detected at room temperature (55). Soon after, these small organic dyes were being applied
to study lipid motion (56) and later receptors (57). Unfortunately, due to their reduced
photostability and decreased absorption cross-section, photobleaching and poor
localization accuracies plagued the experimental design, respectively. These artifacts
restricted molecular tracking to just seconds and increased the localization
indeterminations (48). To reduce photobleaching, scientists added free oxygen scavengers,
which were toxic to cells and (58) severely limited the capacity to do live cell imaging.
Thus, it became evident that an improvement to SPT experimental design would come as
a balance between the physico-chemical and optical properties of these probes.

Quantum dots (QDs) offer a medium between the size and optical limitation of small
organic dyes and larger gold nanoparticles materials, respectively. Two seminal papers
published in Science back in 1998 (59, 60) showed that Quantum dots (QDs) could be
conjugated to biomolecules to selectively target specific biomolecules on the cell surface.
This opened the door to QD-SPT experiments with a large increase in their use into the
present day (61). QDs are ten times as bright as organic dyes with an increased
photostability that removes artifacts associated with photobleaching and allows for longer
acquisition times (up to tens of minutes) (48). Additionally, QDs exhibit a broad absorption
spectra and narrow emission, which allows for multiplex imaging via simultaneous
excitation of spectrally distinct QDs (61). Multi-color SPT experiments with different
spectral properties have been applied to several studies (62, 63). Under this setting distinct
emissions can be sent to separate channels linked to the same charge-coupled device (CCD)
camera. While smaller than gold particles detailed above, QDs are still relatively large (1030nm diameter). Again it has been postulated and shown that certain features of the QD
such as polyvalency (multiple binding sites) might severely impact the local interaction
network. To overcome these hurdles, improved bioconjugation have been implemented to
minimize the number of probes per QD and/or obtain more predictable ratios. Further,
manufacturing efforts are being incorporated to reduce the size of the QDs (64, 65).
Another major shortcoming of QDs is due to blinking, also called power-law on-off
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intermittent emitting behavior (66, 67). Different nanochemistry designs (68, 69) or postprocessing algorithms to reconnect trajectories (62, 69, 70) have been implemented to
overcome this QD limitation.

Incorporation of QDs into SPT experiments allows for the quantitative measurements
including diffusion rates, co-localization and organization within live cells (61). The
technique has been applied to the biomedical research to answer several important
questions involving membrane receptor dynamics (64, 71, 72) and to a variety of other
molecules in a range of systems (73). SPT data consists of trajectories of diffractionlimited images of particles captured by microscope. One of the first steps required in SPT
is to quantitatively determine the location of the particle with subdiffraction resolution. The
theoretical framework is based on the fact that a single point is displayed in the detector as
a concentric ring with decaying intensity as the distance from the center gets larger. The
centermost ring, called the Airy disk, exhibits the greatest intensity and thus its location
can be estimated using the 2D spatial fit to microscopes point spread function (PSF). This
allows for a positional precision and accuracy to within a few nanometers. Another
important criterion to achieve this level of resolution is through low density labeling
whereby individual spots must be well resolved in space. This represents a limitation to
SPT experiment as only a small sample of molecules from the entire population can be
investigated during a given acquisition sequence. After acquiring thousands of images at
select rates (we used 20 frames/sec), these centroid positions are linked to reconstruct
trajectories of individual particles (71, 74, 75). An essential problem to overcome during
the reconnection phase is to account for lost blinking particles or exhibited aberrant
localization. Several groups have developed algorithms to account for these problems (62,
69, 76) and we have incorporated them into our tracking algorithms to study pre-BCR
dynamics (20). Additional algorithms are subsequently employed in order to characterize
the dynamics of proteins, which is often achieved through mean-square displacement
(MSD) calculations from which the diffusion coefficient can be extrapolated based on type
of underlying motion that is being modeled (i.e. Brownian, confined, immobile, directed,
and anomalous)(49). Further, multi-color QD tracking have been utilized to provide insight
into interactions that occur at the membrane surface and provide additional quantitative
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information such as correlated motion, state-specific diffusion, and dimer lifetimes (20, 62,
77, 78).

Many receptor interactions, such as pre-BCR/pre-BCR dimers, at the membrane are
fundamental to cell response regulation. Torreno-Pina et al (73), have characterized
molecular interactions into two broad categories from homo-interactions to heterointeractions based on the nature of the species (identical versus different) involved in the
interactions. Early studies suggested that the fluid mosaic model could readily explain
lateral diffusion of receptors through the lipid bilayer, whereby hetero- and homointeractions between proteins would occur from collisions between particles that displayed
purely Brownian diffusion (79). However, efforts over the years have revealed several
different flavors of motion occurring at the membrane, which includes Brownian, directed,
confined and anomalous diffusion [see (49) for early extensive review]. SPT has provided
insight into the role oligomerization plays in initiating signaling in variety of immune
response (80). Roles that have been implicated for receptor oligomers include an enhanced
capacity to bind multimeric ligands, or forming signaling scaffolds at the cell membrane
(81-83). Characterization of hetero-interactions with SPT technologies, especially through
the interactions to the extracellular glycocalyx matrix, is also gaining an increased level of
attention (84). We provide a more detailed description of the use of two-color SPT
experiments in our paper (20), or can be found elsewhere (62).

Insights into pre-BCR Homotypic Interactions through Quantitative Imaging
Our goal in this study was not only to estimate global diffusion patterns of individual
receptors but also to reliably distinguish and capture two different particles engaging on
the surface of live cells. Capturing two interacting dimers on the extracellular surface of
live cells is non-trivial. The first goal was to generate bright, stable fluorescent probes that
could track individual pre-BCRs for relatively long periods of time. We opted to use
Quantum dots (QD) coupled to monovalent probes. As detailed above, the enhanced photostability and narrow emission spectra properties that allow for long acquisition periods and
concurrent collection of spectrally distinct particles (62, 77, 85, 86). Next, we needed to
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overcome the limitations of the diffraction limit of conventional fluorescence microscopy
(~250nm), by adopting modern practices for single particle tracking of different receptors
with two spectrally distinct probes (62, 63). This approach uses a beam splitter to project
spectrally distinct emissions of quantum dots onto a CCD camera, as detailed above. We
used a custom-designed image registration algorithm that allowed us to map the relative
positions of each spectrally distinct trajectory (62). Third, we needed to avoid potentially
disrupting the pre-BCR dimer itself via crosslinking and/or inhibiting the dimer interface.
We achieved this by targeting the pre-BCR’s Ig signaling subunit with a monovalent Fab.
This prevented crosslinking artifacts and avoided regions implicated in dimerization (21,
41). The relative positions of these two-color trajectories were then processed by a set of
post-processing algorithms that could calculate dimer lifetimes, correlated motion, and
state-specific diffusion (i.e. dimer-state versus free-state)(62). These important measures
provided quantitative information that could be used to compare the impact of selective
modulators that target the pre-BCR pathway.

Using this advanced imaging modality, we were able show that dimer events occur on
surface of live BCP-ALL cell lines and patient samples. These were characterized by
transient homotypic interactions mediated through the SLC. We designed a monovalent
Fab fragment specific for the SLC using phage display technologies. Incorporation of this
Fab as a dimer-blocking agent in our SPT experiments disrupted homotypic interactions as
exemplified by increased pre-BCR diffusion, decreased correlated motion and faster dimer
off-rates. Fab treatment impacted both short- and long-term signaling, leading to decreased
phosphorylation of activation markers (pITAM,pSyk) and downregulation of BCL6
expression, respectively. These downstream signaling readouts were very similar to
profiles observed when directly inhibiting downstream signaling partners such as Lyn and
Syk. Further, this data correlated with decreased survival pre-BCR+ leukemic B cells. In
conjunction with recent evidence that suggested advantages to using potent tyrosine kinase
inhibitors against downstream effector molecules of the pre-BCR pathway, we showed that
we could also target the initiating mechanism at its source to directly impact leukemia cell
survival. After validating that weak signals mediated through the pre-BCR were sufficient
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to maintain leukemogenesis, we also evaluated how larger and more stable pre-BCR
aggregates might impact the signaling profile in BCP-ALL.

Galectin, a pre-BCR crosslinking agent
Galectin-1 belongs to a family of -galactoside binding proteins known for their
carbohydrate binding properties (87). These lectins can form a homodimer of 14kDa
subunits with each monomeric unit containing a single carbohydrate-binding site
(CBS)(88). After secretion into the extracellular space, galectin-1 exists in a
monomer/dimer equilibrium with a binding constant of ~7µM (89), which is mediated
through the extreme N- and C-terminal regions of each monomeric unit (87). It has been
shown that upon carbohydrate binding the dimer/monomer equilibrium shifts in favor of
dimerization (90). Many have suggested that the multivalent nature of galectins entail
crosslinking capabilities that are important to an array of biological responses (91-94). This
includes aggregation of specific cell surface glycoreceptors that have been shown to
promote signal transduction (89, 95, 96). Galectin-1 is of special interest in the context of
BCP-ALL, since it can binds directly to the pre-BCR. As discussed further below, this
binding site is distinct from the carbohydrate binding site (96).
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Bone marrow stromal cells can present galectin-1
by virtue of binding to glycoreceptors, including
integrins, on their extracellular surfaces (97).
Interactions between galectin-1 and the pre-BCR
trigger the formation of a “developmental synapse”
at the contact zone between stromal and B cells,
which has important roles during precursor B cell
development (98). These stromal/pre-B cell
Figure 3 – Galectin-1 Structure.
Galectin-1 with chain A (white)
bound to 5 (purple) and
carbohydrate (green). CBS (pink)
and 5-binding region (orange)
are displayed. Key Trp-68 & Arg73 residues shown as bonds.
Critical
5
binding
sites
magnified.

interactions have also been shown to have an
important role in B cell malignancies (99-101),
with some suggesting galectin-1 as a valid
therapeutic

target

(102,

103).

Considerable

evidence has shown that galectin-1 serves as an
unusual pre-BCR ligand (43, 104, 105). Dimeric
galectin-1 can aggregate the pre-BCR at the
membrane surface (43, 96, 106). Structural

evidence for this hypothesis has been supported through NMR experiments, where it was
shown that galectin-1 could directly bind to the pre-BCR’s 5 region via protein/protein
interactions (96). To understand these multivalent galectin-1 interactions in the context of
pre-BCR+ leukemia, we employed SPT to measure how exogenous galectin-1 impacts preBCR dynamics. Our results not only revealed drastic changes in the pre-BCR’s biophysical
profile but also notable changes in downstream signaling profiles in leukemic B cells.

Introduction of galectin-1 in vitro resulted in large clusters of the pre-BCR that could be
readily captured by confocal microscopy. This also corresponded to a drastic slowdown of
the pre-BCR in SPT experiments. In contrast to what might be expected, galectin-1
introduction correlated to a decreased pre-BCR activation profile. Blocking galectin-1’s
lectin-binding properties increased receptor diffusion. This also, increased phosphoactivation of the pre-BCR pathway above that seen under tonic signaling conditions. These
findings suggest that galectin-1/pre-BCR and galectin-1/glycoreceptor interactions may be
important in driving different signaling profiles in both healthy and malignant settings.
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Interestingly, introducing galectin-1 in both of these conditions (+/- carbohydrate) led to
the downregulation of BCL6 expression. Modulation of the finely balanced pre-BCR signal
upward or downward impacts the expression of a positive feedforward loop implicated in
BCP-ALL. This information adds additional complexity to the pre-BCR signal initiating
mechanism and reveals the differential signaling capacity that can be propagated through
this transmembrane receptor.

Recent studies have suggested that pre-BCR/galectin-1 interactions lead to a changing
affinity of galectin-1 for specific sugars. A recent model proposed that pre-BCR binding
weakens galectin-1 affinity to -linked N-Acetylactosamine (LacNAc) sugars in favor of
3-SiaLacNAc groups found more preferentially on pre-B cells. This finding points to
galectin-1 as the link between the pre-BCRs and eventual escape to new signaling niches
within the bone marrow microenvironment (97). To understand the influence of pre-BCR
and carbohydrate binding on galectin-1 at a more detailed structural level, we turned to
theoretical biology.

Technical Approach II: Molecular Dynamics
Advantages of Coupling Molecular Simulations to Experiments
We are in an age that can understand macromolecular function at a more sophisticated level
(107). Just as SPT continues to be used to overcome spatial and temporal limitations
inherent to low-resolution microscopy (diffraction limit or ensemble average limitation of
FRAP experiments), structural biology and molecular simulations offer a more refined
resolution at shorter spatial and temporal scales (108). Intrinsic to this are advances in
electron microscopy, nuclear magnetic resonance (NMR), and X-ray crystallography that
have significantly expanded our understanding of protein interactions. The protein data
bank (PDB) contains over 100,000 entries with over 20,000 small molecules bound to
macromolecules (109). It is evident that the conformational space, thermodynamic
properties and intermolecular attractions cannot be understood at the desired level of
atomic detail from these experiments alone. Pioneering research back in the 1970s started
to merge experimental (110, 111) and theoretical work (112) to derive function from
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molecular motion. In the advent of enhanced computational power, improved sampling
procedures, and more accurate potential energy functions, we can now construct models
that show a stronger correlation to experimental data. The predominant approaches
currently employed for molecular simulations include molecular dynamics (MD)
simulations and normal mode analysis (NMA). MD simulations are widely used to sample
local (0.1-0.5nm, 10fs-0.1s), rigid body (0.1-1.0nm, 10ns to 1s), and large-scale motions
(>0.5nm, 10µs to minutes) representative of different distributions (113). Implementation
of advanced sampling algorithms coupled with computation parallelization, such as
hybridization that couple CPU/GPU capabilities, have significantly increased the scale of
biomolecular system (114). Through the use of spatial decomposition, the entire system
may be distributed to different processors whereby only a small portion of the system needs
to be simulated by each processor. Due to these improved computing technologies,
simulations that involve > 50,000 atoms are now routine and simulations over 1x106 atoms
are even practical, so long as computing resources are available (109).

Theoretical Framework of MD
A comprehensive description of MD theory can be found elsewhere (115, 116). The basic
premise of MD simulations requires the integration of Newton’s equations of motions at
specified time steps, typically in the femtosecond ranges to account for fastest motions of
the system (i.e. hydrogen bond vibrations). After a defined period of time (typically tens to
several thousands of nanoseconds, depending on computational power), one obtains
molecular trajectories containing information of the positions, velocities and accelerations
of the atoms within a system through the course of the simulation. To develop molecular
trajectories of motion that are more representative of experimental systems, appropriate
assumptions and functions defining the potential energy surface are required. A precise
molecular description of any given system would depend upon solving the time-dependent
Shrödinger equation of N-particle wave function that depends upon both nuclear and
electronic degrees of freedom. Because macromolecular systems involve thousands to
hundreds of thousands of interacting particles, this approach would readily become
computationally exhaustive. The Born-Oppenheimer approximation allows us to assume
that electrons can take on the motion of the nuclei. Thus, only nuclear motion needs to be
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considered while the degrees of freedom of electrons impact the dynamics of the nuclei
through the potential energy surface. With nuclear motion described in this way, to solve
for the potential energy, a large number of semi-empirical energy functions can
characterize both bonded and non-bonded interactions. These force fields are complex
equations but they are relatively easy to calculate. The bonded terms include harmonic
potentials for bond length and angles, periodic functions for bond rotations or improper
dihedrals. Non-bonded terms include Coulombic interactions and Lennard-Jones for
electrostatic and van der Waals interactions, respectively. The defined parameters within
these semi-empirical force fields equations (AMBER (117), CHARMM (118), GROMOS
(119), OPLS(120) are of specific flavors that take on slightly different forms and have been
incorporated into the framework of different molecular dynamic simulations programs (i.e.
AMBER, CHARMM, GROMACS, NAMD).

Practical Application of MD Simulations to Study Protein Allostery
The ability of MD simulations to explore space and timescales concurrently makes it a
particularly useful tool to study protein allostery (121), as we did in this study. Allostery is
defined as a stimulus at one site altering the properties at a different site, often through a
change in conformation and/or dynamics of the protein (122, 123). MD simulations have
shown to be increasingly useful for determination of allosteric effects because they give an
all-atom level of detail at both spatial and temporal scales and allow for defined
perturbations to be introduced into the biomolecular system (121). Allostery is not only
important in understanding basic biological function of proteins, but has also been shown
to be important for immunological escapes (124), drug-design (125), and protein
engineering (126). The allostery problem must consider several different factors. First,
appropriate docking of the protein into the binding site is an essential criterion to
understand the impact of distal binding effects. When there is no information about the
binding site (“blind docking”), several approaches can be employed (127, 128). When
experimental data can provide information on the binding epitope then the determination
of the binding mode can be much more readily predicted. In this manner, one can position
the ligand at the allosteric site at the start of the simulation and allow the protein to undergo
conformational changes so as to adapt during the simulation (129, 130). Second, it is
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important to understand the nature of allosteric coupling. This aims at addressing questions
related to how a stimulus at one end may alter interactions of the protein at a different site
or how sites not initially implicated might be under allosteric control. One of the most
straightforward approaches to studying allostery is to look for interdependent motions at
particular sites of interest (i.e. binding site of interest). This can be done through basic
measurements such as distance distributions or dihedral angles between four consecutive
atoms of interest over the course of the simulation. The determination of allosteric effects
is often challenging because changes that influence one site may be very subtle. This is
made more difficult by the continuous fluctuations inherent in protein dynamics. To
overcome this hurdle a variety of methods have been described to identify residues coupled
allosterically (131). These include protein topological analyses (graph theory, statistical
coupling analysis and perturbation algorithms)(132-134), interaction energy (135) or
correlated matrices (136-138).

Importance of Statistical Mechanics & Advanced Sampling Procedures
Another macroscopic property that can be derived from MD simulations and is important
to understanding the protein interaction network is the free energy of binding. The most
straightforward approach to extrapolate binding energy of a ligand to given protein pocket
would be to run lengthy simulations that could capture different ligand conformations in
both bound and unbound states. However, though improved computing power may allow
for this “brute force” approach, ligand binding still may occur at timescales that are too
slow to be sampled by MD simulations. To overcome this hurdle, a large number of short
simulations may be coupled to statistical modeling to bias the system toward a particular
phenomenon (i.e. ligand in bound versus unbound state). Apart from just understanding
the motion of particles, much more information can be extrapolated about a system through
probabilistic configurations. For a more detailed review of statistical mechanics as it
applies to determining thermodynamic properties through molecular dynamics see here
(139). Through the use of statistical mechanics and its treatment of systems at equilibrium
with a set of probability functions, we can then extrapolate macroscopic properties of a
system (temperature, chemical potential, free energy) through these microscopic
simulations. In order to calculate free energy change of a biomolecular phenomenon, such
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as carbohydrate affinity within galectin’1 binding pocket, one can bias the simulation with
an additional potential along a reaction coordinate (i.e. center-of-mass distance from the
binding pocket). Several different methods have been employed to estimate binding free
energies from MD simulations using these advanced sampling procedures including free
energy perturbation (FEP) (140), Molecular Mechanic/Poisson-Boltzmann surface area
(MM/PBSA) (141), linear interaction energy (LIE) (142), metadynamics (143), replica
exchange umbrella sampling (REUS) (144), or umbrella sampling (US)(145). In this study,
we employed many of these techniques, including linear interaction energy and umbrella
sampling, to show that the conformational changes induced by pre-BCR binding
significantly altered the binding affinity for select carbohydrates. These approaches were
also applied to aid in the discovery of probable binding sites of the scFv within the preBCR’s VpreB. An introduction to these findings are detailed here.

MD Simulations Reveal Allosteric Control of Galectin-1 by the pre-BCR
A model proposed by (97) shows the flexible nature of galectin-1/glycan interactions upon
pre-BCR engagement and may have important implications in pre-BCR signaling profiles.
Further with experimental data also suggesting that

galectin-1’s dimer/monomer

equilibrium may be disrupted upon carbohydrate binding (90) led us to reason that preBCR binding might also impact galectin-1’s dimer stability. Chapter 3 shows our approach
to study the dynamic behavior of this pre-BCR/galectin-1 protein/protein interaction, based
upon use of all-atom MD simulations and statistical mechanics to corroborate experimental
findings in the literature. Using structural coordinates and critical intermolecular
information derived from X-Ray and NMR structures, we built molecular models of the
galectin-1 protein bound to the 5 region of the pre-BCR (96). Next, we constructed an
explicit solvent system and conducted large-scale (>100,000 atoms) MD simulations using
GPU/CPU hybrid acceleration to show that the pre-BCR allosterically modified the
structural integrity of galectin-1’s carbohydrate-binding site (CBS). Through the use
correlated matrices detailing molecular motion, particularly principal component analysis
(PCA)(137), we not only showed that the pre-BCR stimulus exhibited a distal disruptions
that would influence galectin-1’s carbohydrate binding interactions but also might impact
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dimer/monomer equilibrium. Further, we employed linear interaction energy (146) and
umbrella sampling (145) to show that the conformational changes induced by pre-BCR
binding significantly altered the free energy of binding for select carbohydrates. This work
shows another application of MD simulations to study allostery in proteins as well as
incorporation of advanced MD algorithms to extrapolate biophysical measurements that
can be directly compared to experimentally derived calculations.

Small molecule and antibody-based therapeutics for leukemia
There is currently a major call for effective targeted therapies in BCP-ALL, including small
molecule inhibitors of signaling pathways that drive leukemogenesis or promote cell
survival (10, 14). Potential targets in the acute leukemias include Jak-Stat, Abl, PI3K, Map
Kinases, Syk and Btk. Because these proteins are widely expressed in both innate and
adaptive immune cells (9, 37, 147), there is high risk for off-target effects including
dampening of the immune response to secondary infections. Further, treatment with TKIs
in BCP-ALL has shown many reported cases of relapse (36, 148). The potential escape
mechanisms are inherent in the complexities of the B cell signaling network, which can be
easily influenced by microenvironmental factors (99), receptor crosstalk (149),
upregulation of negative feedback regulators(38), genetic lesions (150), protein expression
levels(9), and oncogenic mutations (151).

The other predominant choice for targeted therapy in leukemia involves the use of
antibody-based technologies that target B cell markers expressed on the membrane of
precursor B cells (152, 153). For example, therapy based upon delivery of intact IgG1
induces direct killing of the leukemic B cells via antibody-dependent cytotoxicity (ADCC)
and phagocytosis (ADCP), antibody-dependent toxin delivery(154, 155). As discussed
below, there have been considerable clinical advances with methods that employ the
adoptive transfer of genetically modified immune effector cells (156, 157).

The design and promise of CAR T cell therapy .

18

Dating to more than half a century ago, it has been known that T cells that have been
adoptively transferred may have the potential to find and destroy cancer cells (158). In
many of early studies involving adoptive transfer, T cells did not have sufficient capacity
to kill the cancer (159-161). To improve the ability to hone in on the cancer to improve
efficacy, groups started to engineer T cells with receptors that would improve their
targeting potential. Clinical trials that incorporated engineered T cells first used T cell
receptors (TCRs) with specificity for proteins expressed on tumor cells. While this
approach would allow for the targeting of both intracellular and extracellular targets, cancer
cells resisted this targeted approach by downregulation of MHC class I expression (162).
To overcome this MHC-restriction, required for recognition via the TCR, chimeric antigen
receptors (CARs) have been developed. CAR T cell therapy is based upon genetic
modification of the patient’s T cells made to express a chimeric antigen receptor that can
target membrane receptors on the surface of the malignant B cells (156, 157). “First
generational” CAR constructs were composed of an extracellular domain that recognizes
the target of interest, usually in the form of a single-chain fragment variable (scFv), coupled
with the transmembrane domain and intracellular ITAM-bearing tail of CD3- (163, 164).
(Figure 4). Early clinical trials involving first generational CAR+ T cells exhibited low in
vivo expansion and rapid clearance after infusion (165, 166). This led to the development
of “second generational” and “third generational” CARs that incorporated additional
costimulatory regions (i.e. 4-1BB, CD28) within the cytoplasmic domain (167, 168)[see
Figure 4]. This addition enhanced in vivo expansion and persistence of anti-target effector
function for months to years post-injection (169). The adoptive transfer of CAR T cells has
resulted in complete remission in refractory and relapsed B cell cancers (15, 170, 171). The
reason for the extensive use of CAR T’s in B cell malignances is inherent to the relatively
large number of patients, target accessibility, conservation of surface markers, tolerance
of B cell aplasia, and high rates of success (172). This success has extended beyond B cell
malignancies with reported success in synovial cell sarcoma and multiple myeloma (173,
174).

The current CAR T target in BCP-ALL is CD19, a cell surface receptor that are widely
expressed throughout the different stages of B cell development. We note that CD19
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therapy ablates both healthy and malignant B cells, with complications already being
reported due to the onset of opportunistic infections (86) as well as cytokine storm (175).
Cases of relapse have also
been reported due to loss of
CD19 expression on the
target cells (87) due to
downregulation
mutation

(177),

(176),
or

alternative splicing (177) in
the tumor cell. Still, other
Figure 4. First, Second & Third generation Chimeric
Antigen Receptors (CAR).

cases have reported reduced
CAR T efficacy even though

CD19+ leukemic cells are detectable in the blood (88). Reduced CAR T expression or T
cell exhaustion (89) may be important factors for loss of therapeutic potency. To overcome
this, groups are targeting different markers such as CD20 and CD22 for use in B cell
malignancies (178-180). An anti-CD20 CAR T recently revealed little/no efficacy due to
complete loss of detection of the cells from 1 to 9 weeks after transfer (181). Multivalent
targeting CAR T cells have been utilized with a combo of CD123 and CD19 and prevented
the escape of CD19- mutants in the preclinical setting (182).

Considering all these factors, we set out to test the hypothesis that the pre-BCR could
represent a much more specific target for T-cell mediated therapy in pre-BCR+ leukemias.
We reasoned that the unique structural and development properties of the pre-BCR make
it an optimal target in BCP-ALL. The pre-BCR’s SLC, composed of 5 and VpreB, are
non-polymorphic and contain non-Ig portions, which show no sequence homology to any
other genes (33, 183). In contrast to targeting downstream effectors and/or other surface
receptors like CD19, targeting SLC would protect the mature population of B cells that are
fundamental to a patient’s adaptive immune response. Further, different from the CD19,
we showed that pre-BCR+ leukemias require the pre-BCR for survival. Thus,
downregulation of the pre-BCR, as seen in CD19, may be detrimental to the leukemia cells
that require expression for survival. Targeting receptors on tumors that are central to
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survival confer a proliferative disadvantage and an unlikely source of resistance. This idea
has been suggested previously (172) and has been shown to be advantageous for B cell
maturation antigen (BCMA or TNFRSF17), in plasma cells malignancies (184, 185) and
ROR1 in both ALL and CLL (149, 186).

Several different gene modification strategies have been proposed to engineer T cells.
Retroviral and lentiviral vectors are among the most popular due to their efficiency and
well-developed protocols (187). Of these two, lentiviral vectors are favored because they
can integrate in non-dividing primary human cells and limited risk of insertional
mutagenesis to-date (188, 189). However, these successes with lentiviral vectors have not
ruled out transposon-based systems (190), zinc-finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs) and RNA-based (CRISPR-Cas9) that may be
used to engineer T cells or modify T cells that are resistant to tumor-mediated suppression
(191-196). These latter concept of additional T cell modification to improve CAR T
function is a hot topic. Different groups have proposed the incorporation of molecular
switches. For instance, cells can be produced to engineer deactivating (197, 198) or
activating activity (199, 200). T cells may also be engineered to express certain types of
chemokine receptors such as CCR2b, which has been used to enhance tumour infiltration
(201).
Chapter 4 presents the pre-clinical development of a 2nd-generational CAR T that targets
the pre-BCR. Starting with the DNA sequence of the full-length anti-VpreB murine
antibody that had been shown to block pre-BCR dimerization (20), we employed
computational design principals to successfully engineer an scFv. This scFv retained the
specificity and subnanomolar binding affinity to the VpreB. The scFv was then
incorporated into a lentiviral expression vector that contained a CD28 juxtamembrane
domain and C-terminal region composed of the CD3- cytoplasmic tail. We produced
CD8+ human CAR T cells that were effective killers of pre-BCR+ BCP-ALL cell lines.
Due to the bivalent nature of the pre-BCR, our CAR T represents the first reported CAR
that is directed toward a multivalent antigen. This structural feature may provide select
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advantages for signaling and motivate future studies that will look into the impact of target
antigen valency on signaling proficiency of CAR T cells.

TKIs or antibody-based therapies (ADCs or ADCC) have shown tremendous potential in
long-term survival in variety of cancers (202, 203); however, relapse is still common (36,
149, 153). Further, recurrent treatment through these therapies entails a high cost burden
(204). Therefore, adoptive transfer of CAR T cells with single administration requirements
confers select advantages to existing treatment options (169). Additional strategies for
treatment of B cell malignancies have been proposed to combine CART cells with small
molecule TKI therapy. In fact, Bruton’s tyrosine kinase inhibitor, ibrutinib, has been tested
and has shown improved anti-CD19 CAR T expansion and improved CD8+ T-cell function
by altering the suppressive effects of PD-1 and CD200 expression (205). Additional
preclinical tests are incorporating anti-PD1 treatments in combination treatments, which
has been shown to prevent immunosuppression and boost CAR T therapy (206). Due to
variations seen with the existing repertoire of T cells used to manufacture CAR Ts, groups
have proposed the development of “universal” T cells that could be readily engineered to
express a CAR T toward a given target in addition to provide benefits such as the
minimization of graft-versus-host disease (207). As we build upon the existing library of
available targets, improve CAR T design and understand the differential signaling network
as a case-by-case basis, we expect to see a boost in the number of clinical trials utilizing
this therapy.
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CHAPTER 2

Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell
precursor acute lymphoblastic leukemia
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ABSTRACT
The pre-B cell receptor (pre-BCR) is an immature form of the BCR critical for early B
lymphocyte development. It is composed of the membrane-bound immunoglobulin (Ig)
heavychain, surrogate light chain components, and the signaling subunits Igα and Igβ. We
developed monovalent Quantum Dot (QD)-labeled probes specific for Igβ to study the
behavior of pre-BCRs engaged in autonomous, ligand-independent signaling in live B
cells. Single-particle tracking revealed that QD-labeled pre-BCRs engaged in transient, but
frequent, homotypic interactions. Receptor motion was correlated at short separation
distances, consistent with the formation of dimers and higher-order oligomers. Repeated
encounters between diffusing pre-BCRs appeared to reflect transient co-confinement in
plasma membrane domains. In human B cell precursor acute lymphoblastic leukemia
(BCP-ALL) cells, we showed that frequent, short-lived, homotypic pre-BCR interactions
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stimulated survival signals, including expression of BCL6, which encodes a transcriptional
repressor. These survival signals were blocked byinhibitory monovalent antigen-binding
antibody fragments (Fabs) specific for the surrogate light chain components of the preBCR or by inhibitors of the tyrosine kinases Lyn and Syk. For comparison, we evaluated
pre-BCR aggregation mediated by dimeric galectin-1, which has binding sites for
carbohydrate and for the λ5 component of the surrogate light chain. Galectin-1 binding
resulted in the formation of large, highly immobile pre-BCR aggregates, which was
partially relieved by the addition of lactose to prevent the crosslinking of galectin-BCR
complexes to other glycosylated membrane components. Analysis of the pre-BCR and its
signaling partners suggested that they could be potential targets for combination therapy in
BCP-ALL.
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INTRODUCTION
The cell surface expression of the multimeric pre-B cell receptor (pre-BCR) complex is
required for the survival and differentiation of B cell progenitors. This complex is
composed of the immunoglobulin (Ig) heavy chain (surface μHC), two surrogate light
chain components VpreB (also known as CD179a) and λ5 (also known as CD179b), and
the signaling subunits Igα (also known as CD79a) and Igβ (also known as CD79b). PreBCR signaling stimulates the phosphorylation of Immunoreceptor Tyrosine-based
Activation Motifs (ITAMs) in the cytoplasmic tails of both of the Igα and Igβ subunits by
the tyrosine kinase Lyn (1). The phosphorylated ITAMs form binding sites for the dual Src
homology 2 (SH2) domains of spleen tyrosine kinase (Syk), a critical component of
downstream signaling cascades that determine cell fate decisions (2, 3).

The functional pre-BCR serves several crucial roles in B cell differentiation, including (i)
initiating cell cycle exit (4, 5) and chromatin remodeling (6), which are critical for
rearrangementof the genes encoding the light chains; (ii) regulating major changes in
transcription (7, 8); (iii) providing quality control for Ig heavy chains (9); and (iv) balanced
negative and positive selection of self-reactivity (10-12). Although it is broadly appreciated
that the pre-BCR is positioned at a critical B cell developmental checkpoint, there remain
some controversies regarding the primary signal initiating mechanism. Evidence exists for
the following scenarios: Igα and Igβ signaling in the absence of external factors that might
crosslink the Igα-Igβ heterodimer (13); pre-BCR recognition of self-antigens (14);
involvement of μHC glycosylation at Asn46 (15); and pre-BCR aggregation by soluble or
stromal-bound galectin-1, a lectin that has distinct binding sites for λ5 and for
carbohydrates on glycoproteins and glycolipids (16). However, mutagenesis (17) and
structural studies (18) suggest that autonomous signaling is driven by ligand-independent
self-association of the λ5 components of the surrogate light chains. The weak signals
attributed to these homotypic pre-BCR interactions have led some to refer to it as “tonic
signaling” (19). The compelling evidence for homotypic pre-BCR associations motivates
these questions: Can these interactions be directly measured and what is their lifetime? Do
they engage in serial interactions (20)? How does the relative duration of pre-BCR
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homotypic interactions govern the strength and outcome of pre-BCR signaling? These
questions can now be addressed through high-resolution imaging modalities, such as single
particle tracking (SPT) methods that have captured the diffusion, clustering, and dynamics
of the mature BCR (21, 22) and FcεRI (23, 24).

Our model system is B cell precursor acute lymphoblastic leukemia (BCP-ALL) (25), for
which a substantial fraction of cases depend on pre-BCR autonomous signals for survival,
expression of the gene encoding the transcriptional repressor BCL-6 (B-cell lymphoma 6
protein), and suppression of p53-mediated apoptosis (26). In these cases, there are parallels
between the role of the BCR as a driver of or contributor to diffuse large B-cell lymphoma
and chronic lymphocytic leukemia (27, 28). The knowledge that the BCR generates
survival and proliferative signaling in mature B cell neoplasms provided motivation for
successful clinical trials targeting Syk, Bruton’s tyrosine kinase (BTK), and other
downstream signaling components (29). There is now strong interest in determining
whether targeted agents against the pre-BCR and its signaling partners (such as Lyn and
Syk) (30-32) will also have therapeutic potential for an important subset of BCP-ALL,
particularly in the setting of adjuvant or combination therapy. New insights into the
mechanisms governing pre-BCR activation also have profound implications for normal B
cell development, as well as autoimmunity (33).

Here, we used state-of-the-art SPT methods to capture dimer events between pre-BCRs in
real time. These studies provide evidence that pre-BCRs undergo homotypic interactions
through their surrogate light chain components, and that these interactions stimulate
autonomous signaling. We demonstrated that VpreB-specific monovalent Fab antibodies
blocked self-association and inhibited autonomous signaling. Treatment with anti-VpreB
Fabs resulted in an overall faster pre-BCR diffusion rate by eliminating the proportion of
receptors that was engaged in dimerization. The clinical relevance of our findings was
suggested by evidence that anti- VpreB Fabs sensitized BCP-ALL cells to low-dose
chemotherapy. To complete our studies of pre-BCR oligomerization, we also evaluated
receptor behavior on cells treated with the pre-BCR–crosslinking agent galectin-1. In
addition to its well-known carbohydrate-binding properties (34), galectin-1 binds to the
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unique region of λ5 (35) and serves as a pre-BCR ligand (36). There is intense interest in
galectin-mediated signaling in the leukemia microenvironment (37), in which galectin-1
can crosslink the pre-BCR with integrins and other glycoproteins at stromal–blast cell
synapses (38). In addition to being produced by stromal cells, galectin-1 is secreted by
BCP-ALL blasts for which it may be a soluble or cell-bound ligand for the pre-BCR (39).

We showed that short-lived autonomous signals from the pre-BCR were important to
regulate BCL6 abundance, as a downstream readout of pre-BCR activity. BCL6 protein
abundance was decreased after treatment with inhibitors that target the pre-BCR signaling
partners Lyn, Syk, and SHIP-1 (SH2 domain-containing Inositol 5’-Phosphatase). The
Janus-activated kinase (Jak) inhibitor tofacitinib enhanced accumulation of BCL6 protein,
confirming reports that signal transducer and activator of transcription (STAT) actively
represses BCL6 transcription in BCPALL(40). Completed and ongoing clinical trials for
Jak inhibitors in BCP-ALL (NCT01914484, NCT01251965, and NCT01164163) provide
motivation for further studies to evaluate whether de-repression of BCL6 and other targets
of the pre-BCR pathway offer potential escape mechanisms. Studies of pre-BCR cell lines
and patient-derived leukemia blasts (26, 30, 40, 41) suggest that predicting the therapeutic
responses of individual patients to targeted inhibitors of the pre-BCR and Jak-STAT
pathways may require case-by-case evaluation, the development of reliable biomarkers,
and a systems level approach to understanding the complex crosstalk between both
pathways.

MATERIALS AND METHODS
Cell culture and treatments
Suspension cultures of BCP-ALL cell lines (697 and Nalm6) were cultured in RPMI 1640
with phenol red (Sigma-Aldrich, Saint Louis, MO), with 10% (v/v) heat-inactivated fetal
bovine serum (HI FBS), 1% Penicillin/Streptomycin (Gibco, Gaithersburg, MD), and 2
mM LGlutamine. Patient samples were cultured in IMDM (Iscove’s Modified Dulbecco’s
Medium), GlutaMAX (Gibco) supplemented with 20% (v/v) HI FBS, 1%
Penicillin/Streptomycin, 1x Insulin, transferrin, and selenium (Gibco), 1 mM sodium
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pyruvate (Gibco), and 55 μM 2- Mercaptoethanol (Gibco). Before experiments were
performed, cells were washed twice with Tyrode’s solution. Unless otherwise stated, cells
were pretreated for 10 min with BAY61-3606 (1 μM), dasatinib (1 μM), tofacitinib (1 μM),
anti-VpreB Fab (1 μM), or recombinant galectin-1 (10 μM) in the presence or absence of
lactose in Tyrode’s solution, 0.1% bovine serum albumin (BSA), and 20 mM glucose. For
SPT experiments, galectin-1 was purchased from Peprotech (Rocky Hill, NJ). Inhibitors
were purchased from Santa Cruz Biotechnology (Dallas, TX), Selleck Chemicals
(Houston, TX), and Echelon Biosciences (Salt Lake City, UT).

Recombinant anti-VpreB antibody screening and production
The Contextual Combinatorial Immune Repertoire (ConCIRT) Synthetic Library (87),
consisting of 56 billion synthetically constructed human antibodies arrayed in over 100
phage-displayed sub-libraries, was screened against recombinant “surrobodies.”
Surrobodies consist of a functional human IgG1 heavy chain isolated from an antiinfluenza H5N1 hemagglutinin antibody and paired with either surrogate light chain
components (VpreB1, λ5) or a chimeric polypeptide that is a product of the fusion of human
VpreB1 and λ5. Phage bound to surrobodies coated on a 96-well microtiter plate were
eluted and amplified for use in a subsequent round of screening. After four rounds of phage
screening, individual clones from enriched pools were analyzed for specific binding by
ELISA. Testing for binding specificity to VpreB1 was performed on ELISA plates coated
with a chimeric VpreB1-λ5 polypeptide. Detection was quantified with HRP-conjugated
anti-myc antibodies, which was followed by ELISA-based hit identification. After positive
identification, 16 phage-derived clones with an affinity for VpreB in
the range 0.85 to 250 nM were sequenced. Clone 2460B04 was selected for integration into
a mammalian expression plasmid, which was followed by transient transfection of HEK
293-F cells for the production of recombinant IgG antibodies. Intact IgG was reduced with
2MEA (2- mercaptoethylamine-HCl) to produce anti-VpreB1 Fab fragments. The
reactivity of anti-VpreB1 Fabs against live 697 cells was evaluated by flow cytometry (fig.
S7).

Anti-CD79b IgG purification
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CB3-1 hybridoma cells (generously provided by Dr. Max D. Cooper, Emory University)
were cultured in RPMI 1640 with phenol red (Sigma-Aldrich) containing 10% (v/v) HI
FBS, 1% Penicillin/Streptomycin (ThermoFisher Scientific), 2 mM L-Glutamine (Gibco)
and 1x β- mercaptoethanol (Gibco). Flask cultures were expanded by 2-week culture in
250 ml in RPMI media without FBS, which was followed by media collection, clarification
by centrifugation at 560g, and filtration through a 0.22-μm vacuum filter. The culture
medium was circulated overnight (4ºC) on a protein A/G affinity column and the IgG was
eluted with glycine buffer (pH 2.5 to 3.0). Eluted 1-ml fractions were neutralized with 1 M
TRIS buffer (pH 9.0).
Fab’ generation, biotin conjugation, and QD labeling
Fab’-biotin probes were prepared as previously described (42). IgG derived from the CB31 hybridoma or anti-IgM (Jackson Immuno Research, West Grove, PA) was dialyzed into
sodium acetate solution (pH 4.5) to prepare for addition to pepsin-conjugated agarose
(ThermoFisher Scientific, Waltham, MA) according to the manufacturer’s instructions.
IgG digestion was performed for 5 h at 37ºC, and the eluate was dialyzed at 4ºC into 100
mM phosphate, 5 mM EDTA, (pH 6.0) to prepare for reduction of the interchain disulfides
of F(ab’)2 by 2- mercaptoethylamine (2-MEA, ThermoFisher Scientific). The sample was
incubated in 2-MEA (50 mM) for 90 min at 37ºC and then dialyzed into storage buffer
[100 mM phosphate, 5 mM EDTA, (pH 6.5 to 7.0)] for 4 hours at 4ºC, exchanging buffer
multiple times. The exposed thiol groups, generated from the reduction of interchain
disulfides, were selectively conjugated to biotin with the EZ-Link Maleimide-PEG2-Biotin
(ThermoFisher Scientific) and resolved by SDS-PAGE. To remove higher molecular
weight bands (F(ab’)2 and undigested IgG, digested fragments were recovered at room
temperature by FPLC size-exclusion chromatography with Superdex 75 10/300 column
(GE Healthcare Life Sciences, Marlborough, MA) at a flow rate of 0.5 ml/min in
phosphate-buffered saline (PBS) (fig. S1A). Residual intact Fc fragments were removed
by batch processing with protein A/G agarose beads (ThermoFisher Scientific). The purity
of the anti-CD79b Fab’-maleimide biotin conjugates was determined by Coomassie stain
and Western blotting analysis (fig. S1, B and C) after the samples were resolved by SDSPAGE under nonreducing conditions. The biotin to Fab’ molar ratio was determined with
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the FluoReporter biotective green reagent (ThermoFisher Scientific) with a reported mean
biotin:Fab
molar ratio of 1:1. Anti-CD79b Fab’-Biotin or Anti-IgM Fab’-Biotin were mixed at a 1:1
ratio with Qdot655-strepavidin or Qdot585-streptavidin in PBS containing 1% (w/v) BSA
to generate stock solutions.

QD labeling of live cells
Lab-Tek imaging chambers were coated with poly-l-lysine hydrobromide (Sigma-Aldrich)
at 1mg/ml in sterile water for 20 min at room temperature, which was followed by three
washes with water. BCP-ALL cells were serum-starved in RPMI 1640 without FBS for 2
hours before being added to coated wells and incubated for 15 min at 37°C. QD-Fab’CD79b or QD-Fab’-IgM were added at a final concentration of 100 pM in Tyrodes’s
solution with 0.1% (w/v) BSA and 20 mM glucose and were incubated for 10 to 15 min at
37°C.

Single particle tracking and analysis
All corresponding GPU SPT and track elongation, squared displacement, mean square
displacement, correlated motion, fiducial data acquisition and image registration, and
three-state hidden Markov Model used in this study were described in detail previously
(43).

Galectin-1 cloning, expression, and purification
MGC human galectin-1–encoding cDNA (LGALS1, accession# BC001693) was PCRamplified with the CACC forward primer (FWD: 5'- CAC CAT GGC TTG TGG TCT GG
-3') and reverse primer (REV: 5'- TCA GTC AAA GGC CAC ACA TTT GAT CT -3').
The amplified product was subcloned into pET101 by directional TOPO expression. The
cloned product was transformed into One SHOT TOP10 Escherichia coli by heat-shock.
Cells were grown overnight on ampicillin. Resistant cultures were selected and were used
for DNA isolation. BL21 StarTM One Shot cells were transformed with the pET101 vector
with LGALS1 by heat-shock, brief outgrowth in SOC medium, followed by transfer to 10
ml of LB containing ampicillin, and the cultures were grown overnight at 37ºC while
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shaking. The next day, 50 ml of LB containing ampicillin was inoculated with 1 ml of the
overnight culture. The culture was grown at 37ºC with shaking (225 to 250 rpm) for 2 to 3
hours. IPTG (1 mM) was added to induce the expression of galectin-1 for 3 to 4 hours. The
cells were then harvested by centrifugation at 3000g for 10 min at 4ºC. The cells were
purified by α-lactose/agarose (Sigma-Aldrich) as detailed previously (88).

Western blotting
After the cells were incubated in the presence or absence of the appropriate inhibitors or
crosslinking agents, they were washed with ice-cold PBS and incubated for 15 min on ice
in Tris-based lysis buffer containing 1% NP-40 and protease and phosphatase inhibitors
(Thermo Scientific). To examine the effects of inhibitors on BCL6 abundance, treatments
were performed for 24 hours. Cell lysates were clarified by centrifugation at 14,000g for
10 min at 4°C and then were added to Laemmli’s Reducing buffer (final 2x). Proteins were
resolved by SDS-PAGE and transferred to nitrocellulose membranes. After the blots were
blocked with Tris-buffered saline containing 5% BSA, they were incubated with antibodies
specific for pCD79a-Tyr182 (CST, Danver, MA), pSyk-Tyr348 (Novus Biologicals,
Littleton, CO), pSyk-Tyr348 (Abcam, Cambridge, MA), pSyk-Tyr352 (CST), or BCL6
(Santa Cruz Biotechnology). Antibody specific for β-actin (Sigma-Aldrich) was used to
confirm equivalent loading of gels.

Pervanadate treatment
The use of pervanadate to enhance signaling in various cell types has been reported
previously (89-91). Here, all BCP-ALL cells were treated with freshly prepared
pervanadate solution (0.2 mM sodium orthovanadate and 1 mM hydrogen peroxide) in the
presence or absence of inhibitors and then treated for the times indicated in the figure
legends.

Chemosensitization
To establish an effective concentration range for the potential synergy of targeted inhibitors
with vincristine, 697 cells (50,000 cells per condition) were incubated for 3 days at 37oC
with a range of concentrations of vincristine (0.1 to 100.0 ng/ml) (Sigma-Aldrich). Controls

31

are indicated in the figures, including vincristine alone and vehicle at the highest DMSO
concentration used (0.2%). Curves were fit with a sigmoidal dose-response curve with the
curve fitting toolbox of MATLAB.

Flow cytometry assays
Leukemia cell apoptosis was determined based on measurement of the binding of AnnexinV-FITC (BioLegend, San Diego, CA) or Pacific Blue Annexin-V (BioLegend), whereas
loss of cell viability was measured by 7-AAD labeling (BioLegend), according to the
manufacturer’s procedures. For receptor-binding experiments, cells were incubated under
saturating conditions for 1.5 hours on ice in PBS with anti-CD79b-APC antibody
(BioLegend) or anti-VpreB-PE antibody (BioLegend). Flow cytometry data were
calibrated with QuantumTM Simply Cellular beads (Bangs Laboratories, Fishers, IN) with
anti-mouse Fc antibody according to the manufacturer’s instructions. Dissociation
constants were estimated with nonlinear regression analysis under KD-controlled
conditions as described previously (92). All flow cytometry data collection was conducted
on HyperCyt (93) or BD LSRFortessa flow cytometers and analyzed with the FlowJo
Software Suite (Tree Star, Ashland, OR).

RT-PCR mRNA sequence analysis
Total RNA was extracted from the 697 and Nalm6 cell lines and from patient samples #238
and #280 with NucleoSpin RNA XS (Macherey-Nagel, Duren, Germany). cDNA synthesis
was performed with both random hexamers and d(T)20 primers with SuperScript FirstStrand Synthesis System (ThermoFisher Scientific). Primers were designed for the 5’-UTR
(FWD:

5’-

GAGCTCTGCATGTCTGCACC-3’)

and

3’-UTR

(REV:

5’-

CGTGCCTCTGCTGTCTTCAG- 3’) based upon the sequence of the reference VPREB1
mRNA (NM_007128.3) sequence. PCR reactions used the Platinum PCR SuperMix
(ThermoFisher Scientific). The Thermo Cycler setup was as follows: 94°C for 2 min to
denature the DNA and activate the enzyme; 35 cycles of PCR amplification followed by
30 s at 94°C, 30 s at 55°C, and 72°C for 1 min. All PCR amplicons were agarose gel–
purified (Macherey-Nagel) and subcloned into the pCR-BluntIITOPO vector according to
the guidelines of the Zero Blunt TOPO PCR cloning kit (ThermoFisher Scientific). One
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Shot Competent E. coli were then transformed with the plasmids, and 10 to 20 colonies
were selected on LB plates with kanamycin (50 μg/ml) and grown in 5 ml of LB containing
kanamycin overnight. Plasmids were purified with the NucleoSpin Plasmid Miniprep
(Macherey-Nagel).

Purified

plasmids

were

sequenced

(Genewiz,

Cambridge,

Massachusetts) using their predefined Sp6 and T7 primers. Only sequences that passed
Genewiz quality control were analyzed. Each DNA sequence was compared to the
reference sequence (NM_007128.3) by NCBI BLAST search. All multiple protein
sequence alignments were performed with the MUSCLE server (94) and were compared
to the reference sequence (UniProt #P12018). Prediction of the N-glycosylation of the
reference and variant sequences was assessed with the NetNGlyc 1.0 Server.
Composite 3D model of preBCR Fab-like arms and Fcμ
Because the Fab-like X-Ray crystal structure of the preBCR (PDB: 2H32) does not contain
the unique region, we used the MODELLER software suite (95) to build a homology model
including the surrogate light chain unique region (UR) components. These surrogate light
chain λ5-UR and VpreB-UR structural components were derived from the NMR solution
structure (PDB: 2LKQ) and de novo peptide design PEP-FOLD online server (96),
respectively. The composite 3D model shows the Fab-like arms extended from the Fcμ
region derived from NMR and X-Ray structures (PDB: 4JVU, 4BA8, and 4JVW).
Residues implicated in polymorphism were analyzed and highlighted with the VMD
software package (97).

RESULTS
SPT captures serial pre-BCR engagements
The first step in the experimental plan to track pre-BCR self-association dynamics was the
design and production of monovalent Quantum Dot (QD) probes. We base our probes on
the CB3-1 antibody to the Igβ (CD79b). As a positive control, we also generated probes
based upon antibodies that recognize the Fc portion of the membrane-bound pre-BCR
heavy chain (mIgμ). Both reagents have the advantage of not recognizing the VpreB and
λ5 moieties of the surrogate light chain, which are proposed to mediate pre-
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Fig. 1. Direct evidence of pre-BCR dimerization on the surface of BCP-ALL cells. (A)
Experimental model with estimation of the interaction distance based upon the pre-BCR
crystal structure (PDB ID: 2H32), streptavidin (PDB ID: 1STP), and the estimated QD
radii. (B) Timelapse imaging (20 frames/s) of a single cell under resting conditions. (C)
Viterbi plot of the most likely state (dimer, domain, and free) between two QD interactions
as derived from hidden Markov model (HMM) with separation distance as the observed
parameter. (D) Two-channel 3D trajectory of anti-Igβ Fab’-QD655 (magenta) and Fab’-
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QD585 (green) bound to two receptors that serially engaged repeatedly over 14.5 s, with
several instances of correlated motion before separating toward the end of acquisition. Data
are representative of 35 independent experiments with 697 cells. (E and F) Analysis of
displacement (magenta, jump magnitude) and degree of uncorrelated motion (green) as a
function of separation distance (between 150 to 200 nm),observed with both 697 cells (E)
and Nalm6 cells (F) . (G and H) Diffusion by state, as determined by HMM analysis. (I
and J) Distribution of dimer lifetimes in 697 and Nalm6 cells, with estimated off-rates as
predicted by HMM analysis. Interaction distances in the HMM were set to 100 and 300
nm, respectively. Data in (E) to (J) represent 26,447 trajectories in 697 cells and 2,800
trajectories in Nalm6 cells.
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BCR homotypic interactions (18). In brief, intact IgG antibodies were collected from
hybridoma culture supernatants, which was followed by controlled pepsin cleavage to
initially produce F(ab’)2 fragments. Anti-Igβ Fabs’ with exposed thiol groups (42) were
generated by incubation in 2-mercaptoethylamine (MEA) containing EDTA, followed by
covalent, maleimide-based coupling of the free cysteines to PEG2-biotin. Protein G beads
were used to remove any contaminating intact IgG or Fc fragments. Monovalent Fab’PEG2-biotin was purified by FPLC (Fast Protein Liquid Chromatography) and then mixed
1:1 with avidin-conjugated QD585 or QD655 for dual-color SPT. We then characterized
the anti-Igβ Fab’ probe (fig. S1).

Our strategy for observing pre-BCR dimers by SPT involved tagging each multi-subunit
pre-BCR with a different color of QD (QD585 or QD655) (Fig. 1A). Although there is
limited structural information for the entire pre-BCR complex, if we assume a side-by-side
orientation of all subunits, there would be approximately 80 to 100 nm between the two
bound Fab’-QD probes in a dimer. Consistent with this, we found a best fit dimer distance
between the QD probes of 100 nm with the Hidden Markov Model (HMM) to analyze large
sets of two-color tracking data (43). Through SPT imaging (Fig. 1B), we captured pre-BCR
dimerization in real time on the surface of live 697 cells [a cell line derived from a BCPALL patient (44)]. The two diffusing anti-Igß Fab’-QD probes were distinguished by
pseudo-coloring them as green or magenta dots throughout a 25-s time series. At 2.6 to 3.3
s into image acquisition, the dots were clearly overlaid, indicating the presence of dimers.
The pair became segregated at 5.9 s, which was followed by two rebinding events (at 7.3
and 13.6 s) (Fig. 1B). The Viterbi plot (45) reported the state-specific transitions of these
two receptors over time (Fig. 1C), using rate constants determined by the HMM as
previously described in detail (43). The HMM distinguished three states for mobile
receptors: (i) dimers; (ii) pairs that are transiently co-confined in the same region; and (iiii)
pairs of receptors that are widely segregated (“free”). The two receptors cycled between
dimer and co-confined states over a ~14.5-s time window, after which diffusion resulted in
their separation by a distance of > 1 μm (Fig. 1C). For this pair, homotypic interaction
lifetimes were short (<3 s).
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Our three-dimensional (3D) view of the same pre-BCR dimer pair (Fig. 1D) illustrated the
relative X and Y positions of each anti-Igß Fab’-QD probe over time. Based upon their
close proximity and correlated motion, the two pre-BCRs became dimerized at the
beginning of the imaging. Their dissociation at 5.9 s was readily apparent, which was
followed by a short reengagement period and then dissociation and diffusion in separate
directions toward the end of the image acquisition period. Additional examples of pre-BCR
dimer events were analyzed (fig. S2 and movie S1). We applied two other criteria to
evaluate dimerization (Fig. 1, E and F), which examine whether pairs of molecules in the
entire data set move independently (“uncorrelated motion”, with dissimilar jump
magnitudes) or together (correlated motion with similar jump magnitudes). These plots
show characteristic drops in pre-BCR uncorrelated motion (green lines) and jump
magnitude (magenta lines) that were a function of close separation distances, an expected
requirement for interactions. These analyses were performed for 697 cells (Fig. 1E), as
well as for Nalm6 cells (46) (Fig. 1F). These data provide statistically rigorous validation
that pre-BCR dimerization occurred frequently on the surface of two distinct BCPALL cell
lines. Analysis of the cytogenetics and the cell surface expression of BCP-ALL markers
for both cell lines was also performed (table S1).

We then compared the relative mobilities of pre-BCR monomers and dimers on the surface
of both cell lines (Fig. 1, G and H). In the free state, pre-BCRs had a relatively fast diffusion
coefficient (0.16 and 0.12 μm2/s on 697 cells and Nalm6 cells, respectively). By
comparison, the diffusion rates for interacting pairs of pre-BCRs (representing jump
distributions only during the intervals when the receptors were identified as being
dimerized) were markedly slower at 0.06 and 0.015 μm2/s on 697 cells and Nalm6 cells,
respectively. When considering the whole population of receptors (that is, not statespecific), the ensemble Mean Square Displacement (MSD) plots for pre-BCRs on these
cells were similar when either the anti-Igβ or the anti-mIgμ QD probes were used (fig. S3).
The mean diffusion coefficients for the pre-BCR on the surfaces of 697 and Nalm6 cells
were 0.13 and 0.09 μm2/s, respectively (table S2). We also summarized the number of
trajectories tracked under each experimental condition in this work (table S2).
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The dissociation of individual receptors from dimers was previously shown to be a
stochastic process, resulting in a characteristic range of dimer lifetimes that represent all of
the binding and unbinding events within a data set (43, 47). For 697 cells, most (84%) of
lifetimes of the 146 bound events were less than 2 s, with an off-rate of 1.14 +/- 0.18/s
calculated by the HMM (Fig 1I, fig. S4, and table S3). Homotypic interactions of the preBCR were slightly more stable on Nalm6 cells, as evidenced by a higher percentage of
longer lifetime binding events (43% > 2 s) and an off-rate of 0.230 +/- 0.08/s (Fig 1J, fig.
S4, and table S3). Note the correlation between the slower overall diffusion rate of the preBCR in Nalm6 cells and the slower off-rates for homotypic interactions.

Because lateral diffusion can be restricted by barriers and protein-protein interactions in a
nonlinear fashion (48), the observation of slower pre-BCR diffusion rates on Nalm6 cells
may reflect intrinsic differences in the cortical cytoskeleton, the increased size of pre-BCR
complexes and their associated adaptor proteins, or both. The possibility of self-associated
pre-BCR aggregates has been suggested previously (18, 19); their side-by-side
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Fig. 2. Galectin-1 stabilizes receptor dimerization and promotes the formation of
higher order complexes. (A) Analysis of the binding of labeled galectin-1 (red) to the preBCR (green) in 697 cells. Arrows indicate cluster formation and the colocalization of
galectin-1 with the pre- BCR. Images are representative of three experiments. (B and C)
Blocking the carbohydratebinding domain of galectin-1 with 10 mM lactose revealed
differences in displacements for the uncorrelated jump distance and the jump magnitude of
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distinct anti-Igβ probes at different separation distances. (D) Analysis of the diffusion of
the pre-BCR in 697 cells treated with galectin-1 (GAL-1) in the absence or presence of 10
mM lactose. Plots represent cumulative data from 1491 (galectin) and 1560 (galectin +
lactose) trajectories tracked over five independent experiments.
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alignment would orient them in the form of chains. A potential outcome of the five-fold
slower off-rate (Fig. 1J and fig. S4) for selfengaged pre-BCRs on Nalm6 cells, compared
to that of pre-BCRs on 697 cells, may be the greater likelihood of them forming pre-BCR
oligomers larger than dimers. We captured a pair of QD probes undergoing correlated
motion on the surface of Nalm6 cells that were further apart than the 80 to 100 nm
theoretical distance consistent with receptor dimers and their probes (movie S2). We
interpret this movie as evidence for the diffusion of homotypic pre-BCR trimers or
tetramers with the two Igβ Fab’-QD probes bound to the ends. We found that a median
distance of 227 nm was maintained by the two probes undergoing correlated motion before
blinking of the QD655 occurred (fig. S5, magenta).

Galectin leads to the formation of complex pre-BCR–glycoprotein aggregates with
slow diffusion rates
Galectin-1 binds to λ5 with high specificity (Ka =2 x 106 M-1) (36). We next evaluated
the effects of exogenous galectin-1 on the diffusion and aggregation dynamics of preBCRs. We first verified the purity of the protein used in our experiments (fig. S6A) and
took note of a structural model for monomeric galectin-1 (fig. S6B). Incubation of 697 cells
with Alexa 555–conjugated galectin-1 (red) led to the marked clustering of the pre-BCR
(Fig. 2A, green) within 5 min. The merged image shows substantial colocalization (Fig.
2A, yellow) of galectin-1 and the pre-BCR in these clusters. For these experiments, we
used 10 μM galectin-1, a concentration at which soluble galectin-1 should be >90%
dimerized (49).
We performed SPT with the anti-Igβ Fab’-QD probes to evaluate the effects of galectin-1
on pre-BCR diffusion. We observed a marked decrease in both jump magnitude and
uncorrelated motion for pre-BCRs on the surface of galectin-1–treated 697 cells (Fig. 2, B
and C). A large fraction of pre-BCR essentially became immobile (Fig. 2D and movie S3),
which is best explained by the formation of complex aggregates containing pre-BCR,
galectin-1, and other cell surface glycoproteins. To provide evidence that the marked
slowdown of the pre-BCR bound to galectin-1 could be attributed in part to carbohydratemediated lattices with other glycoproteins (37), we also performed experiments in the
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presence of excess lactose (10 mM) to block the lectin-binding site of galectin-1 (fig. S6B).
Under these conditions, we observed larger overall jump distributions for diffusing
receptors and a shorter interaction distance for the onset of correlated motion (Fig. 2, B and
C, green dashed lines). The overall diffusion rate of galectin-1– crosslinked pre-BCRs was
markedly faster in the presence of lactose (Fig. 2D), approachingvalues for pre-BCRs
under autonomous signaling conditions (table S2). Note that controls were performed with
lactose alone (see fig. S6C) to ensure that the addition of lactose in the absence of galectin1 did not alter the average diffusion behavior of the pre-BCR. Additional controls included
the treatment of cells with 2 μM galectin-1, a concentration at which galectin-1 monomers
predominate, which failed to markedly slow the diffusion rate of the pre-BCR (fig. S6D).
Thus, these data suggest that soluble galectin-1 dimers are required to provide a bivalent
ligand that binds to λ5 and promotes the aggregation of cell surface pre-BCRs (36).

Fabs against VpreB block the self-association of pre-BCRs
Our next goal was to test the effects of dimer-disrupting and dimer-stabilizing reagents
upon the overall diffusive behavior of pre-BCRs. We reasoned that monovalent antibody
fragments specific for the surrogate light chains of the pre-BCR would have potential as
dimer-disrupting reagents. As described in the Materials and Methods, we screened the
ConCIRT Synthetic Library to identify 16 phage-displayed clones that bound to
recombinant VpreB1 polypeptide. A high-affinity clone was selected for the production of
recombinant human IgG, and we then prepared anti-VpreB1 Fabs. The parent IgG bound
to the pre-BCR on the surface of 697 cells with subnanomolar affinity (fig. S7).

We then generated MSD plots (Fig. 3A) for the pre-BCR in the absence and presence of a
saturating concentration of anti-VpreB1 Fabs (1 μM). In these experiments, Fabs were
added to 697 cells for 10 min at 37°C before we performed SPT. We observed that targeting
the pre-BCR with these monovalent blocking reagents markedly increased the overall
diffusion rate of the pre-BCR. The overall diffusion coefficient for the pre-BCR on
untreated 697 cells was 0.129 μm2/s, which was slower than the rate of 0.172 μm2/s that
was observed when anti-VpreB Fabs blocked pre-BCR self-association (Fig. 3B and table
S2). For comparison, we also plotted the values for pre-BCR diffusion in 697 cells after
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treatment with galectin-1 (Fig. 3A, black lines). After crosslinking with galectin-1, a
greater percentage of pre-BCRs approached an immobile state, with an ensemble MSDderived diffusion coefficient of 0.069 μm2/s (table S2 and movie S3). We also performed
an overall comparison of the changes in jump magnitude (Fig. 3C) and uncorrelated motion
(Fig. 3D) for pairs of pre-BCRs tracked on the surface of untreated cells (red lines;
autonomous signaling) compared to those of cells treated with the anti-VpreB Fabs (blue
lines) or galectin-1 (black lines). These data underscore our observations that pre-BCR
self-association was prevented by monovalent blocking antibodies specific for the
surrogate light chain and that galectin-1 induced the formation of large-scale pre-BCR
aggregates.

Other studies suggest that early B cells are governed by a balance of finely tuned thresholds
that govern early B cell checkpoints on self-reactivity and survival (40, 41, 50). We
investigated the abundance of BCL6 protein as a readout of pre-BCR signaling under cell
autonomous and galectin-mediated crosslinking conditions. We found that BCL6 protein
abundance in 697 cells was greatest under autonomous signaling conditions (Fig. 3, E and
F, left lanes). BCL6 abundance was decreased after overnight treatment with anti-VpreB
Fabs, which inhibited homotypic interactions (Fig. 3E, right lane). Galectin-1–mediated
crosslinking of the pre-BCR, in the absence, but not presence, of lactose, led to
substantially reduced amounts of BCL6 (Fig. 3F).
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Fig. 3. Comparison of the effects of VpreB Fabs and galectin-1 on pre-BCR diffusion
and dimerization. (A and B) Ensemble MSD values (A) and diffusion coefficients (B)
revealed changes in pre-BCRs after 10 min of treatment with anti-VpreB Fabs (1 μM, blue)
or galectin-1 (10 μM, black). The two-tailed t test from MATLAB was used to confirm
statistical significance (see table S2). (C and D) Changes in uncorrelated jump distance and
jump magnitude after 10 min of treatment with either 1 μM anti-VpreB Fab (blue dotted
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lines) or 10 μM galectin-1 (black dotted lines). (E and F) 697 cells were left untreated or
were treated for 24 hours with 5 μM anti-VpreB Fab (E) or with 10 μM galectin-1 in the
presence or absence of 10 mM lactose (F) before being subjected to Western blotting
analysis with antibodies against the indicated proteins. Each blot is representative of three
or more independent experiments. Bar graphs report total densitometry data for the
abundances of the indicated proteins normalized to the abundance of actin.

Tyrosine phosphorylation and leukemia cell survival are finely tuned by autonomous
pre-BCR Signaling
We next evaluated the extent of Syk and CD79a phosphorylation under each of these
experimental conditions (Fig. 4). We found that Syk phosphorylation at Tyr348 was
detectable in lysates prepared from 3 x 107 Nalm6 cells under autonomous signaling
conditions (Fig. 4A, left lane). Furthermore, treatment of cells for 30 min with anti-VpreB
Fabs reduced the amount of Syk phosphorylated at Tyr348 by 40%. In addition, cells were
treated for 5 min with galectin-1 either alone or in combination with lactose to block the
carbohydrate-binding site of galectin-1. Addition of galectin-1 alone decreased the amount
of Syk phosphorylated at Tyr348 (Fig. 4A), whereas crosslinking in the presence of lactose
led to enhanced Syk phosphorylation on this site. This finding suggests that the inclusion
of other glycoproteins and their signaling partners in the galectin-1–pre-BCR aggregate
rapidly inhibits Syk-mediated signaling. Because the surface of BCP-ALL blasts is rich
with ITIM-containing inhibitory receptors (50), co-aggregation of pre- BCRs with these
glycoproteins might explain the reduced phosphorylation of Syk in response to galectin-1
alone. In our hands, detection of phosphorylated Syk (pSyk) under autonomous signaling
conditions often required the overexposure of Western blots. Wienands et al. previously
showed that treatment of B cells with the pan phosphatase inhibitor pervanadate reveals
kinase activity that is constitutively opposed by phosphatase activity (51). We found a ~7fold enhancement in the phosphorylation of Syk at Tyr348 after a 30-min treatment of
Nalm6 cells with pervanadate (Fig. 4A).

Because phosphorylation detection under basal conditions required large quantities of
cells, we took advantage of pervanadate to enhance the amounts of phosphorylated Igα
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(CD79a) ITAM and pSyk (Y182, Y352) (Fig. 4, B to D). We interpreted the presence of
two or more bands corresponding to phosphorylated CD79a (Fig. 4C, lane 2) as differential
mobility caused by the unequal phosphorylation of tyrosine residues in the cytoplasmic tail
of CD79a. Treatment of cells with the combination of pervanadate and anti-VpreB Fabs
resulted in the near-complete ablation of phosphorylation of both Syk Tyr182 and CD79a.
Thus, the increased phosphorylation of these proteins, revealed by inhibiting phosphatase
activity, was completely dependent on homotypic pre-BCR interactions that stimulated
autonomous signaling. Receptor phosphorylation by the Src family kinase Lyn precedes
the recruitment and activation of Syk in the canonical ITAM signaling pathway (19). There
is also evidence that once Syk is recruited to the receptor, it also participates in the
phosphorylation of ITAMs (52).

We next evaluated these early steps in the autonomous pre-BCR signaling pathway in
experiments with kinase-selective, cell-permeable inhibitors. Dasitinib is a cell-permeable
inhibitor of the tyrosine kinases Src and Abl (53). Consistent with our earlier findings and
those of others (26), we found that the addition of dasatinib to pervanadate-treated 697
cells blocked the Lyn-mediated phosphorylation of the pre-BCR, as detected by antiCD79a-pY182 antibodies (Fig. 4D). The combination of the Syk inhibitor BAY61-3606
and dasatinib abolished the accumulation of phosphorylated CD79a during phosphatase
inhibition, suggesting that trans-phosphorylation by Syk combined with Lyn activity was
required for the robust phosphorylation of CD79a. The Syk inhibitor also resulted in a 20%
reduction in the amount of pSyk phosphorylated at Tyr352, consistent with this tyrosine
residue being a substrate of both Lyn and Syk (2). Treatment of 697 cells with the Jak
inhibitor tofacitinib (54) did not substantially alter Syk phosphorylation in the presence of
pervanadate (Fig. 4E).
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Fig. 4. Western blotting analysis of pre-BCR signaling. (A) Western blotting analysis of
Nalm6 cell lysates (3 x 107cells) for Syk phosphorylation at Tyr348 (pSyk Y348) after the
indicated treatments. Blots were stripped and incubated with antibodies against total Syk
and actin. Note that the pervanadate lane is shown after gray scale adjustment of the digital
image, to adjust for the intensity of the signal for pSykY348 compared to that in resting
cells and after treatment with inhibitors. (B and C) Western blotting analysis of 697 cells
(1.0 x 106) with antibodies specific for pSyk and pCD79a (Igα) after the cells were treated
for 30 min with anti-VpreB Fab in the presence of pervanadate. (D) Western blotting
analysis of 697 cells (1.0 x 106)with antibodies against pSyk and pCD79a (Igα) after the

47

cells were treatment with BAY61-3606 (Syk inhibitor) or dasatinib (Lyn and Abl inhibitor)
in the presence of pervanadate. (E) Western blotting analysis of 697 cells (1.0 x 106) with
antibody specific for pSyk after the cells were treated for 30 min with 3AC (SHIP inhibitor)
or tofacitinib (Jak inhibitor) in the presence of pervanadate. (F) Western blotting analysis
of 697 cells (1.0 x 106) with antibody specific for total BCL6 protein after the cells were
treated for 24 hours with dasatinib, tofacitinib, or 3AC. All blots are representative of three
or more independent experiments. Accompanying bar graphs report total densitometry data
for all experiments for a given condition, with the abundance of the protein of interest
normalized to that of actin or total Syk.

48

We also demonstrated the contribution of the pre-BCR–Lyn-Syk axis in autonomous
signaling to BCL6 production, because treating 697 cells overnight with dasatinib resulted
in reduced BCL6 abundance (Fig. 4F). Overnight treatment of 697 cells with tofacitinib
increased the abundance of BCL6 protein, which we attributed to relief from a Jak-STAT
pathway that represses BCL6 transcription (Fig. 4F) (26, 55). Genetic deletion of SH2containing inositol-5 phosphatase-1 (SHIP1, also known as INPP5D) or inhibition of its
phosphatase activity with the small molecule inhibitor 3AC (3-a-aminocholestane) leads
to cell death in BCR-ABL1+ acute lymphoblastic leukemia cells (50). We also evaluated
the effects of 3AC on 697 cells. As reported previously (50), 3AC slightly increased Syk
phosphorylation in these cells (here performed in the presence of pervanadate) (Fig. 4E).
In addition, overnight treatment with 3AC alone resulted in a decrease in BCL6 protein
abundance (Fig. 4F).

Inhibitors of tyrosine kinases and inositol phosphatases differentially affect the
survival of BCP-ALL cells
We next evaluated whether anti-VpreB Fabs or our panel of pharmacologic inhibitors could
induce apoptosis in 697 cells, either alone or in combination with low concentrations of
the chemotherapeutic agent vincristine. Overnight incubation of the cells with VpreB Fabs
slightly enhanced the labeling of the cells with both 7-AAD and Annexin-V (14.9%
compared to 8.5% of untreated cells, Fig. 5A). The combination of VpreB Fabs with
vincristine (10 ng/ml) also slightly enhanced apoptosis (81.4% apoptotic cells compared to
69.9% for vincristine alone). At least for 697 cells, which lack Jak mutations known to be
present in a minor subset of BCP-ALL cases (56), treatment with tofacitinib did not directly
induce apoptosis (Fig. 5B). By comparison, both dasatinib (a Lyn inhibitor) and
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Fig. 5. Analysis of apoptosis and viability in BCP-ALL cell lines after treatment with
pre-BCR pathway inhibitors. (A) Annexin V (FITC-conjugated) and 7-AAD labeling of
697 cells after 3 days of culture in the absence (autonomous) and presence of anti-VpreB
Fabs or vincristine, as indicated. (B) 7-AAD and Annexin-V labeling of 697 cells treated
for 3 days with a range of concentrations (0.1 to 100 μM) of tyrosine kinase inhibitors
(BAY61-6306, dasatinib, tofacitinib) or inositol phosphatase (3AC). (C) 7-AAD and
Annexin-V labeling of 697 cells treated for 3 days with or without a single dose (10 μM)
of tyrosine kinase inhibitors (BAY61- 6306, dasatinib, tofacitinib) in combination with
increasing concentrations (0.1 to 100 ng/ml) of vincristine. (D) 7-AAD and Annexin-V
labeling of 697 cells incubated for 3 days with or without 3AC (0.1 to 50 μM) in
combination with increasing doses of vincristine (0.1 to 100 ng/ml). In all plots, the
percentage of cells that were 7AAD+Annexin-V+ is plotted against increasing
concentrations of vincristine or inhibitor and fit with a sigmoidal dose-response curve. All
data were acquired by flow cytometric analysis of at least 10,000 events for each condition
and are representative of xxx independent experiments.
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BAY61-3606 (a Syk inhibitor) resulted in increased 7-AAD labeling of non-viable cells
(Fig. 5B). All three inhibitors (tofacitinib, dasatinib, and BAY61- 3606; each at 10 μM)
modestly potentiated apoptosis in 697 cells treated with vincristine over a range of 0.1 to
2 ng/ml (Fig. 5C). When used at 1 μM, 3AC sensitized cells to low concentrations of
vincristine (0.1 to 2 ng/ml) (Fig. 5D). Higher concentrations of 3AC (10 to 50μM) were
required to induce direct killing of 697 cells, as determined by analysis of 7-AAD labeling
(Fig. 5D and figs. S8 to S10).

Tracking of pre-BCRs in primary cells reveals differential effects of anti-VpreB Fabs
and Lyn inhibition
The pre-BCR is absent from BCR-ABL1+ acute lymphoblastic leukemia cells (50);
however, its presence in other BCP-ALL subsets likely defines those patients for which
therapies that target autonomous signaling are of potential value (26). We identified two
distinct BCP-ALL patient samples (#280 and #238) that had measurable amounts of preBCR on the cell surface (Fig. 6). To enable repeated measurements to be made of primary
cells to validate pre-BCR diffusion and drug sensitivity studies, the patient samples were
cryopreserved on the day of acquisition and then were either placed in tissue culture
immediately after thawing or were passaged through Nod-SCID-γ2–deficient mice (a
necessary step to expand primary leukemia blasts, which have a limited lifespan in culture).
The cell surface abundance of the pre-BCR, based on quantitative binding of anti-VpreB
antibodies (fig. S11), for these two patient samples ranged from ~4000 to 15,000 copies
per cell, with average values of 6000 to 7000 (Fig. 6A). These values were very similar to
those determined from experiments with Nalm6 cells and are equivalent to about half of
the abundance of the pre-BCR on 697 cells. The pre-BCR complex is commonly assumed
to have a uniform stoichiometry of two mIgμ:VpreB:λ5 complexes to one Igα−Igβ
heterodimer; however, our flow cytometry–based quantitative measurements suggest that
both sets of patient cells had an average of 4000 Igβ molecules, whereas there were ~6500
copies of Igβ on Nalm6 cells and ~8000 copies on Igβ on 697 cells. We found that there
were slightly differing ratios (0.7 to 1.1) of mIgμ:Igβ for each cell type (Fig. 6B). We
speculate that this variability may be explained by some of the pre-BCRs being composed
of homodimers of Igβ or Igα.

51

We next performed SPT with the anti-Igβ Fab’-QD probes to evaluate the diffusion of preBCRs on untreated primary cells. We found that the overall diffusion coefficient for preBCRs on the plasma membrane of B cells from patient #238 was similar to that of 697 cells
(Fig. 6C). The range of the observed values, as well as the overall diffusion coefficient for
pre-BCRs on cells from patient #280, matched well with the diffusion characteristics of
pre-BCRs on Nalm6 cells. As an extension of the drug profiling reported earlier, we also
treated 697 cells with each of the three tyrosine kinase inhibitors and performed SPT
experiments. Treatment of 697 cells with the Lyn and Syk inhibitors (dasatinib and
BAY61-3606, respectively) increased pre-BCR mobility (Fig. 6D), as was expected given
that ITAM phosphorylation generates docking sites for signaling partners that slow
receptor diffusion. Incubation of B cells from patient #280 with either anti-VpreB Fab or
dasatinib resulted in a marked increase in pre-BCR mobility (Fig. 6E). In contrast, there
was little change in pre-BCR diffusion in cells from patient #238 after either treatment
(Fig. 6F).

Together, our earlier findings related to the diffusion and dimerization properties of preBCRs (Figs. 3 and 6) suggest that these receptors fall into at least two distinct categories.
To address potential explanations for these observations, we isolated mRNA from each of
the two cell lines, as well as from the two patient samples. After RT-PCR amplification,
we performed sequencing analysis for comparison to the reference sequence for VpreB
(UniProt #P12018). We found that a substantial fraction of VpreB sequences expressed in
each cell source differed from the reference sequence (fig. S12). Furthermore, the two
groups with distinct diffusion profiles also sorted together based upon single nucleotide
polymorphisms (SNPs). For 697 cells and those from patient #238, which had the fastest
pre-BCR diffusion rates, we documented substitutions of lysine for glutamic acid at
position 132 and glutamic acid for lysine at position 77. For Nalm6 cells and those from
patient #280, which showed the slowest overall pre-BCR diffusion rates, we found either
a 33 or 80% frequency, respectively, in substitution of asparagine for the aspartic acid at
position 76. This latter change results in a putative N-linked glycosylation site, which is
worth pursuing further because there are no N-linked glycosylation sites in the other forms
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of VpreB. With the exception of the K77E variant, all of these variants are listed on the
UniProt site as natural variants.

Fig. 6. Expression profile and single particle tracking of pre-BCRs on different
primary BCP-ALL cells. (A) Comparison of the cell surface abundances of VpreB and
CD79b (Igβ) on 697 cells, Nalm6 cells, and blasts from patients #238 and #280, as a
readout of pre-BCR on the membrane of BCP-ALL cells. Cells were incubated with
saturating concentrations of labeled fluorophore-conjugated anti-VpreB or anti-CD79b
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antibodies and binding values were quantified by flow cytometry. Results were calibrated
by saturation binding of each antibody to Simply Cellular anti-mouse IgG microspheres.
Data are representative of at least three independent experiments. (B) Comparison of the
mean fluorescent values after anti-VpreB and anti-CD79b labeling of the indicated cell
types, plotted as a ratio of pre-BCR (2 VpreB = 1 pre-BCR) to CD79b. (C) Comparison of
the diffusion coefficient (μm2/s) of the pre-BCR in 697 cells (n = 26,447 trajectories) and
Nalm6 cells (n = 3,573 trajectories) to primary cells from patient 238 (304 trajectories) and
patient 280 (353 trajectories); single particle tracking was performed onuntreated cells in
all cases and performed over multiple days. (D) Ensemble MSD plots derived from SPT of
the pre-BCR on 697 cells with or without a 10-min treatment with the indicated tyrosine
kinase inhibitors. (E) Ensemble MSD plots derived from SPT of the pre-BCR on the
surface of primary cells from patient 280 with and without a 10-min treatment with
dasatinib (1μM) or anti-VpreB Fabs (1 μM). (F) Ensemble MSD plots derived from SPT
of the pre-BCR on the surface of primary cells from patient 238 with and without a 10-min
treatment with dasatinib (1 μM) or anti-VpreB Fabs (1 μM). Data in (D) to (F) are
representative of xxx independentexperiments.
Primary BCP-ALL cells show differential sensitivity to blockade of autonomous preBCR signaling.

Given our observations that BCP-ALL cells fall into at least two distinct classes with
respect to pre-BCR mobility and their possible linkage to VpreB polymorphisms, we
evaluated whether blockade of homotypic pre-BCR self-associations might differentially
sensitize the two primary patient samples to vincristine. We found that incubation of cells
from patient #280 with anti- VpreB Fabs enhanced apoptosis, whether administered alone
or in combination with a low concentration of vincristine (Fig. 7A). Blasts from patient
#280 were also very sensitive to dasatinib as a single agent; 80% of cells were strained
with 7-AAD and Annexin-V after 24 hours of culture. Longer incubations were not
feasible, because the cells from this patient were 40% 7-AAD–positive when incubated
with no drug or in the presence of up to 5 ng/ml vincristinel (Fig. 7A, blue line).
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Blasts from patient #238, which is a high-risk case with MLL-rearrangement (table S1),
were relatively resistant to vincristine alone up to concentrations of 10 ng/ml (Fig. 7B).
Anti-VpreB Fabs did not potentiate low-dose vincristine treatment of cells from patient
#238; however, we observed a ~50% increase in 7-AAD labeling of patient #238 cells
when dasatinib was added over a range of concentrations of vincristine (1 to 100 ng/ml).
Thus, the combination of dasatinib and vincristine was effective in killing cells from both
patients, but higher concentrations of dasatinib were required to kill the cells from patient
#238. Finally, basal amounts of BCL6 protein were slightly greater in patient #280 cells
compared to those in cells from patient #238 (Fig. 7C). The addition of VpreB Fab to block
autonomous signaling decreased the abundance of BCL6 only in the cells from patient
#280 (Fig. 7C). Furthermore, BCL6 abundance was reduced or became undetectable in
cells from either patient when treated with either dasatinib or 3AC (Fig. 7D). Because the
cells from patient #238 cells harbor an MLL-AF4 fusion, they fall into a category of BCPALL that is not frequently associated with the “Ph-like” transcriptional signature (57).
Nevertheless, based upon the inhibitor studies, the basal activities of Lyn and SHIP (and
possibly Abl) apparently contributed to the survival of the cells from patient #238. As for
697 cells (Fig. 4D), BCL6 abundance in both sets of primary cells was markedly increased
in response to the Jak inhibitor tofacitinib, which suggests that BCL6 expression was
repressed by the Jak-STAT pathway. Together, our results suggest that agents targeting the
pre-BCR or its downstream partners lead to lymphoblast killing in vitro. However, the
extent to which this will apply in a clinical setting will require further evaluation, including
analysis of surrogate light chain polymorphisms as well as of the abnormal activation of
alternative tyrosine kinase signaling pathways linked to specific mutations in non-pre-BCR
pathways.
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Fig. 7. Flow cytometric and Western blot analyses of primary BCP-ALL cells after
treatment with tyrosine kinase inhibitors or anti-VpreB Fab. (A and B) Left: Plots
show Annexin V (FITC-conjugated) and 7-AAD labeling of primary cells from patient
#280 (A) and patient #238 (B) after 24 hours of culture with or without anti-VPreB Fabs
(5 μM ) or vincristine (1 to 100 ng/ml) as indicated. Right: Scatter plots report flow-based
measurements of primary cells from patient 280 (A) and patient 238 (B) that were double
labeled for 7-AAD and Annexin- V after 24 hours of culture with or without a single dose
of anti-VpreB Fab (5 μM), vincristine (10 ng/ml), or both, as indicated. All data in (A) and
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(B) were acquired by flow cytometric analysis of at least 10,000 events for each condition
and are representative of xxx independent experiments. (C) Western blotting analysis of
cell lysates (1.0 x 106 primary cells each) for patients 280 or 238 to compare the relative
abundance of BCL6 protein after the cells were treated for 24 hours with dasatinib (10 μM)
or anti-VpreB Fab (5 μM). (D) Western blotting analysis of cell lysates (1.0 x 106 cells)
from patients 280 and 238 to compare the relative abundance of BCL6 protein after the
cells were treated for 24 hours with BAY61-6306, dasatinib, tofacitinib, or 3AC. Each blot
is representative of three or more independent experiments. Bar graphs show total
densitometry data for all experiments for a given condition, with the abundance of the
protein of interest normalized to that of actin.

DISCUSSION
Seminal studies over 20 years ago led to the discovery of the surrogate light chain
components, VpreB and λ5, which proved to be critical for the cell surface expression of
the μH chain in early B cells (58). The assembly of Igμ with surrogate light chain
components generates a functional cell surface receptor that signals the successful
recombination of the heavy chain, initiates a burst of pre-B-cell proliferation, and then sets
the stage for cell cycle arrest and the recombination of light chain–encoding genes (59).
Reviews have covered critical aspects of the pre-B cell checkpoint, including the proximal
events associated with pre-BCR signaling (19) and complicated transcriptional regulation,
which are important to control B cell development and avoid autoreactivity (60). These
checkpoints are often overridden in the pre-B leukemia setting (25).

We chose to study the pre-BCR in the context of BCP-ALL, which is one of the most
prevalent neoplasms in children (61) and an aggressive cancer in adolescents and adults
(62). Although therapies have markedly increased the number of relapse-free patients in
the past 40 years, there remain inherent concerns with existing treatments (63). Among
these include the association of early chemotherapeutic administration with serious effects
that alter early and late life stages (64). Considering these factors and the fact that highrisk leukemia outcome appears to have generally plateaued with conventional therapy (65),
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a push for new therapeutic approaches and agents is of rising importance. Based on success
in mature B cell neoplasms (66-68), the pre-BCR and its signaling partners (31) may also
offer new promise for targeted therapy in BCP-ALL.

We focused here on the earliest events in pre-BCR signaling: the homo-oligomerization
that drives autonomous signaling. We applied state-of-the-art imaging techniques to
demonstrate the highly transient nature of homotypical pre-BCR interactions. These
interactions influence pre- BCR diffusion in the plasma membrane of early lineage B cells.
We found that pre-BCRdiffusion in 697 cells and blasts from patient #238 was relatively
fast at ~0.12 μm2/s (table S2 and Fig. 6C). HMM analysis of >50,000 trajectories in 697
cells enabled these trajectories to be further divided into 2 groups: The fast group, traveling
at 0.16 μm2/s, were considered “free” QD-tagged receptors and assumed to be mostly
monomers, with the caveat that interactions with dark receptors cannot be captured under
these SPT imaging conditions. The slow group, traveling at 0.059 μm2/s, represents QDtagged pairs during the intervals in which they are engaged in homotypic interactions (Fig.
1G). It is likely that the slow population also reflects the transient residency of the preBCR in protein islands, which is already described as a mechanism to cluster the TCR and
BCR in lymphocyte membranes (69, 70). Our results, which capture repeated interactions
between the same pair of pre-BCRs (Fig. 1C), are consistent with the transient coconfinement of pre-BCRs in these specialized membrane microdomains and within
cytoskeletal corrals.

Diffusion of the pre-BCR in the plasma membranes of Nalm6 cells and patient #280 blasts
was slightly slower overall at ~0.09 μm2/s, with values of 0.12 μm2/s for free receptors
and 0.015 μm2/s for receptors engaged in homotypic interactions. The slower diffusion
rates for Nalm6 receptors in the bound state might reflect the five-fold slower off-rate for
pre-BCR in Nalm6 compared to 697 cells (Fig. 1J and fig. S4), and therefore a greater
propensity to form slow-moving, higher-order oligomers. We observed several instances
in Nalm6 cells in which interacting pre-BCR pairs had an interaction distance >100 nm
(fig. S5 and movie S2). Similarly, single-molecule imaging studies of the BCR
demonstrated that higher affinity interactions support an enhanced ability of the receptor
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to oligomerize (71). We do not currently have a definitive explanation for the two distinct
off-rates that we observed for the homotypic pre-BCR interactions on different BCP-ALL
cells, but we speculate that it could be because of the observed VpreB SNPs that we
documented for this group (fig. S12A). Of particular interest is the SNP variant that
introduces a putative N-glycosylation site (substitution of asparagine for aspartic acid at
position 76). A 3D structural model based upon the solved NMR and X-ray crystal
structures of the pre-BCR (fig. S12B) reveals that this amino acid (and any putative
posttranslational modification) is at a protein surface that is exposed to be solvent.
Differential N-glycosylation of Asn46 of the pre-BCR heavy chain was previously noted
to have a major influence on pre-BCR autonomous signaling, possibly by neutralizing an
inhibitory influence imposed by the arginine-rich λ5 tail of the surrogate light chain (15).
The substitution of lysine for glutamic acid at position 132, seen in those 697 cells with a
faster off-rate for pre-BCR homotypic interactions, could also reflect the change in charge
near the putative VpreB dimerization site (17).

The BCRs of naïve and mature B cells have been the subject of impactful, high-resolution
imaging studies (22, 70-73) that provide a context for the current work. BCR diffusion
rates in the absence of ligand are generally slower than those of the pre-BCR, with
variability amongst B cell sources and across imaging conditions. For example, BCR
diffusion in J558L B cells was measured in TIRF mode on antigen-free lipid bilayers to
have a range from 0.039 to 0.069 μm2/s (71). Up to 20% of BCRs are immobile under
those conditions (D < 0.01 μm2/s). On the surface of A20 B cells, wild-type IgM BCR
travels at an average rate of 0.031 μm2/s, with the caveat that those IgM BCRs that are
outside actin-rich regions diffuse at a faster rate (0.108 μm2/s) than that of BCRs within
actin-rich membrane (0.039 μm2/s) (22). The heavy chain moiety of BCR is very
influential, because the IgD BCR exhibits very slow diffusion (0.005 μm2/s) (22). The
cellular context also matters, particularly the influence of the actin cortical cytoskeleton,
which forms corrals to restrict receptor motion (24). The BCR undergoes faster diffusion
in B cells treated with latrunculin A (22) or in cells stimulated with ligands for Toll-like
receptors, which induce cofilin-mediated severing of actin filaments (73). We speculate
that variability in the cortical actin cytoskeleton of Nalm6 and 697 cells and in cells from
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the two primary patients could contribute to our observed differences in pre-BCR diffusion
rates.

Our experimental design was inspired by mutagenesis and structural studies that implicate
the unique regions of λ5 in pre-BCR homotypic oligomerization for ligand-independent
signaling (17, 18). We reasoned that Fabs directed at the VpreB component of the surrogate
light chain would sterically block λ5-mediated homodimerization. This strategy was
successful, because incubation with these monomeric antibody fragments resulted in faster
pre-BCR diffusion rates and a marked reduction in observed dimerization events.
Furthermore, the Fabs also blocked the accumulation of pCD79a and pSyk in the presence
of pervanadate and H2O2, a strategy that reveals the close control of autonomous signaling
by phosphatases (51). Kinetic proofreading is proposed as a generalized schema by which
the number of receptors occupied and the duration of receptor occupancy translate into
functional signals (74). In the absence of high-affinity interactions, frequent rebinding
events associated with spatial confinement appear to provide the TCR a mechanism to
propagate even weak signals (75). We speculate that frequent, low-affinity rebinding
events also provide exactly the right threshold needed for the pre-BCR to maintain the
narrow window for early B survival.
Galectin-1 binds to the λ5-UR domain of the pre-BCR (35) and, although this interaction
is independent of the glycan-binding site of galectin, engagement with the pre-BCR
induces local conformational changes that alter the affinity of galectin-1 for carbohydrates
(37). Thus, it was important to evaluate the behavior of pre-BCRs that were crosslinked
with soluble, dimeric galectin-1 in the presence and absence of lactose to distinguish
“lattice-like” complexes, which include other cell-surface glycans, from dimers and chains
of pre-BCRs and galectin-1 alone. We showed that the pre-BCR rapidly became immobile
after the addition of galectin-1 alone (Fig. 3B and movie S3), forming clusters that were
large enough to observe by standard epifluorescence techniques (Fig. 2A). Inclusion of
lactose during galectin-1–mediated crosslinking disrupted complex, glycan-mediated
aggregation, which was observed as a substantial change in the values for uncorrelated
jump distance (Fig. 2B) and jump magnitude (Fig. 2C), as well as in overall diffusion (Fig.
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2D). It is remarkable that galectin-mediated crosslinking in either context did not support
accumulation of BCL6 protein. The need for a perfectly tuned autonomous pre-BCR signal
was previously described as the “Goldilocks” threshold that optimally supports the PI3KAkt pro-survival pathway (76, 77). The role for galectin-1–mediated crosslinking of the
pre-BCR in ALL deserves further study. There may be a difference between galectin-1–
mediated pre-BCR signaling when galectin-1 is produced as a soluble autocrine factor (a
notable feature of MLL-rearranged BCP-ALL cells) (39) versus galectin presentation on
the surface of stromal cells (78). It has been proposed that early B cells occupy different
bone marrow niches as they progress from dependency on IL-7 to stromal presentation of
galectin (16).

One challenge will be to identify those BCP-ALL patients for which pre-BCR targeted
therapy is appropriate, because there are multiple mechanisms that enable leukemia cells
to bypass the pre- BCR checkpoint (25). A recent study of 830 cases from four clinical
trials identified 13.5% of patients as being particularly reliant on autonomous pre-BCR
signaling (26). On face value, the two patient samples (#280 and #238) that we studied here
would fall within this class, because they expressed pre-BCR on the cell surface and were
sensitive to dasatinib (Fig. 7). However, only one patient sample (#280) exhibited faster
diffusion of the pre-BCR after exposure to anti- VpreB Fabs, which was accompanied by
an increase in the fraction of apoptotic cells. This indicates that the cell surface expression
of the pre-BCR alone does not predict reliance on autonomous signaling for survival.

Important BCP-ALL subsets rely on aberrant Abl or Jak signaling pathways, indicating
that they are arrested very early in the B cell developmental process. Twenty-five percent
of BCP-ALL cases express BCR-ABL because of a 9:22 translocation (Philadelphia
chromosome, Ph+), and their responses to BCR-ABL kinase inhibitors can be short-lived
(79). A “Ph-like” transcriptional signature has been linked to poor outcome in 10% of
childhood ALL and 27% of adult ALL cases; the novel translocations and activating
mutations associated with Ph-like ALL involve a number of cytokine receptors (FTL3, IL7R, CRLF2, EPOR, PDGFRB, TSLF) and their associated signaling partners (kinases of
the Jak and Abl families) (80). It appears that the ITAM-Syk and the ITIM-phosphatase

61

are operating in the background of these oncogenic signaling pathways, because inhibitors
of both pathways can stimulate pre-existing B cell programs for cell death (50). ITIMbearing receptors (including, PECAM1, CD300A, LAIR1, and CD22/SIGLEC-2) are
expressed in BCP-ALL cells, where they serve critical roles in recruiting the tyrosine and
inositol phosphatases SHP1 (PTPN6) and SHIP-1 (INPP5D), respectively (50, 81).
Whereas SHIP-1 acts as a mediator of negative signaling from ITIM-bearing receptors in
immune cells, SHIP-1 is important in negative regulatory loops downstream of the BCR
(82). SHIP-1 can be engaged under conditions that promote the incomplete
phosphorylation of Igα and Igβ ITAMs, which favors the recruitment of single SH2
domain– bearing phosphatases over the recruitment of the dual SH2 domain–bearing
kinase Syk (83). The Lyn–SHIP-1–PTEN–SHP1 negative regulatory axis is an essential
and constitutively engagedregulator of the BCR, particularly in the context of anergy (83,
84).

The complexities of the pre-BCR and its downstream partners (Syk, SLP65, and BCL6)
alternatively serving as oncogenes or tumor suppressors have been reviewed (25). Central
to understanding this complexity will be accurate maps of the stage-specific transcription
factor network, which normally coordinates B lymphoid progression, and how disruption
at key checkpoints leads to oncogenesis (85). We expect that improved understanding of
pre-BCR dynamics and signaling outcomes, begun here with the current study, will be
particularly important as tyrosine kinase inhibitors are incorporated into BCP-ALL
therapy. Because of complex regulatory feed-forward and feed-back loops in early B cell
development (26, 41, 85), it is critical to understand if low-level pre-BCR signaling events
offer potential sources of drug resistance when the strongly proliferative signals from BCRABL and mutant Jak-STAT signaling pathways are suppressed. The exquisite sensitivity
of BCP-ALL cells to inhibitors of Lyn, Syk, and SHIP-1, as shown here, underscores that
a substantial number of BCP-ALL cases are likely to benefit when chemotherapy and
kinase inhibitors are administered in combination This concept has already been
demonstrated in an animal model of Ph+ ALL, combining dasatinib (which inhibits Abl
and Lyn) with ruxolitinib (which inhibits Jak) (86). Serial administration or
immunotherapy may be possible if toxicity is a barrier when chemotherapeutics and kinase
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inhibitors are co-administered.
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CHAPTER 3
Molecular Dynamic Simulations of Galectin-1 with Carbohydrates:
Influence of Binding to pre-BCR 5-UR
M. Frank Erasmus1, César A López2, Bridget S. Wilson1 and S. Gnanakaran2
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Department of Pathology, University of New Mexico, Albuquerque, New Mexico
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ABSTRACT
Early B cell development requires functional expression of the pre-B cell receptor (preBCR) composed of the Igµ heavy chain associated with surrogate light chain components,
5 and VpreB. Precursor B cells pass the first critical development checkpoint based upon
appropriate survival signals mediated through the pre-BCR. This autonomous signal is
initiated through transient pre-BCR/pre-BCR homodimers and is important in both B cell
development and malignancies. In contrast, the binding of Galectin-1, a known pre-BCR
ligand, promotes the formation of complex higher order oligomers. This complex
modulates important signals required in early B cell development and may also have an
important role in leukemia progression through crosstalk with stromal cells in the bone
marrow microenvironment. Galectin-1 is known for its glycan-binding properties, which
promotes cell-to-cell contacts between precursor B cells and bone marrow stromal cells
and forms a galectin-1 dependent signaling niche. Upon binding the pre-BCR’s 5 subunit,
galectin-1 undergoes a conformational change within its carbohydrate-binding site (CBS)
altering its affinity for N-acetyllactosamines (LacNAc) on the stromal surface in favor of
glycoreceptors on the precursor B cell membrane. This remodeling of the galectin binding
preference can potential lead to differential crosslinking of the pre-BCR with cell surface
glycoproteins and glycolipids, modifying signaling outcomes downstream of the pre-BCR.
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Here we use molecular dynamics (MD) simulations to study how the pre-BCR 5/galectin1 protein-protein interaction modifies the carbohydrate binding properties of galectin-1.
The MD results support recent experimental findings that implicate critical conformational
changes within galectin-1’s conserved binding core. These structural modifications disrupt
the hydrogen bonding network and aromatic stacking interactions that are central to
galectin-1/carbohydrate interactions. Computational calculations of binding free energies
exhibit a distinct reduction in the affinity for LacNAc molecules induced by pre-BCR
binding. Our results also suggest that the pre-BCR 5/galectin-1 interaction also influences
galectin-1’s dimer/monomer equilibrium.
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INTRODUCTION
Functional expression of the pre -B cell receptor (pre -BCR) is an essential
checkpoint in the early stages of nor mal B cell development. The first step in
pre -BCR expression i s the successful rearrangement of the i mmunoglobulin
heavy chain (HC or Igµ), which is then co -expressed with the 5 and VpreB
components of the surrogate li ght chai n (SLC)(1). Igµ and SLC assemble with
Ig and Ig signaling subunits in the endopl asmic reticulum soon after synthesis
(2), then traffic as an oligomeri c pre -BCR to the cell surface. Once resident at
the plasma membrane, pre -BCRs diffuse in t he membrane and undergo transient
homo -di merization events that propagate weak, li gand -independent signaling (3).
Referred to as autonomous or “tonic” si gnaling (4, 5) transient pr e -BCR homo oligomerization engages the src famil y kinase, Lyn, for phosphor ylation of Ig 
and Ig immunorecept or tyrosine -based acti vation motifs ( ITAMs) (6). Duall y
phosphor ylated ITAMs ser ve as docki ng si tes for the Src homology 2 (SH2)
domains of spleen t yrosine kinase (Syk), the critical kinase responsible for
driving healt hy B cell development. Dysregulated pre -BCR si gnali ng pathway is
emer ging as an i mpor tant contributor to early stage B cell malignancies (7).
Recently, it has been shown that autonomous signals mediated through the pre BCR leads to increased BCL6 expression i n B cell precursor acute leukemia
(BCP-ALL) (8), dri vi ng a positi ve feedback loop that results in worse clinical
outcome in subpopul ations of leukemi a patients. While targeting the homo di merization interface with monovalent Fabs has shown promising r esults in vitro
(3), evi dence suggests that alternative mechanisms can dri ve pre -BCR si gnaling
following interactions with extracellular proteins within the bone marrow.

Galectin -1, expressed in wide variety of tissues including bone marrow (9), is a
pre -BCR li gand (10). Galectin -1 mediates cell -to-cell contacts bet ween the pre B cell and stromal cel ls, through both carbohydrate/protein and pr otein/protein
interactions (10-12). Upon galectin -1 binding on stromal cells, the pre -BCR
redistributes to one pole to for m a “devel opmental synapse” at the cell -cell
interface and initiate robust downstream phosphor ylation

(12, 13). This

interaction likely plays an i mportant role in early healthy precursor B cell
development, as these cells mi grate from an IL -7+-dependent niche to a galectin -
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1+ niche within the bone marrow (13, 14). T he galectin -1+ si gnaling niche also
has an i mportant role contributing to B cell survi val (14, 15).
Galectin -1 is a member of the large famil y of  -galactoside binding lectins, each
with a highl y conser ved carbohydrate recognition domain (CRD) (16). Galectin 1 is a homodi mer in solution composed of two identical 14.5kDa monomers.
Galectin -1 folds into a  sandwich topology with t wo antipar allel  -sheets
for ming a concave and convex side. The concave side creates a groove composed
of five subsites (A -E) that are responsible for carbohydrate binding. Subsites C
and D represent the conserved core responsible for  -galactoside interactions .
This includes an electrostatic interactions mediated through a hydrogen bonding
networ k from hydroxyl groups within the carbohydrate and key residues within
galectin -1 (His -44, Asn -46, His -52, His -54, Ar g-48, Trp -68, Glu -71, and Ar g-73)
and detailed previously (17). This also includes a key hydrophobic aromatic
stacking interaction mediated through the galactosyl of the carbohydrate and six membered ring of Trp -68 in galectin -1. Though each CBS appears structurally
independent, evidence suggests t hat binding of a saccharide wit hin one CBS
results in increased confor mational entropy t hat drives negati ve cooperativit y of
binding in the CBS of adj acent site when binding to the same carbohydrate (18).
Recent NMR data has shown that galectin -1/pre -BCR binds directly to the 5
subunit of the pre -BCR surrogate li ght chai n, tar geting the N -ter mi nal unique
region ter med “ 5-UR” (11). This protein/protein interaction interface is in close
proxi mit y to amino acid residues contributing to carbohydrate affinity and has
been shown to alter galectin -1’s carbohydrat e binding affinity (19) . A plausible
model ( 19) proposes t hat, in the bone marrow, galectin -1 is initial ly bound to N acetyl galactosami ne ( LacNAc) -gl ycosylated receptors on stromal surfaces. Upon
pre -BCR engagement, galectin -1 then undergoes a confor mational change that
alters its carbohydrate affinity. This frees the carbohydrate -binding site (CBS)
of galectin -1, which now has differential preference for select saccharides,
altering the crosslinking complexity of galectin -1 and the pre -BCR with
gl ycolipids and gl ycoproteins in the microenvironment.

It is i mportant to note

that the affinity of galectin binding to the pre -BCR is not changed by the presence
or absence of the carbohydrate (11). We recently showed that i nhibiting the
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lectin-binding properties of galectin -1 with saturating concentration of lactose
modulates the downstream signaling profile in pre -BCR+ leukemic B cells to
galectin challenge (3).

Prior experi mental and computational methods have raised many questions
regarding galectin -1 r egulation (17, 18, 20 ). The accommodation of different
sugars in the carbohydrate binding pocket suggests considerable fl exibility, but
fails to provide detailed explanations for galectin -1’s enhanced affi nity for select
sugars. A recent repor t made the intri guing observation that pre -BCR/ galectin -1
engagement alters gal ectin -1 affinity for specific saccharides (19).

Here, we

employ molecular dynamics si mulations to evaluate how carbohydrate binding
properties of galectin -1 are altered in presence and absence of 5-UR of the pre BCR. We also explore the i mpact of carbohydrate or 5-UR binding on galectin 1 di meri zation. MD simulations are useful in studying allosteric effects

because the enhanced level of molecular detail at both spatial and temporal
scales and can be used to incorporate specific perturbations into the
biomolecular system (21). Allostery has shown as an important for
regulation of protein function and MD simulations have enabled scientists
to

elucidate

function

in

variet y of

biologi cal

processes

including

immunological escapes (22), drug-design (23), and protein engineering
(24). Mechanisticall y, we note galectin -1 in complex with the pre -BCR
under goes a si gnificant alteration of the hydr ogen bonding networ k , resulting in
increased overall fluct uation and destablizat ion of the conser ved carbohydrate binding core. Our si mulations support recent findings (19) that show binding of
5-UR to galectin -1 induces structural changes within subsite D of the CBS that
disrupts key interact ions to specific gl ycans., We also observed a si gnificant shift
in aromatic stacking interactions between Trp68 of galactin -1 and t he galactosyl
ring, which can modulate between more favorable or less favorable distributions
dependent on the carbohydrate d ocked in the CBS. We are the first to report that
pre -BCR engagement mi ght also i mpact galectin -1 di mer stability.

METHODS
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Systems Set -Up
Carbohydrate construction
The complete galectin -1 homodi mer was used as a structural framework for these
studies.

Four

differ ent

galectin -1

X -Ray

structures

bound

to

different

carbohydates were obt ained from the protein data bank . Sugars used in this study
are detailed in Figure 1. These include sugar 1A, ( gal( 14)glcNAc) (pdb
id:4Y1U); sugar 1B ( gal( 14)(6CO2) gl cNAc) (pdb id: 4Y1Z), sugar 2A
(gal( 13)glcNAc) ( pdb id: 4Y1V); sugar 4A (neu5Ac( 23) gal( 14)glc)
(pdb id: 4Y20). We used galectin -1 X -Ray structure (pdb id: 1GZW) for the
unbound structure. The coordinates of the sugar neu5Ac( 23) gal( 14)glc,
sugar 4A, bound to galectin -1 were copied and moved to a separate file. We
added an N-acet yl group to the 3’ -carbon usi ng Mar vin Sketch and validated with
the 3D structure check tool (25) . This sugar ( see sugar 4B , Figure 1) was named
neu5Ac( 23) gal( 14)glcNAc
gal( 14)glcNAc

was

neu5Ac( 23) gal( 14)glc

throughout

superi mposed
bound

to

to

text.
equi valent

galectin -1.

Neu5Ac( 23) carbons

within

Lact oNNeotetraose

(gal( 14)glcNAc( 13)gal( 14)glc) (see sugar 3A,B, Figure 1 ) was
constructed using the GLYCAM Carbohydrat e Builder Online Software tool (26).
The carbons ( C1 -C6) of non -t er minal and ter minal gal(  14)glcNAc and
gal( 14)glc groups of the gal(  14)glcNAc( 13)gal( 14)glc (see red
outline, Figure1 - sugar 3A,B ) were super imposed within

gal(  14) glcNAc

and gal( 14)glc , respectivel y, using the Chi mera Software suit e (27).
Docking of  5-unique region to galectin -1
The pre-BCR 5-unique region ( 5-UR) that interacts directly with galectin -1
was recentl y sol ved by 1 H TOCSY and t wo -di mensional

1

H NOESY experi ments

(11). CD measurement s confir med a low level -helical secondar y structure (19).
The coordinates of this 24 -mer peptide 5-UR 2 2 - 4 5 were obtained from the protein
data bank (pdb id 2l kq). The 5-UR (renumbered 1 -22) was docked to galectin -1
(pdb id: 4Y20) cha in A using the online ZDock ser ver (28). This method
incorporates shape complementarit y, desol vation free energy and electrostatic
scoring functions into the docking al gorithm. Shape complementarity invol ves
the explicit rotation (15° increments around each Cartesian angle) and translation
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of the ligand with respect to a fixed receptor. For each rotational transfor mation,
a Fast Fourier Transfor m (FFT) algorithm scans the translational space. Two
shape complementarity functions for the receptor and ligand R S C and L S C are used
to describe the geo metric characteristics of the receptor (i.e. galectin -1) and
ligand (λ5 -peptide), r espectivel y. An N x N x N grid is established with 1.2Å
spacing, with N sufficiently large to cover maxi mal spans of receptor and ligand.
The surface and core of the protein are identified by computing sol vent accessible
area with a water pr obe radius set to 1.4Å. Core grid points are set to predefined
penalty scores as det ailed (28). Shape complementarit y scores could then be
calculated using a cor relation function between functions R S C and L S C . Surface
grid point contacts contributed to positive correlation (with 1.0 being opti mal),
while core -core contacts contribute to a large negati ve penalty. Surface -core
contacts results in a milder penalt y co mpar ed to core -core contacts. A discrete
Fourier Transform (DFT) and Inverse Fouri er Transform ( IFT) function are used
to calculate the correlation between the two separate R S C and L S C f unctions. The
next phase of the ZDock al gorithm incorporates desolvati on free energy which
implements atomic contact energy ( ACE) developed by Zhang et al (29). These
desolvation ener gies are the free ener gies associated with replaci ng a protein atom/water contact wi th a protein -atom/prot ein atom contact. Finally, Z -Dock
also uses electrostatics, which uses the Coulombic for mula and partial charges
derived from the CHARMM19 (30). Each of these criteria are combined whereby
top prediction models are produced. ZDock reduces the overall search space by
setting restraints to the receptor and ligand binding partners and/or through the
exclusion of residues not i mplicated in the binding interaction. W e set initial
binding restraints to conserve the key electrostatic and hydrophobi c interactions.
Electrostatic interactions include Ar g -6 and Ar g-8 of 5-UR to Asp -102 and Glu 74 of galectin -1, respectivel y. Hydrophobic interactions include Trp9 of the 5UR buried within Val76, Tyr104 and Phe106 of galectin -1.

Solvating galectin -1 f or MD simulations
This galectin -1/5-UR model was equilibrated in a cubic box and solvated with
~18,000 T IP3P water molecules, with 150mM of Na and Cl ions. Counter ions
were added to the system to maintain neutr ality. Periodic boundary conditions
were applied in x, y and z directions. Al l system set -up, equi libration and
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simulations were conducted using the GROMACS package (31, 32), version 5.1
and run on li nux super computer cluster using multiple CPU nodes coupled with
GPU acceleration.
Homology model of carbohydrates to galectin -1/  5-UR
After ener gy mini mi zation and equilibration a 1ns production MD si mulations
was conducted on the galectin -1/5-UR complex (see MD Computational Details
for additional infor mat ion). The final frame was collected and anal yzed to ensure
key galectin -1/pre -BCR interactions were maintained (i.e. Tpr -9 of 5-UR buried
within galectin -1 pocket). This equilibrated structure was used to construct a
homology model of each galectin -1/carbohydrate complex. This was achieved
using the MODELLER software package (33) using multiple template alignment.
The carbohydrate -binding site of chain A was modeled by ali gning residu es 1 to
73 with galectin -1 bound to carbohydrate (without 5-UR). Resi dues 74 to 134
of chain A were ali gned to mi mic the galecti n -1/5-UR binding region. All chain
B residues (with no sugar or 5-UR) wer e aligned using averaging of both
template structure s. Five models were generated and the top structure for each
sugar was selected based upon best DOPE score (34). All str uctures were
analyzed using RMSD whereby protein residues showed < 0.1nm RMSD deviation
from X -Ray structure and the carbohydrat es were aligned with an identical
starting orientation.

Topology generation using ACPYPE tool
The 3D coordinates fr om each carbohydrate docked into galectin -1’s CBS were
processed separatel y t o prepare them with appropriate parameters for use in MD
simulations. Hydrogens were added using the AddH function in Chi mera sof tware
(35). Protonated structures were output with the mol2 for mat and used as input
for ACPYPE, which was used to generate carbohydrate topologies and parameters
for MD si mulations compatible with AMBER99SB force field in GROMACS. The
AnteChamber Pyt hon Parser (ACPYPE) (36) interface is a wrapper script for use
with the ANTECHAMBER software (37).

MD Computational Details
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Parameters from the AMBER99SB parameter set (38) were appli ed and short range non -bonded interactions were cut off at 1.0nm. Long -range electrostat ics
were calculated using the Particle Mesh Ewald (PME) al gorithm (39) and the
model was ener gy mi ni mized using steepest descent algorithm ( 40). Position
restraints were applied to the heavy atoms and a constant volume (NVT) ensemble
simulation was conducted for 100ps. During NVT (and NPT) equilibration, the
protein/sugar and non -protein atoms were coupled to separate temperature baths
and maintained at 310K using the V -rescale scheme (41) to maintain pressure
isotropically at 1.0bar for 100 ps. Next, constant pressure (NPT) equilibration
was conducted with Parrinello -Rahman barostat (42, 43) to maintain pressure
isotropically at 1.0bar for 100ns. For NVT and NPT equilibration, temperature,
density and pressures were plotted over time to ensure the values conver ged.
Preliminar y production MD si mulations were conducted without restraints for
30ns, unless other wise stated, whereby the V -rescale ther mostat and Parinello Rahman barostat were applied.

MD Analysis
Dihedral Angle and Aromatic Stacking Measurements
For dihedral angle calculation for the carbohydrate molecule we used the
intergl ycosidic linkage between the  -galactosyl ring and the glucosyl ring
within galectin -1’s conserved binding core ( subsite C and D) . The dihedral /
torsion angles were defined by ( O 5 -C 1 -O 1 -C n ’ and C 1 -O 1 -C n ’ -C n - 1 ’) for the  13
and  14 intergl ycosi dic linkages as detailed previousl y (44, 45).

Two criteria fulfill the aromatic stacking int eraction: 1) stacking angle bet ween
planar rings and 2) centroid distance between the COM of the different rings
(17). By taking the nor mal vectors proj ecting from the centroid of the aromatic
ring of Trp68 and pyranose ring of galactosyl group of the carbohydrate, we can
measure the stacking angle between these t wo groups. If t wo aromatic rings sit
parallel to one another the angle would have a value of 180º. For the second
criterion, the distance (R) from the centroids of the galactosyl ring of the
carbohydrate and aromatic ring of Trp -68. Again we onl y consider t he galactosyl
ring bound to conser ved galectin -1 C/D subsite.
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Principal Component Analysis
We used principal component (PCA) analysis to gain insi ght into internal
fluctuations of galectin -1 in presence of pre -BCR relative to unbound state. An
in-depth mathematical formalism for princi pal component anal ysis (PCA) is
found elsewhere (46) . In brief, the center -of -mass of each configuration of
galectin -1 bound to 5-UR (C-carbons of galectin -1 onl y) were translated to the
origin. Atoms are then subj ect to rotational least squares fit to a reference (i.e.
galectin -1 unbound to 5-UR). Diagonaliza ti on of a variance -covar iance matrix
of

positional

fluctuations

is

perfor med

using

an

orthogonal

coordinate

transformation. This transfor ms the symmetri c covariance matrix, which contains
the eigenvalues ( ). Each column of the diagnolized matrix contains the
eigenvector or princi pal component. The mean square positional fluctuation
along a gi ven ei genvector is represented by each ei genvalue, whi ch represents
the contribution of each principal component to the total fluctuation. It has been
shown that the f irst 10-20 ei genvectors contribute to 90% of the total fluctuations
of the protein (47). The RMSF of the first 10 eigenvec tors of the PCA are plotted.
The covariance and matrix and r msf values were extrapolated using the covar and
anaeig tools in GROMACS.

Iterative Linear Interaction Calculations
We applied a slightly altered method proposed by (48) that employed an iterati ve
LIE method to exclude configurational transitions and appl ying weighted factor
to the LIE eq uation (49).

𝑾𝒊 =

𝒆

−∆𝑮𝒄𝒂𝒍𝒄,𝒊
𝒌𝑩 𝑻

∑𝑵
𝒊 𝒆

−∆𝑮𝒄𝒂𝒍𝒄,𝒊
𝒌𝑩 𝑻

(1)

where W i is the wei ght ed factor used below i n equation 2. W i depends on the free
energy of binding that is deter mi ned from each respecti ve si mulation (∆G c a l c , i ).
T is the temperature ( Kelvin) and k B is the Boltzmann constant. Each si mulation
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(i) is run over total N number of si mulations. This weighted f actor is then
incorporated into a weighted LIE equation pr oposed previousl y (50).

∆𝑮𝒄𝒂𝒍𝒄 =
𝒗𝒅𝑾
𝒗𝒅𝑾
𝑵
𝒆𝒍𝒆𝒄
𝒆𝒍𝒆𝒄
𝜶 ∑𝑵
𝒊 𝑾𝒊 (〈𝑽𝒍𝒊𝒈−𝒔𝒖𝒓𝒓 〉𝒃𝒐𝒖𝒏𝒅 − 〈𝑽𝒍𝒊𝒈−𝒔𝒖𝒓𝒓 〉𝒇𝒓𝒆𝒆 ) + 𝜷 ∑𝒊 𝑾𝒊 (〈𝑽𝒍𝒊𝒈−𝒔𝒖𝒓𝒓 〉𝒃𝒐𝒖𝒏𝒅 − 〈𝑽𝒍𝒊𝒈−𝒔𝒖𝒓𝒓 〉𝒇𝒓𝒆𝒆 )

(2)

With the scaling parameters  and  for the van der Waals and electrostatic
contributions, respecti vel y. The bracketed ter ms represent the van der Waals or
electrostatic interaction of ligand and its surr oundings. A key assumption is that
each si mulation covers different parts of the config urational space with mini mal
overlap. The inclusion of maj or transitions within si mulation may result in
inaccuracies within ensemble averages of vdW or coloumbic contr ibutions. We
identify these transitional changes within local parts of the confor mationa l space
by employing a method proposed previousl y (48)

We then include these local

parts that occur after or before a gi ven transition as different confor mational
states that can be weighted according to equation 1. In brief, the method proposed
by (48) and adapted f or our purpose collects the traj ectories from each sugar
bound pose. These ar e filtered with a discr ete Fourier transfor mation filter to
exclude hi gh -frequency fluctuations associ ated with ther mal fl uctuations. A
univariate spline is applied to the filtered Fourier set and gradients are evaluated.
If the gradient exceeds a gi ven cut -off value, the change in configuration is
identified (Fig 5A). The ranges that are bel ow the gradien t cut -of f can be used
for subsequent si mulations and the weighted LIE (equation 2) can then be applied
to obtain the ∆G c a l c . The training set of LIE parameters of   were derived from
experi mental data detailed in (19, 51). These parameters were developed using
two-parameter linear regression model with values of  and  0.18 and 0.06,
respectivel y. The free ligand esti mates wer e conducted for each sugar in the
absence of li gand, usi ng the same conditions as proposed above.
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Umbrella Sampling
The protein and the ter mi nal lactnoneotetraose complex were extract ed after 10ns
and moved into umbrella sampling procedures. For each carbohydrate complex,
the sugar molecule was placed at different center -of -mass (COM) di stances from
the CBS. To ensure equivalent pull direction in x,y, and z Cartesian space, we
defined a pull vector that was nor mal to a plane defined by three C  residues
(44,50 and 62) l ying within the CBS. Not only does this ensure a unifor m pull
direction among each galectin -1/carbohydrat e complex but also these coordinates
were i mplicated in conserved binding region of galecitn -1’s CBS. Each molecule
was placed in a cubic box with di mensions 8.1 x 8.1 x 8.1nm with center of the
galectin -1 offset to al low the carbohydrate with enough space to be pulled in
direction of the pull vector. There was at least 1.2nm spacing from the box edge
to the protein. For each complex, all restraints were removed except to chain B
to allow free molec ular fluctuation of chain A and the carbohydrate. Each
umbrella sampling wi ndow was defined at 0.1nm spacing from 0 t o 1.0nm from
the

binding

pocket.

We

used

a

spring

constant

of

1807.5kJmol - 1 nm - 2

(300.15pN/Å), used previousl y with lactose (52), for each umbrella sampling
window. A har monic r estraint was placed at t he COM of each carbohydrate within
the defined window at di fferent distances away from the CBS. Each window
consisted of 20ns of si mulation ti me for a tot al si mulation ti me of 160 -200ns. A
potential of mean for ce (PMF) was calcul ated with the wei ght ed histogram
analysis method (WHAM) (53) with error estimates using bootstrapping using
GROMACS wham tool .
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RESULTS
We set out to deter mine the allosteric impact of the pre -BCR on galectin -1 bound
to variety of sugars ( Fig. 1). Before deter mi ning how each car bohydrate was
altered within galectin -1’ binding pocket, we first looked at the effect of pre BCR on galectin -1’s CBS without any carbohydrate bound ( Fig. 2A). Our
simulations were initi alized with the di meric for m of gal ectin -1.

Figure 1. Illustration of structures featured in this study. A). The galectin-1 heterodimer is
composed of A and B monomeric subunits (pdb 1GZWs) B). Carbohydrates used in this study are illustrated,
along with colored symbols used to represent each monosaccharide unit in subsequent figures. Disaccharides and
polysaccharides with different molecular properties were modeled. This includes 1) galaactosyl groups attached
to different reducing sugars at the reducing end (glcNAc versus 6CO2-glcNAc), 2) LacNAc with different
(14

vs

13),

gal(14)glc(13)gal(14)glcNAc),

and

4)

interglycosidic

linkages

3)

lactonneotetraose

Neu5Acetylneuramic

neu5Ac(23)gal(14)glc) attached to different reducing sugars (glcNAc vs glc).

acid

(LNN(3S

-
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Relative Fluctuations by Subsites of Galectin -1 at the CBS i n presence of pre BCR  5-UR
Since prior evidence has suggested negati ve cooperati vity of bi nding in the
adj acent chain when l actose is bound to one monomeric unit (18), our first goal
was to assess whether binding of the pre -B CR 5-UR 2 2 - 4 5 also induced notable
molecular changes in a bound monomer or the adj acent chain. The final model is
shown in Fig. 2A. Hi ghlighted in pink are the hydrophobi c (dark) and
electrostatic (light) residues of galectin -1 at t he N -ter minal region of the peptide;
subsites A -E are color -coded. Subsites C and D represent the conserved binding
core of galectin -1 with the core galactosyl -gl ucosyl moieties of the carbohydrate.
Subsites A, B, and E c onfer specificity for different carbohydrate groups. The
di merization interface of galectin -1 is found at the N - and C-ter mi nal regions of
each monomer.

To determine how pre -BCR binding i mpacts galectin -1 in the absence of
carbohydrate, we conducted MD s i mulations in explicit solvent . The system was
heated to 310K and equilibrated. During t he production MD si mulation, all
restraints were removed. Root -mean-square deviation (RMSD) of C  atoms were
calculated across indi vidual frames of MD traj ectories and are shown in Fig. 2B
(red, orange). Subsites A and B exhibited minimal change in RMSD over the 10ns
time period bet ween t wo states. There was an increased RMSD in subsite C and
D (Fig 2B, green, purple), which is the conserved binding core of the CBS.
Subsite E, responsible for carbohydrate specificity, explores a confor mational
space with decreased RMSD before transitioning back to RMSD values that
correspond to unbound galectin -1 (Fig 2B , yellow). To assess the relati ve
fluctuations by residue across chai n A and B, we monitored the root -mean-square
fluctuations by residue. We collected the RMSF from chain A to chain B during
same traj ectory in the pre -BCR 5-UR bound and unbound state. We then
subtracted the RMSF f rom pre -BCR 5-UR bound (preBCR( -)) from pre-BCR 5UR bound (pre -BCR(+)) state ( Fig. 2C). This allows us to extrapol ate where the
largest fluctuations occur when bound to pre -BCR 5-UR. We note a relative
increase in RMSF acr oss residues 51 -54 (subsite C,D) and 100 -102 (pre -BCR
binding region) wh en bound to the pre -BCR (Fig. 2C, negati ve values). In
contrast, there is a relativel y lar ge reduction i n RMSF in residues 61 -70 (subsites
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C,D, and E), 76 -77 (pr e -BCR, hydrophobic), 92 -94 (adj acent to preBCR binding
region), 108 -111 (near pre -BCR 5-UR bindi ng region) and 133 (di mer interface)
(Fig. 2C, positi ve val ues). This analysis of RMSD and RMSF showed increased
fluctuations at the CBS, especially within regions C and D, which is associated
with the conser ved β -galactoside binding cor e.
To evaluate potential allosteric effects of pre -BCR 5-UR / galectin -1 on
proxi mal or distal regi ons, we employed principal component anal ysis (PCA).
We proj ect the eigenvectors onto the reference structure (galectin -1 without 5UR bound) to visualize the regions that exhi bit a higher degree of change ( Fig
2D, residues listed ). By monitoring RMSF across each of these ei genvectors,
we note lar ge fluctuati ons localized to subsit e C, D and around the pre -BCR
5-UR binding site ( Fig 2E, top panel ). Interestingl y, an appare ntl y lar ge
fluctuation can be seen across multiple eigenvectors within the N -terminal
region of the adj acent chain B ( Fig 2E, bott om panel). Essential dynamics
revealed increased fluctuations at within sel ect regions within the CBS in
addition in addition to increased fluctuations at the N -ter minal regi on of chain
B in galectin -1.
Pre-BCR 5 Binding Impacts Solvent Accessible Surf ace Areas i n Galectin-1
and its Hydrogen Bonding Netw ork
With evidence suggesting that the pre -BCR 5-UR i mpacts r esidues within
galectin -1’s CBS, we next laid out a strategy to understand how d ifferent
carbohydrate subgroups i mpact buried surface and the hydrogen bo nding
networ k. The X -ray crystal structures of galectin -1 bound to dif ferent sugars
reveals a networ k of hydrogen bonds contributing to carbohydrate affinity.
Within the galactosyl ring, His -44, Trp -68 and Asn -46 (subsit e C) for m a
hydrogen bond with the 4 ’ -hydroxyl group of the galactose ring wit h remar kabl y
short and stable interatomic distances. The hydroxyl groups within the glucosyl
ring f or m hydrogen bond contacts with residues His -52, Asp -54 and Ar g-73
(subsite C/D) . Lastly, residues Glu -71 (subsi te D) and Ar g-48 (subsite C) f or m
contacts with both galactosyl and glucosyl rings. Using preset cutoffs for the
angle donor -acceptor and the distance donor -acceptor, we calculated the number
of hydrogen bonds over the course of a gi ven traj ectory. We compare d these
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results with distribution profiles of sol vent accessible solvent ar ea (SASA), to
provide insi ght into the relative buried surface area of the carbohydrate.

Figure

2.

Binding

of

galectin -1

by

pre-BCR

modifies

relative

fluctuations CBS subsites. A) Model of galectin -1 bound to pre -BCR (5UR). Key electrostatic interactions occur bet ween Glu -74 and Asp -102 with Ar g6 and Ar g-8 of the N -terminal region of the peptide (blue). Trp -9 of the 5-UR
is buried within Val -76, Tyr -104 and Phe -106 for ming an essential hydrophobic
interaction

(dark

pi nk).

Subsite

residues

A -E

are

color -coated,

with

corresponding residues displayed in chart bel ow . B) Root -mean-square deviation
(RMSD) of subsite residues A -E.in presence (blue) and absence (or ange) of pre BCR C) Root -mean-square fluctuation (RMSF) difference bet ween pre -BCR
unbound and bound ( RMSF u n b o u n d = – RMSF b o u n d ) state by residue within chain A
(black) and chain B (r ed) of the galectin -1 homodi mer. Di mer interface is at the
N- and C-ter minal segment of each monomer unit. D) Principal component
analysis (PCA) of gal ectin -1 bound to pre -BCR relative to refer ence structure
(unbound state). E) PCA deri ved RMSF for the first 10 eigenvectors for each
residue within chain A and chain B with galectin -1 in presence o f pre -BCR.
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We compared different LacNAc molecules comprised of different linkages (  14
versus  13) (Fig. 1B, group 2 ) . Our results suggest  13 linkages correspond
to an enhanced hydrogen bonding profile ( Fig. 3A). There is a notable drop in H
bond number 22000ps into the simulation for the  14 linkage, which was not
observed in galectin -1 model bound to the pre -BCR (Fig. 3A). There is on overall
increase in the sol vent accessible area within  14 suggesting a de creased
buried surface area rel ative to  13 linkage.
Attachment of 6’ -CO2 group to glucosyl ring of reducing sugar ( Fig. 1B, group
1) results in an increased number of hydrogen bonds relative to the LacNAc ( Fig.
3B). This corresponded with a decreased SASA. Si milar to  13 linkage, the
SASA and H bond are not si gnificantl y alter ed when galectin -1 is bound to the
5-UR peptide ( Fig. 3B).

Clear

differences

polysaccharides with

in

galectin -1

affinity

have

been

reported

between

ter minal versus non -ter minal galactosyl groups, with a

binding preference for the former over the l atter (54). We next determined the
binding properties of LNN ( gal  14glcNAc 13-gal 14glc) molecules with
either the ter minal or non -ter minal galactoysl ring engaged with galectin -1’s
conserved subsite C/D ( Fig. 1B, group 3) . Measuring SASA bet ween ter mi nal
(conserved C/ D subsit e bound to galactosyl end, Fig. 2) and non -t er minal bound
LNN exhibits mini mal differences in the SASA, with a modest increase in the
latter. In contrast, we note a large disparity in the H Bond network ( Fig. 3C)
when the non -ter minal versus ter minal galactosyl is engaged to t he conser ved
galectin -1 binding cor e. The terminal LNN pose shows large fluctuations early
in the si mulation before transitioning to a confor mation showing an enhanced H
bond networ k relati ve to the non -ter minal pose. Introduction of the pre -BCR 5UR si gnificantly dest abilizes the H bond networ k of both ter minal and non terminal LNN at 100ps and 17ns for the non -terminal and ter minal LNN.
Addition of N -Acet yl functional group to 3’ position of reducing sugar attached
to the Neu5AcGal pol ysaccharide ( Fig. 1B, group 4 ) exhibits a dif ference in the
SASA profile ( Fig. 3D, upper panel ). In bot h Neu5AcGal groups attached to
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Figure 3. pre-BCR impact on SASA and H bond network within CBS. A) SASA (upper
panel) and H Bond (lower panel) calculation of galactosyl-glcNAc sugars containing
different interglyosidic linkages (13 vs 14) in pre-BCR bound and unbound state.
B) SASA (upper panel) and H Bond (lower panel) calculation of LacNAc with carboxylic
acid attached at 6’ positon of the sugar (gal14(6CO2)glcNAc) in pre-BCR bound and
unbound state. C) SASA (upper panel) and H Bond (lower panel calculation of
polysaccharide (gal14glcNAc13gal14glc) in pre-BCR bound and unbound
state. The poses differ by whether the glcNAc (non-Term) or glucose (term) are docked
within galectin-1’s conserved subsite C/D. D) SASA (upper panel) and H Bond (lower
panel) calculation of neu5AcGal(14) moieties with either glucose or glcNAc attached
at reducing end.
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different reducing sugars, we obser ve an incr eased median SASA value upon pre BCR engagement ( Fig. 3D, upper panel ). In the absence of the pre -BCR 5-UR,
the H bond networ k between the two different polysaccharides remains relativel y
stable and si milar thr ough the course of the simulation ( Fig. 3D, low er panel ).
Interestingl y, addition of the pre -BCR 5-UR substantiall y disrupt s the H Bond
networ k of both Neu5AcGal  14glc and Neu5AcGal 14glcNAc ( Fig. 3D,
low er panel ). Overall, polysaccharides bound to galectin -1 show have a
substantial disruption in the interaction network with the 5-UR bound.

Pre-BCR  5-UR aff ects structure of sugars in bindi ng site.
Gl ycosidic torsion angles are a measure of the relative stability of the
carbohydrate within the galectin -1 binding pocket. All inter gl ycosi dic  -linkage
considered are between the galactosyl and glucosyl bound to conserved C/D
subsite of the CBS. The median / angles for the  13 and  14 are 72.4±7.3º/ -94.9±7.2º and -75.6º ±7.9/137.7±16.2º, respectively ( Fig. 4A,B ).
When the pre -BCR is bound the / angle of  13 and  14 linkage slightl y
changed to -81.0±8.4º / -97.8±7.4º and -75.7 ±7.9º/142.9±7.0º, respectivel y (Fig
4A,B). The variance of the  angle for the  14 lin kage decreased when bound.
The addition of carboxylic acid group to the glcNAc residue at the 6’ -position of
the glucosyl ring showed si milar median / angle of -76.98± 8.5º/138.3±6.7º
to glcNAc in unbound state. This value showed modest change / angle, 80.5±9.0º/136.0±6.7º, in presence of the pre -BCR 5-UR (Fig. 4C). We obtained
a / angle of -72.8±8.1º/138.6±7.2º and -78.3º±17.0/133.7± 20.5 for the
terminal and non -ter mi nal LNN, respecti vel y ( Fig. 4D,E) When the 5-UR bound
to galectin -1, the ter minal LNN shows a si gnificant shift in the / angle and
increased variance -73.7±11.3º /140.6±56.4º ( Fig. 4D). Si milarl y galectin -1
bound to non -ter minal galactosyl of LNN wi th 5-UR boudn shows a si gnificant
change in / angle plot with values of -102.6±23.7/95.4±18.7º ( Fig. 4E).
Neu5Ac -Glc and Neu5Ac -GlcNAc exhibit  14 linkage / dihedral angles of
-83.7 ±9.9/134.1±9.4 and

-84.9±9.3/142.8±7.2, respecti vel y ( Fig. 4D,E).

We noted a change in these angles when bound to the pre -BCR (Fig. 4F,G) with
measured

/

dihedral

angles

of

-74.7±8.3º/129.5±11.0º

and

-
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80.4±11.4/121.1±16.3, respectivel y ( Fig. 4D ). In contrast to the 6’ carboxylic
acid or β13 linked dissacharide, β1 4 li nked N -acet yl glucosami nes with no
additional attachments to glucosyl ring display a clear disruption the / angles,
likel y altering the sugars stability within the CBS pocket.

Figure 4. Dihedral angle and aromatic stacking angle distribution in pre-BCR bound
vs. unbound state. A-G) Phi () and psi () dihedral angle of the interglycosidic linkage
between glucosyl and glycosyl groups within subsite C/D for listed carbohydrates in preBCR bound versus unbound state. E-K) Aromatic stacking angle (top panel) and centroid
ring distance (lower panel) between Trp-68 of galectin-1 and galactosyl ring within
conserved subsite C/D within the CBS for listed carbohydrates in pre-BCR bound versus
unbound state.
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Aromatic

Stacki ng

Interactions

Signi f icantly

Altered

with

pre -BCR

engagement
In addition t o electr ostatic interactions, key hydrophobic interactions occur
between the carbohydrate rings and aromatic side chains, particularly tr yptophan.
The schematic for the calculation of aromatic stacking angle ( ) and distance ( R)
is shown ( Fig. 4H, left of graph) and detailed in methods. X -Ray data exhibits
a stacking angle around 142º for the LacNAc carbohydrate and a measured
distance between t wo centroids of 0.51nm. The stacking angle of the  13
LacNAc in pre -BCR 5-UR bound versus unbound state was calculated at
137.9±8.9º (bound) versus 139.8±8.6º and the mean centroid distance at
0.5085±0.0352nm

(bound)

versus

0.4975±0.0285nm

( Fig.

4H,blue).

The

carbohydrate with  14 linkage exhibits a bi modal distribution ( Fig. 4H, red)
shifting to more favor able angle through the course of the simulati on. The mean
stacking angle of the  14 LacNAc were in pre -BCR 5-UR bound versus
unbound state were calculated at 143.1±16.4(bound) versus 135.8± 16.2º in the
unbound state. The measured centroid distance was 0.5063 ±0.0618nm for pre BCR bound and 0.5036±0.0453nm pre -BCR 5-UR unbound state ( Fig 4H, red
and pink). Addition of the carboxylic acid t o the reducing sugar also showed a
slightl y more unfavor able downward shift of the aromatic stacking angle when
bound to the pre -BCR 5-UR

(Fig 4I, light green) We calcul ated values of

135.6±8.8º (bound) and 140.43±12.2º (unbound) with measured distance of
0.5212±0.0356 (bound) and 0.5394nm±0.0610 (unbound) .

The LNN pol ysacchar ide displayed a ri ght ward ( more favorable) shift in the
distribution of the stacking angle in presence of the pre -BCR 5 -U R. Within the
pre -BCR 5-UR unbound state the ter minal and non -ter minal gal actosyl bound
LNN had mean aromatic stac king angles of 141.1±10.3º and 137.52±11.5º,
respectivel y. This cor responds to a calculated mean centroid distance of the
terminal

and

non -t er minal

LNN

poses

were

0.4935±0.0319nm

and

0.5119±0.0415nm, respectivel y. When bound to the pre -BCR 5-UR,

the

aromatic angle shifts upward to 149.7± `14.7º for ter mi nal LNN and 161.3±8.6º
for

the

non -ter minal

LNN

pose.

This

corresponded

to

a

distance

of
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0.5001±0.0423nm and 0.4424±0.0218nm for t he non -ter minal and ter minal poses,
respectivel y.

We note a si gnificant di sruption of the aromatic stacking angle wit h both poses
of N-acet ylneuramic acid attached to the LacNAc moiet y ( Fig 4J). This
corresponded to distance values of 0.5518±0.0382 0.5537±0.0333 i n unbound
pre -BCR 5-UR state for the glc and glcNAc sugar attache d at the reducing
end, respecti vel y. The calculated aromatic st acking angle was 136.5± 10.0 and
139.0±9.0º in the unbound pre -BCR 5-UR st ate for the glc and glcNAc sugar
attached at the reducing end, respecti vel y. The corresponding distances changed
dramatically through course of si mulation as can be seen ( Fig 4K, l ow er
panel). Clearl y N -Acetylneuramic acid and both non -ter minal and t er minal
lactonneotreatose pol ysaccharides exhibit clear disruption in the ar omatic
stacking angle when t he 5-UR is bound to galectin -1.
Galectin-1 subsite D residue Arg -73 undergoes large conf ormation change
altering interaction distance
Because Ar g-73 displayed the greatest decrease in chemical shift variations (19)
and is located at the intersection between the CBS and the pre -BCR binding site,
we looked at the minimum distance of this residue relative to t he sugar. All
residues containing  14 linkages and coupl ed to glcNAc showed drastic shifts
when bound to the pre -BCR (Fig. 5A,D- G). In contrast, the  13 linkage or
when a carboxylic aci d is attached at the 6’ position of the  14, there was a
mi ni mal i mpact on this mini mum distance cal culation ( Fig. 5B-C). When the pre BCR is bound Ar g -73 under goes a side -chain reorientation whereby Ar g -73 faces
away from the CBS toward the λ5 -peptide. This event subsequent ly destabilizes
critical hydrogen bonding interactions at this site and may be indicative of the
loss of carbohydrate affinity for select sugar s. Interestingl y, this appears
dependent on the t ype of sugar within the binding pocket, with 6 -CO2 attachment
or  13 linkage both showing relati vel y constant distances in the presence and
absence of 5-UR.
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Figure 5. Minimum distance between carbohydrate and Arg-73. A-G) Minimum
distance (nm) measurement between the carbohydrate and Arg-73 of the galectin-1 along
the trajectory.
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Linear interaction energy calculations of the carbohydrate i n presence /
absence of the pre -B CR

To estimate the bindi ng free ener gy of the carbohydrate to galectin -1 in the
presence and absence of the pre -BCR 5-UR, we incorporated the i mproved LIE
method as detailed in Methods that includes both Equation 1 and Equation 2.
The Weighted factor (W i ) in addition to  and  are was obtained using iterati ve
scheme described previously (48) and detailed in methods above. Data shows the
different vdW and electrostatic energies deri ved from Neu5AcNGlc MD
simulation, for which a filtered Fourier Transfor m series was fit. Fitting a cubic
spline to the filtered set and calculating the gradient, w e plot the absolute value
of the gradient as shown in ( Fig. 6A). From this particular si mulation, we note
three different local confor mational spaces (1 -3000ps 6000 -18000ps and 1750 30000ps) corresponding with two transitions as exhibited with increased gr adient
(Fig. 6A, top panel ). When gradient value exceeds a set value ( Fig. 6A, red line,
upper panel ), it is flagged and excluded from the anal ysis. For ∆ G b i n d evaluated
for this set, all non -tr ansitional states were weighted according t o Equation 1
and subj ect to the weighted LIE ( equation 2). ∆G b i n d was calculated for each
carbohydrate ( Fig. 6B ). We note a decreased affinity bet ween galect in -1 for most
of the polysaccharides tested when the pre -BCR was bound. We did observe a
more favorable binding ener gy when the pre -BCR was bound between galectin -1
and LacNAc bearing t he  13 linkage or when the carboxylic aci d was attached
at the 6’ position of the glcNAc moiet y.
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Figure 6. Free energy of binding by different carbohydrates with galectin-1 in preBCR λ5 bound versus unbound state using improved LIE method. A) The electrostatic
(light blue) and vdW (grey) contributions of carbohydrate binding in presence of
Neu5AcLacNAc bound to galectin-1. Each data set are filtered with discrete fourier
transform filter and splines are fit to filtered data. Gradients are calculated from these spline
fits and plotted (upper panel). A transitional state is determined when the absolute value of
the gradient is greater than a set cut-off point (i.e. 0.02kJmol-1ps-1). B) Experimental data
and LIE calculated from 30ns simulations are shown in table..
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Umbrella Sampling Simulations
We incorporated umbrella sampling and the wei ghted histogram anal ysis
procedure to construct a potential of mean f orce (PMF) cur ve for the ter minal
lactoNNeotetraose ( Figure 1, sugar 3 ) in presence and absence of the pre -BCR
5-UR. The reaction coordinate was defined as the COM distance from the nor mal
unit vector that protrudes from the CBS. Each sampling window w as spaced at
0.1nm inter vals that extended along this vector, whereby a har monic restraint is
on the COM of the carbohydrate. The PMF was plotted as a function of COM
distance (Fig. 7A), with errors evaluated usi ng block averaging of 5ns segments
through that stretched through each umbrella sampling window. The PMF shows
clear differences in the ener gy landscape wi th a deeper basin when pre -BCR is
not engaged to galecti n -1. The structural insets reveal the hydrogen bonds are
clearly disrupted bet ween the Ar g-73 and sugar. This breakage occurs at shorter
timescales when pre -BCR was bound. There is a more notable change in the in
electrostatic interactions, as revealed from Lennard -Jones and Coul ombic e ner gy
differences across each US window (Fig. 7B ). It is clear that the overall i mpact
on affinity when the pre -BCR is bound is likel y dictated through electrostatic
hydrogen bonds bet ween galectin -1.
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Figure 7. Potential of mean force (PMF) of Neu5AcLacNAc bound to galectin-1. A)
The weighted histogram analysis method (WHAM) was used to calculate the Potential of
Mean Force as a function of the distributions of COM umbrella sampling windows for the
terminal lactoNNeotetraose sugar molecule (Figure 1, sugar 3) in presence and absence
of pre-BCR. B) The mean Lennard-Jones and Coulomb energy differences were calculated
from each US window
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DISCUSSION
Recent evidence has provided definiti ve evi dence that galectin -1 binds the pre BCR’s surrogate light chain subunit 5 (11) . When presented on t he surface of
stromal cells, galectin -1 engagement with the pre -BCR leads to stable cell -cell
contacts and a synapse -li ke redistribution of pre -BCR on precursor B cells to the
contact sites (11). Binding of soluble galectin -1 di mers leads to pre -BCR
aggregates with mar kedly reduced diffusion (3, 11). We recently showed that
incubation of precursor B leukemia cells wit h galectin -1 plus satur ating doses of
lactose ( gal 14glc) r estored pre -BCR diffusion to pre -BCR-galect in complexes
(3) interpreted as evidence that monosaccaride binding prevents galectin mediated crosslinking of the pre -BCR to other cell surface glycoproteins and
gl ycolipids. Importantly, the addition of lactose also amplified the downstream
signaling response of pre -BCRs after galecti n -1 binding. These results suggest
that the complex aggr egates for med by galectin -1 binding to bo th the pre -BCR
and gl ycoreceptors activel y attenuate si gnal ing. Galectin -1 has been shown to
interact with a variety of negati ve regulatory membrane gl ycoproteins, including
the t yrosine phosphatase CD45. Thus, different gl ycosylation patterns on surface
of stromal cells and/or precursor B cells may dri ve different si gnaling profiles
dependent on the composition of gl ycoproteins that are co -crosslinked with the
pre -BCR/ galectin -1 complex.

These concepts strongl y motivate detailed

explorations of the galec tin-1 carbohydrate binding characteristics in the
presence of the pre -BCR.

In agreement with NMR data (19), we have demonstrated that bindi ng of the pre BCR 5-UR i mpacts the flexibility of residues with in galectin -1 CBS,
particularly in subsites C and D ( Fig 2). Inter estingl y, we note a decreased RMSD
profile within subsite D with addition of pre -BCR that may i mpact interactions
within this subsite. Using PCA deri ved RMSF across the first 10 eigenvectors ,
we noted a substantial RMSF within the N -t ermi nal region of chain B of galectin 1 homodi mer. This suggests that pre -BCR binding may i mpact di mer/ monomer
equilibrium. Experi mental data shows that l actose binding leads to a shift in the
homodi mer equilibr ium and factors the di meric state compared to when galecitn 1 is not bound to any carbohydrate (55). Galectin -1 di mers can then protect

91
galectin -1 from oxidat ive inacti vation, a process of disulfide bond for mation that
significantl y

decreases

galectin -1’s

for

carbohydrates

(56).

In

future

experi mental wor k, it would be interesting t o test the prediction that pre -BCR
engagement modifies the galectin -1 di mer/monomer equilibrium and thus alter
the lifetime of di mer bonds that dri ve oli gomerization.
We noted a disruption of the H -Bond net wor k for all re sidues with  14 linkages
containing a glcNAc or glucose reducing end ( Fig 3.B-D). Attachment of a 6’ COO group or LacNAc with a  13 did not disrupt the H Bond networ k.
Interestingl y, these results directly correlate with data on the mini mum distance
profile of the sugar molecule to Ar g -73 of gal ectin -1 (Fig. 5). The Arg-73 residue
lies within subsite D, which rests at the intersection between the  5-UR binding
region and the carbohydrate binding site. In fact, li ke the hydr ogen bonding
networ k profile, al l carbohydrates with the  14 linkages (excepti ng those with
a 6’ -glucosyl attachment) are i mpacted by t he shifted movement of this residue
away from the CBS t oward the 5-UR binding region. It has been shown that
addition of anionic moieties at different positions (i.e. 3’ or 6’) drastically
impacted the relative affinity of gi ven sugars to galectin -1 (57). We see here that
attachment of a 6’ -carboxylic acid on the glucosyl ring s till retains Ar g -73
binding through the course of the si mulation. Si milarly, the  13 also does not
lose this critical electrostatic interaction upon pre -BCR engagement. A look at
the molecular structure reveals that, withi n the  14 linkage, the glcNac
functional group is in direct contact with the Ar g -73 residue and t he glcNAc is
attached via the  13.

In general we obser ved a more substantial i mpact of pre -BCR 5 binding on
galectin -1’s affinity f or pol ysaccharides, relative to the disaccharides tested .
Altered affinity is mor e readily apparent as the polysaccharide lengt h is increased
(Figs 3-6). We noted an overall increase in binding affinity when the non terminal galactosyl gr oup when bound to conserved binding core. This increased
affinity is dri ven thr ough interactions wit hin subsites A/B.

While binding

energies of galactose -terminating and non -galactose ter minating carbohydates
rates have been measured (54, 58, 59) it had been proposed that four LacNAc
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units can be accommodated by galectin -1; non -ter mi nal galactosyl residues were
not required for binding.

Experi ments i n CHO cells reveal teat terminal

galactosyl resid ues ar e not required for binding (60) . Our data corroborate this
finding and actually show that sufficient binding ener gy may occur to to n ongalactose ter mi nating carbohydrates.

In summar y, we employed molecular dynamics si mulations t o extrapolate
additional detail about the pre -BCR/ galectin -1 interaction with mol ecular -level.

This work provides an example of how MD simulations can be util ized to
understand the impact of allostery in molecular function, as has been shown
in a variet y of other studies (61-63). Galectin -1 has been directly i mplicated
in BCP -ALL, where niches that nor mall y support the pre -BII population of
developing B cells have the undesired eff ect of promotng

enhanced overall

survi val of leukemia blasts. Due to the diverse nature of gl ycoreceptors on the
surface of precursor B cells, as well as stromal cells, understanding these
interactions in great er detail is i mportant to understand how changing
carbohydrate binding may effecti vel y shift the composition of bystander
gl ycoproteins recruited to galectin -1/pre -BCR heterocomplexes. Of particular
interest is the impact on co -crosslinking of the pre -BCR with negati ve regulatory
signaling partners, such as CD45 and other phosphatases. Different ial recruiting
of positive or si gnali ng co -receptors is expected to lead to altered signaling
profile and opposing cell -fate decisions.

In addition, gal ectin -1 has been

considered as a potential therapeutic target (19, 64). Understandi ng how these
protein/protein interactions alter galectin -1’s CBS will aid in the design process
of key inhibitors that may specificall y exploit disease processes, including
precursor B neoplasms and inflammator y pr ocesses that are specific to galectin 1 when engaged with t he pre -BCR.
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CHAPTER 4
Preclinical characterization of a chimeric antigen receptor T cell therapy targeting
the pre-B cell receptor
M. Frank Erasmus1,2, Ichiko Kinjyo1,2, Stuart S. Winter2,3, Michael Horowitz4, and
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ABSTRACT
Current immunotherapy options in B cell precursor acute lymphoblastic leukemia (BCPALL) are primarily based on antibodies targeting CD19, CD20 or CD22. Recent successes
in clinical trials include T cells engineered to express anti-CD19 chimeric antigen receptors
(CAR). Because CD19 is widely expressed on mature B cell lineages, anti-CD19 CAR T
cell therapy impacts the patient’s entire existing B cell repertoire. We focus here on
targeting the pre-BCR, which is expressed only at the precursor B cell stage of normal
development and represents a highly specific target for subsets of BCP-ALL patients with
poor prognosis. The pre-BCR is distinguished from the mature BCR, based upon
of 5 and VpreB subunits, which show no sequence homology to any other expressed gene
within the human genome. In normal B cell development, the SLC assembles with
successfully rearranged Igµ for expression of the pre-BCR.

Autonomous pre-BCR

signaling then enables the immature B cells to pass a critical checkpoint. In this study, we

94

design a CAR T cell therapy against the pre-BCR SLC with the aid of computational
antibody design. We demonstrate high affinity binding of recombinant scFv to pre-BCR
expressing cells, forming the basis of the lentivirus construct for expression of a novel antipre-BCR CAR. We present evidence that CD8+ T cells expressing the anti-pre-BCR CAR
bind and kill target leukemia cells. The anti-pre-BCR CAR T cells form robust synapses
with pre-BCR expressing leukemia cells, leading to polarization of CAR T receptors to the
cell-cell interface. Cytolytic granules subsequently redistribute to synapse, leading to
fusion and killing of pre-BCR+ BCP-ALL cell lines and patient samples. CAR density and
target density are shown to be important factors in the robustness of killing. These CAR T
cells can expanded in vitro for preclinical studies in a human xenograft model of BCPALL in immunocompromised mice. This study sets the stage to utilize mouse models to
study T cell-mediated killing of both target and off-target B cell lineages, as well as T cell
exhaustion, focusing on potential advantages of the pre-BCR CAR T cells versus the panB cell CAR T cells that target CD19+ normal and neoplastic cells.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most prevalent neoplasm in children (1) and
an aggressive cancer in adults (2). Treatment of patients with intensive combination
chemotherapy is often considered a modern success story, with relapse-free survival rates
approaching 90% in children (3). Unfortunately, high-risk cases of ALL remain incurable
(4) and there are inherent concerns with toxicity and long-lasting side effects of existing
treatments (5).

ALL arises from both early B cell (BCP-ALL) and T (T-ALL) cell lineages. There is
considerable interest in developing more targeted therapies for these diseases, based upon
advances that have identified mutations and genetic alterations associated with specific
ALL subsets (6). For example, ALL patients expressing oncogenic forms of specific
cytokine receptors exhibit sensitivity to tyrosine kinase inhibitors (TKIs) such as dasatinib,
ruxolitinib and crizotinib (7, 8). The high risk group termed “Ph+ ALL” was coined based
upon transcriptional profiles with similarity to BCR-ABL+ cases; these cases may respond
to TKIs, which are typically delivered in combination with multi-agent induction, postremission and maintenance chemotherapy (9). Yet, even in the advent of improved
outcomes of BCP-ALL patients treated with TKIs, relapse is still common (9). Targeted
therapy options may also include antibody-based approaches that support antibodydependent cytotoxicity (ADCC) and phagocytosis (ADCP) (10, 11), antibody-dependent
toxin delivery (12) or establishment of T cell-mediated immunity based on adoptive
transfer of genetically modified immune effector cells (13, 14). Recent, highly successful
clinical trials based on the latter approach have led to intense efforts to improve cell-based
therapies, as well as to limit the considerable risks during treatment (15).

CD19 is a B-cell surface marker that is expressed throughout the different stages of B cell
development. To date, this receptor is the most common target used for T cell-mediated
cell therapies in ALL and B cell malignancies (16). In brief, the approach is based upon
genetic modification of the patient’s effector T cells to enable the expression of
recombinant, chimeric antigen receptor (CAR) that targets CD19 on the surface of
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leukemia target cells. The original CAR was a fusion protein comprised of an extracellular
domain bearing the antigen recognition domain of an anti-CD19 antibody, in the form of a
single-chain fragment variable (scFv), together with a transmembrane domain and the
intracellular ITAM-bearing tail of the CD3- chain (17, 18). Poor response rates in early
clinical trials were linked to limited in vivo expansion and rapid disappearance of CAR+ T
cells upon infusion (19, 20). This led to the design of “second generation” CARs that
incorporated costimulatory domains (4-1BB, CD28) into the receptor cytoplasmic tail and
enhanced antitumor activity relative to CARs composed only of the CD3- C-terminus (21,
22). Use of these costimulatory domains results in enhanced in vivo expansion of T cells,
persistence of anti-target effector function for months to years after injection, and
expression of a memory-like phenotype (23).

Anti-CD19 CAR therapies can ablate both healthy and malignant B-cells. Although B cell
aplasia has been reported to be highly tolerable in patient populations (24), we propose that
there may be advantages for developing novel CAR T approaches that avoid loss of
existing B cell adaptive immunity. In addition, several cases of relapse have still reported
due to loss of CD19 expression (25) or reduced CART cell efficacy (reduced CAR T
expression or increased T cell exhaustion) even when CD19+ leukemic cells are still
detectable in the blood (26). The desire for co-infusion of CAR T’s that target multiple
targets on the surface of ALL blasts has been proposed (25, 26).

Our focus here is on the pre-BCR as a therapeutic target, as proposed recently based on its
supportive role in leukemogenesis of CD179+ BCP-ALL (27, 28). It is noteworthy that
targeted therapies against the BCR in mature B-cell neoplasms are already well advanced
in clinical trials (29). Unique structural and developmental properties of the pre-BCR
makes for a highly desirable target for pre-BCR(+) cases. In normal B cell ontogeny, up
to 10 million pre-B cells are produced daily (30). The majority of these are destroyed due
to failure to pass the pre-BCR checkpoint (31), which occurs at the pro-B to pre-B cell
junction after successful recombination of Ig heavy chain (IgH) genes (32). Two identical,
covalently linked IgH chains each associate with the surrogate light chain (SLC) and
signaling subunits Ig and Ig (32). A weak, autonomous (“tonic”) signal is propagated
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via transient pre-BCR homodimers at the extracellular surface (28), mediated through
homotypic interactions of surrogate light chain components (33). Distinct from light chain
(LCs) found on B cell receptors at later stages during B cell development, the SLC is
composed of two unique polypeptides known as 5 and VpreB that are non-polymorphic.
The C- and N-terminal regions of the VpreB and 5 subunits each contain non-Ig unique
regions (UR) that do not show sequence homologies to any other genes (31, 34). Similar
to healthy B cells, many of the pre-BCR(+) leukemias are trapped at this particular stage
of development and undergo constitutive pre-BCR signaling. A recent report, covering four
clinical trials and 830 patients, showed that BCP-ALL can be divided into different
subtypes dependent on pre-BCR function with pre-BCR(+) exhibiting worse outcome (35).
Targeting the pre-BCR pathway in these pre-BCR(+) leukemias with small molecule
inhibitors (35) or with an anti-VpreB Fab (28) significantly impacted leukemia cell
survival.

We describe the pre-clinical development of a precursor B cell-specific, 2nd generational
CAR T cell therapy. We began with an anti-VpreB murine antibody selected using highthroughput phage display screening (28). Applying computational design principals for
antibody engineering, we generated a scFv that retained the specificity and subnanomolar
binding affinity of the parent antibody. This scFv was incorporated into a lentiviral
expression vector, creating an anti-pre-BCR CAR with a CD28 juxtamembrane domain
and C-terminal derived from the CD3 cytoplasmic tail. Human CAR T cells were
produced and shown to be effective at killing pre-BCR+ BCP-ALL cell lines, as well as
patient blasts passaged through immunocompromised mice. Fluorescence imaging was
employed to characterize CAR T synapses with target leukemia cells. Since the pre-BCR
is bivalent, to our knowledge this is the first reported CAR directed at a multivalent antigen.
This novel feature of anti-pre-BCR CAR T cells may offer advantages for amplification of
signaling by CARs, motivating future studies of the impact of target antigen valency on
signaling competency of CAR T cells.
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MATERIALS AND METHODS
Computational Design of the scFv
Antibody design was based upon the sequence of the complementary determining region
(CDR) of the parent mouse IgG1 anti-VpreB antibody, as previously described (28). The
Rosetta structure prediction tool was used to develop a high quality antibody Fv homology
model. The RosettaAntibody protocol has been described in detail (36) with an
improvement to the VL-VH orientation (37). In brief, VL and VH framework and non-H3
complementarity determining region (CDR) loops regions use the BLAST (Altschul SF,
Gish: Basic Local Alignment Tool) algorithm with BLOSOM and PAM30 scoring
matrices used for each, respectively. The bit score is used to identify best match across the
antibody sequence and structure database for each region. Each V L and VH framework is
superimposed on the barrel of the template with greatest sequence similarity and non-H3
CDR loops are superimposed of backbone atoms of two root residues on either side of the
loop. CDR H is modeled using Rosetta loop modeling and Kinematic Closure to close the
loops. All atoms are refined with VL-VH rigid-body minimization with CDR H3 is
restrained. The H3 region is then minimized within the surrounding environment. Average
RMSDs of templates for each model tested relative to experimentally determined template
were sub-Ångstrom for the framework regions and non-H3 CDRs.

Construction of the HC/LC scFv in E. coli
Plasmid DNA (PTT5-2460BO4) bearing the HC and LC of the parent anti-VpreB antibody
was transformed into NEB competent E. coli (New England Biolabs, Ipswich, MA).
Framework regions (CDR, constant region) were defined using RosettaAntibody
bioinformatics tool. We applied a two fragment assembly as laid out previously (38). Based
upon the information from computational modeling, we designed a 20mer Gly4Ser linker
with the HC-linker-LC orientation. In brief, the VH and VL domains were PCR-amplified
from the PTT5 vector. Primers were designed to be compatible with a pET101/TOPO
vector that contains C-terminal His-Tag. We used a CACC-HC forward primer (5’CACCATGGAGGTGCAGCTGGTCG-AGTC-3’) and the LC-Reverse without a Stop
Codon (5’-GGTCCGCTTGATCTCCA-CCT-3’). Primers for the HC-20mer linker-

99

reverse complement (5’-GGAGCCGCCGCCGCCAGAACCACCACCACCAGAACCACCACCACCggacacggtgaccag-3’) and LC-20mer-Linker(fwd)(5’GGTTCTGGCGGCGGCGGCTCCGGTGGTGGTGGATCCgacatc-cagctgacccagag-3’). For fusion of each
segment, we used the protocol established previously (38). PCR conditions were 5min at
95ºC, then 25 cycles of 1min at 95ºC, 1 min at 57ºC, 30s at 72ºC and 5min at 72ºC. Primer
for the 3’region of VH was extended to convert the linear region and 5’ end of VL was
extend to cover the other amino acids. The first round PCR products were amplified
individually. Band were excised from agarose cells and purified products were joined by
overlapping extension PCR, resulting in a scFv with the correct linker sequence. For this
PCR, 5µL of each purified VH and VL template were joined without the addition of
primers by cycling seven times: 30s at 95ºC, 1min at 50ºC and 30s at 72ºC. 50pmol of the
forward primer for VH and VL-reverse primer were added at 95ºC, then cycling was
continued 25 times: 1min at 95ºC, 1min at 50ºC and 1min at 72ºC and finally 5min at 72ºC.
The PCR product was then run on 1.2% agarose gel and the band excised (757bp). The
fusion product was cloned into a pET101/TOPO vector using the (ThermoFisher Scientific,
Waltham, MA) according to manufacturer’s instructions. After 1hr incubation in SOC
media at 37ºC with shaking, 200µL of bacterial culture was spread on a pre-warmed LBAgar plate with ampicillin selection antibiotic and incubated overnight. A BamHIHiEfficiency and EcoRI-HiEfficiency (New England BioLabs, Ipswich, MA) restriction
digest was performed to check for proper insertion. Bands were excised and purified;
sequencing results showed 100% sequence identity with the 6x-His tag encoded in frame
at the C-terminal end.

The pET101/TOPO vector containing the scFv construct was transformed into BL21 Star
TM

(DE3) OneShot® (ThermoFisher Scientific) according to the manufacturer’s

instructions. In brief, transformed E. coli were cultured in 10ml of LB media containing
the ampicillin antibiotic, then grown overnight at 37ºC with shaking. Bacteria were then
transferred to LB media containing antibiotic; after 3 hr culture at 37ºC with shaking, mM
IPTG was added to induce expression and cultures were expanded for an additional 4 hours.
Proteins were purified from bacterial lysates using the ProBond® Ni-NTA purification
procedure as described by the manufacturer (ThermoFisher Scientific).
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Binding Affinity and Specificity Measurement of the scFv
To detect binding of scFv to BCR-ALL cell surfaces, purified scFv-HisTag was diluted to
100µM in HANKS buffer and serially diluted. Cultured 697 cells were resuspended in 90µl
buffer, followed by additions of varying dilutions of purified scFv and incubation for 1 hr
at 4ºC. Cells were washed 3x with ice-cold PBS, then incubated on ice for 30 min with
anti-His(PE) antibody (BioLegend, San Diego, CA) according to manufacturer’s
instructions. After washing, cells were re-suspended in 500µl PBS for flow cytometry
analysis. Data was collected on the LSR Fortessa (BDBioscience, San Jose, CA) and
analyzed using the FlowJo® software (FlowJo, LLC, Ashland, OR). Dose response curves
calculate the apparent KD and hill coefficient given two vectors, plotted on a semilog graph
and fitted with the Hill Equation sigmoid using MATLAB’s nonlinear fit statistics toolbox.

For specificity of the scFv for the VpreB target, we competed the scFv with the parent
antibody (anti-VpreB mouse IgG1). The parent VpreB antibody was prepared at different
concentrations ranging from .001 to 500nM. The scFv-His was incubated at saturating
conditions >20xKD(100nM) with 697 cells (1.0x105). After 1hr incubation at 4ºC, cells
were washed 3x in ice-cold PBS. Each dose from the parent antibody was added in separate
conditions to each saturated scFv condition for 1-hr on ice. After the incubation period,
cells were washed 3x and incubated with anti-His(PE) antibody (BioLegend) for 30min on
ice. Cells were washed 3x with 1xPBS and spun down at 300xg for 5min at each wash.
Cells resuspended in 500µL of 1xPBS for flow cytometry analysis. Data was collected on
the LSR Fortessa (BDBioscience, San Jose, Ca) and analyzed using the FlowJo® software
(FlowJo, LLC, Ashland, OR). Dose response curves calculate the IC50 using competitive
binding curve equation after conversion of the responses to %total binding:

Y  Nonspecific 

(Total  Nonspecific )
1 10log[parentAb]log(IC 50 )

Y represents the total binding, log[parentAb] is the logarithm of the concentration of the

parent antibody plotted along the X axis. Nonspecific binding is defined as binding in
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presence of saturating conditions of parent antibody and total binding as binding in absence
of parent antibody. Fits were conducted using MATLAB’s nonlinear fit statistics toolbox.

Construction of the CAR T cell cassette
To generate the lentiviral vector containing the scFv, XbaI and EcoRI, the scFv-His
sequence was prepared to include EcoRI and XbaI restriction sites. The HC-linker-LCHisTag fragment was ligated into second XbaI and EcoRI-digested fragment that encoded
the retroviral backbone and extracellular portions of CD28, the entire transmembrane and
cytoplasmic portions of human CD28 and the cytoplasmic portion of the human TCR-CD3
using services of Promab, Inc (Richmond, CA).

Culture Media
T cells were cultured in T cell medium: AIMV medium (ThermoFisher Scientific, Walham,
MA) plus 5% AB (blood type AB) (Gemini Bioproducts, Woodland, CA), 100U/mL
penicillin, 100µg/mL streptomycin and 1.25µg/mL amphotericin B) (39). During culture,
T cell media was supplemented with 300IU/mL IL-2 (Peprotech, Rocky Hill, NJ). PBMCs
were cultured in 1640 medium plus 5% FBS, 100U/mL penicillin, 100µg/mL streptomycin
and 2mM L-glutamine.

Peripheral blood mononuclear cells (PBMCs) isolation
Fresh blood was obtained from United Blood Services (Albuquerque, NM). Donor blood
was added to 5 separate 50mL collection tubes to aliquot into 20 separate SepMateTM tubes
(STEMCELLTM Technologies, Cambridge, MA) according to manufacturer’s instruction.
Whole blood (12.5ml) blood was added to equal volume of RPMI and mixed. 25ml of the
Blood/RPMI mixture was added to top of SepMateTM tube containing 15ml Ficoll-Paque
PlusTM (GE Healthcare, Little Chalfront, UK). Tubes were centrifuged at 1200xg for 10
min at RT. The mononuclear layer (middle layer) of cells were collected, then re-suspended
in 5ml RPMI for cell count. Cells were diluted in RPMI to a final concentration of
2.0x106cells/ml.
CD8+ T cell Enrichment from PBMC population
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Solutions of PBMCs were combined for a total of at least 50x107cells for CD8+
enrichment. After washing, cells were resuspended in 1ml sterile PBS, 0.1% BSA, 2mM
EDTA and 2% FBS. 50x107cells/ml were added to 5ml polystyrene round bottom tubes.
TM

CD8+ negative selection

kit (STEMCELLTM Technologies, Cambridge, MA) was added, followed by gentle mixing
and incubation at RT for 10 min. Meanwhile, magnetic particles were vortexed (30s) and
150µl added to the tubes. After gentle mixing, tubes were incubated at RT for 5 min before
addition of 5 ml PBS, 0.1% BSA, 2mM EDTA. Tube were placed into magnet holders and
incubated for >1 min before removing fluid. Magnetic bead-bound cells enumerated to
evaluate CD8+ yield and re-suspended in 2.0x106cells/ml T cell media, supplemented with
300IU/ml IL-2.

CD3/CD28 Activation/Expansion Beads
After CD8+ enrichment and every 7-8 days thereafter, cells were activated with CD3/CD28
beads (Promab, Inc., Richmond, CA) according to manufacturer’s instructions. Cell
densities were maintained at 2.0x106 cells/ml and 25µl of the activation macrobeads were
used per 1.0x106 T cells/well.

RetroNectin Coating for Prior to Viral Transduction
Following two day stimulation with CD3/CD28 macrobeads, activated CD8+ T cells were
combined and diluted to 2.0x106cells/ml. Wells of a 24h well plate were coated with
38.0µg/ml of retronectin (Clontech/Takara, Mountain View, CA) that had been

aspiration and addition of 500µl blocking solution (0.1µM filtered PBS, 3%BSA) to each
well. Plates were blocked for 30 min at FT, then wash sterile HANKS buffer. Plates were
either used immediately or stored at 4ºC for up to a week prior to use.
Transduction of CD8+ T cells
Lentiviral products were supplied at 3.23E8 IFU/ml. CD8+ T cells (1.0x106) were
transduced with a multiplicity of infection (MOI) of 10. To prepare for lentiviral
transduction, lentiviral particles were diluted in T cell media, with 300IU/mL of IL-2). The
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viral particle solution was added to retronectin-coated plates, followed by centrifugation of
plates (2000xg, 2hrs at 32ºC). 500µL of the media was kept in well and 500µl of CD8+
(CD3/CD28 beads removed) within T cell media (supplemented with 300IU/ml of IL-2)
were added to the plates for a final concentration of cells at 1.0x106cells/ml. Untransduced
T cells were added to the plates that only contained retronectin. After cell addition, plates
were centrifuged for 10 minutes (200xg) and then cultured at 37º for 24 hr before a second
round of transduction.

Expansion Protocol
Following transduction, cells were maintained in culture at an average density of
1.0x106/ml. For expansion, the CD3/CD28 macrobeads were added at 25µl/ml and cultured
for 3-days. If cells exceeded 2.0x106cells/well they were split into fresh wells of a 24-well
plate to optimize density. CD3/CD28 beads were added every 7-8 days.

FACS Analysis of Intracellular and Extracellular Receptors
Extracellular staining protocol was conducted as follows, unless otherwise stated. Primary
conjugated antibodies were used to detect extracellular receptors: anti-CD69-AF488
(Biolegend, San Diego, CA), anti-IgM-PacificBlue (Biolegend), anti-GranzymeB-APC
(Biolegend), anti-IFN-AF488 (Biolegend), Anti-His-AF555(ThermoFisher Scientific),
anti-CD45-FITC (Biolegend), anti-CD8-PacificBlue(Biolegend), anti-PD1-FITC, antiTIM3-APC (Biolegend). Cells were incubated with manufacturer’s recommended
antibody volume prepared for 100µl of cells at 1.0x106cells/ml in PBS and typically held
for 30-45min on ice. Between steps, cells were routinely washed 3x and recovered by
centrifugation (300xg, 5min), then re-suspended in 500µl of PBS and moved to LSR
Fortessa for data collection. If intracellular staining procedure was conducted, the cells
were fixed with 4% paraformaldehyde in PBS for 15 min at RT, permeabilized with
1%Triton-X in PBS for 30min at 37ºC, followed by 10 min incubation at RT with primary
antibodies. All data was processed with FlowJo Software. Where so noted, flow cytometry
data were calibrated sing the Quantum Simply Cellular beads (Bang Laboratories) with
anti-mouse Fc antibodies according to the manufacturer’s instructions.
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Induced Stimulation of T cells with Ionomycin/PMA treatment for FACS
In stimulated wells, phorbal myristate acetate (PMA) was added at final concentration of
20ng/mL and ionomycin (1µg/mL), with 1:1000 dilution of BD Golgi stop solution. After
4 hr, cells were labeled with surface and/or intracellular staining protocols.

Immunofluorescence Staining Protocol for Confocal Microscopy
For confocal microscopy imaging, CAR T and 697 were co-incubated for 24 hour time
period in 96-well round bottom plate at 2:1 CAR T:697 ratio. Cells were transferred to
poly-l-lysine coated well for 30 minutes at 37ºC. Cells rincesed with PBS and fixed with
1% paraformaldehyde in PBS for 15min at RT. Cells rinsed with PBS and blocked for
60min (PBS, 3%BSA). Cells were incubated with primary antibody for 1-hr at RT using
dilutions recommended by manufacturer. For the intracellular staining protocol, cells were
permeabilized with 1% Triton-X in PBS prior to incubation with primary antibodies for 2
hrs at RT. After final washes, Prolong gold® (ThermoFisher Scientific) was applied to
coverslips and samples were cured overnight at RT in the dark.

Cytotoxicity measurement to assess CAR T target efficacy
Target cell death was measured using the non-radioactive cytotoxicity assay, cytotox 96®
(Promega, Madison, WI). Controls included spontaneous release of target cell line (697 or
Nalm6 alone), max LDH release (target cell line with lysis buffer added), effector cell
spontaneous release (CAR T alone), culture medium background. For the LDH release
assay, the CAR T:target cell ratio was 5:1. Alternatively, cytotoxicity was measured in 697
and Nalm6 cell lines stably expressing GFP, varying CAR T:target cell ratios at 4:1, 2:1,
1:1, 0.5:1, 0.25:1,0.125:1 and 0.0625:1. Effector and target cells were incubated for 3 days,
followed by labeling with anti-CD19 or anti-IgM FITC-conjugated antibodies.
Cytotoxicity was measured as a loss of target cell fluorescence.

Epitope Prediction using MD simulations
The structural coordinates from the pre-BCR Fab-like region were downloaded from the
protein data bank (pdb id: 2H32) and used to build a homology model. To dock the antiVpreB to the scFv, we used a blind prediction of the binding site limited the solvent-
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exposed regions. We coupled a soft docking approach using ZDock followed by a refined
model using RosettaDock. ZDock is an inistial stage unbound docking algorithm that uses
minimal assumptions of the binding site. We localize binding region to the CDR regions
within the scFv using the Kabat Chothia, and Rosetta protocols. For docking to the VpreB
region, we excluded the HC and 5 regions from the search criteria. The mathematical
formalism and algorithm have been described in detail previously (40). In brief, the scFv
and VpreB solvent exposed regions and the core atoms are identified using solventaccessible solvent area (SASA) and a penalty grid to identify the geometric characteristics
of the of each receptor and ligand. These functions are then fed into 1) shape
complementarity 2) desolvation free energy, 3) and electrostatic calculations, which are
later combined to find the top predicted scores. Each group was clustered according to their
RMSD before each model was refined using the RosettaDock Algorithm(36). Output
scores were generated from Rosetta Dock and top refined structures from each group were
moved forward into MD simulations in explicit solvent.

Epitope Mapping Rupture Force from Steered Molecular Dynamics
To predict the top docked pose from the selected output from the ZDock and RosettaDock
algorithms, we used steered molecular dynamics (SMD) using the GROMACS package,
version 5.1. A recent study showed that there is a linear correlation for umbrella sampling
(US) and rupture force calculation derived from SMD allowing for fast free energy
predictions (41). We applied this approach to estimate relative binding energies among the
different poses. First we measured the radius of gyration of the anti-VpreB scFv to gain an
idea of the spacing required for SMD pull calculation. The system was set with 2.0Å
spacing on either side of the VpreB/scFv complex. The principal axis was determined from
the first complex for the scFv and the entire complex was aligned. Each scFv was
superimposed onto the scFv so in subsequent SMD pull simulations the same pull force
would be applied equally to the scFv in the same direction. The pull distance was estimated
as the diameter (2 x radius of gyration) x 3 diameter lengths as depicted in Figure 2. Each
complex parameter from the GROMOS96 53A6 parameter set (42) were used. Short-range
non-bonded interactions were cut off at 1.4nm and the particle mesh Ewald (PME)
algorithm used for long-range electrostatics. We used periodic boundary conditions in all
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directions. Starting structures were equilibrated in the predefined box as detailed above and
filled with SPC water molecules. We added 100mM NaCl and neutralizing counterions.
We performed energy minimization using steepest descents. Equilibration was conducted
over two 100ps periods with position restraints applied to heavy atoms for both protein
units. The initial phase of equilibration was conducted for 100ps using an NVT ensemble.
All protein and non-protein atoms were coupled to separate temperature coupling baths
and maintained at 310K with the Berendsen weak coupling method. An NPT ensemble was
conducted for 100ps to maintain pressure at 1.0bar. Equilibrations used as starting
configurations the SMD simulations, as detailed above. We performed 10 SMD
simulations over 500ps using a range of spring constants of 200, 400, 600, 800, 1000, 1500,
2000, 2500, 3000, 4000kJ/mol/nm2. Each all heavy atoms of the pre-BCR were restrained
while all restraints were removed from the scFv. Each scFv was pulled along the single xcoordinate. Rupture force was calculated as the max pull force when all the bonds broken
between the scFv and pre-BCR. After comparing each group derived from the initial
docking, the best scored pose was then subjected to screening alanine mutagenesis to
predict the epitope on the surface of the VpreB region.

RESULTS
Design of the scFv for functional surface expression
ScFv are composed ~25-30kDa fragments comprised of VH and VL domains. In practice,
each of the domains are linked together by established Gly-Ser linkers of varying sizes. It
is well established that the scFv have characteristic problems with self-aggregation, lack
of binding specificity, loss of binding affinity to target, and improper orientation. These
problems arise from the inherent sequence of the scFv (framework and CDR regions),
whereby some fragments simply do not orient properly to retain appropriate efficacy. Other
problems are associated with the linker region. Due to these inherent problems with scFv,
and before proceeding with subcloning the scFv into a lentiviral vector, we incorporated
advances in antibody computation methods to design the scFv. This included selection of
an antibody fragment with the appropriate binding orientation and linker region that would
confer binding affinity to the VpreB target.
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Table 1. RosettaAntibody Algorithm output. Each region of the scFv (CDR-L1, CDRH1, etc.) show information for each region. Resolution is the experimental structure
resolution. % identity is the percent sequence identity. The E-Value and Bit-Score are
relative measures of the probabilities associated with given matches.
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Computational Construction of scFv Homology using RosettaAntibody Algorithm
The RosettaAntibody algorithm is composed of two main steps with recent improvements
on VH-VL orientation. The first step involves the selection of an appropriate template and
grafting from known structures to construct a coarse-grained model. The second step
incorporates Monte Carlo sequence disruptions and minimization of the CDR-H3 loop
followed by further refinement of the remaining CDR loops and redocking of the VL and
VH domains. The first step utilizes the BLAST algorithm with the BLOSUM and PAM30
scoring matrices to identify sequence homology with a curated database of solved antibody
structures with resolution ≤ 3.0Å. The output from the initial RosettaAntibody score is
shown in Table 1, with a good match for our protein sequence and those within the
RosettaAntibody database. For instance, the framework regions of the heavy and light
chain of the scFv showed % sequence similarity of 100% and 98.4% for the framework
region of the light chain (FR-LC) and heavy chain (FR-HC), respectively. The low E-value
and high Bit-Score values show the framework regions could be grafted to backbone atoms
with high predictability. The non-CDR regions exhibited sequence similarity of 60-100%
with acceptable E-value/Bit-Scores. The best predicted model was selected and moved
forward into MD simulations.

MD Simulations Provide Insight into Optimal Sequence Orientation
Next we used MD simulations to predict which scFv orientation, Nterm-VL-linker-VHCterm versus Nterm-VH-linker-VL-Cterm, would confer a more stable linker connection
and evaluate the impact on the CDR binding region of the model. The output
RosettaAntibody homology model displayed inherent differences between the N-term end
of the VL region and C-terminal end of the VH region and vice versa (Fig1A). If the VLlinker-VH sequence was utilized, this would entail VL-Cterm would couple to the VHNterm region with a linker. There was a spatial distance distribution of this orientation
ranging from 35-44Å, which is on average 13Å greater than the distance between VHNterm coupled to VL-Cterm (Fig 1A). Before the computational incorporation of the
flexible glycine-serine (Gly4Ser) linker, we wanted to see the inherent stability of the
Nterm and Cterm region at the framework regions within the VH (aka HC) and VL (aka
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LC) regions. We note larger over root-mean-square deviations (RMSD) compared to initial
conformation at time = 0ps. This measure allows us to predict the relative flexibility of
each region. The RMSD of the Cterm-LC and Nterm-HC (LC-linker-HC orientation) show
a larger overall RMSD relative to the Cterm-HC and Nterm-LC (HC-linker-LC orientation)
(Fig 1B).

Figure 1. Computational modeling of scFv for optimal orientation and linker length.
A, Minimum distance measurement of the N-terminal and C-terminal regions of the VH
(LC) and VL (HC) domains to which the linker would be attached. B, Comparison of the
RMSD (nm) of the different N-terminal and C-terminal regions of the VH and VL domains.
C, Output homology model of the scFv attached to a 20mer and 15mer linker in the HClinker-LC orientation. D) Relative linker stability using RMSD over the course of a 1ns
MD simulation for different orientations and linker lengths E) Relative complemenarity
determining region (CDR) stability with different orientations and linker lengths.
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Next, we built a homology model of the scFv containing the 15mer or 20mer linker,
attached between either the Cterm-LC and Nterm-HC (LC-linker-HC orientation) or
Cterm-HC and Nterm-LC (HC-linker-LC orientation). The scFv model generated
(without linker region) by the Rosetta algorithm served as the template and the missing
Gly4Ser 15mer or 20mer linkers were “filled-in” using the MODELLER software
package. Because the glycine-serine is flexible and disordered with minimal secondary
structure (43), we set out to determine how this flexible linker would impact the CDR
regions of the antibody allosterically. The top predicted model from MODELLER is
shown in Figure 1C, with the 15mer and 20mer linker attached between the LC-Cterm
and HC-Nterm regions for the HC-linker-LC orientation. As expected there was an
increase in the RMSD of the 20mer linker relative to 15mer linker in both orientations
(Fig 1D). Interestingly, even with higher amount of flexibility within the linker region
itself, we noted a significant decrease in the RMSD of residues within the CDR region
when using the longer (20mer) relative to the shorter (15mer) linker (Fig 1E). In both
cases the HC-linker-LC showed decreased RMSD values in the CDR region.
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Figure 2. Cloning and Expression of the scFv in E. coli. A, General schematic of the
fusion PCR approach. B, VH and VL PCR products that are excised and brought forward
for fusion PCR. C, Fusion PCR product of the full-length scFv DNA. D, Detection of
purified anti-VpreB-scFv-6xHis via Western blotting.
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Production of anti-VpreB1 scFv
From our computational prediction above, we selected the HC-linker-LC orientation with
at 20mer linker for scFv fragment engineering. A soluble version of His-tagged, antiVpreB scFv was produced in E. coli to ensure the engineered monomeric antibody retained
appropriate affinity and specificity. The steps in the production of recombinant scFv are
shown in Figure 2A; details are described in Materials and Methods. Results at specific
steps are illustrated in Fig 2B-D, showing a yield of appropriate-sized fragments for the
VH and VL regions (2B), PCR-mediated fusion and amplification of VH-linker and linkerVL regions using the HC-forward and LC-reverse primers to yield a product at the
predicted size (2C). After subcloning into a BL21(DE3) compatible vector, cell lysates
were collected from IPTG-induced bacterial cultures. The scFv was purified by nickel
chromatography, detected by western blotting (2D), and stored at a concentration of
500µM.

scFv binds with subnanomolar binding affinity to VpreB
To ensure the purified scFv detects the VpreB component of the pre-BCR on the surface
of leukemic pre-B cells, we used the 697 BCP-ALL cell line as a model system. Tubes
bearing cultured suspensions of 697 cells (1x105) were incubated with recombinant scFv,
followed by incubation with PE-conjugated anti-6xHis antibodies. Results in Fig 3A show
strong binding of the scFv to 697 (blue histogram), compared to an isotype-control (pink
histogram). To estimate the binding affinity, cells were incubated with serially diluted scFv
over a range of concentrations. Based upon a nonlinear regression fit to the sigmoid Hill
equation, the scFv bound to 697 cells with subnanomolar binding affinity (KD= 0.63nM;
Fig 3B).

Fig. 3C show results of a competitive binding assay performed in the presence

of increasing concentrations of unlabeled, anti-VpreB IgG. The effective competition with
whole (dark) IgG antibodies confirmed that the engineered scFv retains the same
specificity as the parental antibodies.

Transduction of CAR T Construct into PBMCs
Our next step was to cloning of the scFv antibody fragment into a CAR T lentiviral vector.
As illustrated in Figure 4A, the construct orients an N-terminal scFv-6xHis in frame with
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a CD28 hinge/transmembrane/cytosolic region. Following the cytosolic CD28
costimulatory domain is the CD3 cytoplasmic tail.

Figure 3. Binding affinity and specificity measurements to live BCP-ALL cell lines.
A, Binding of the scFv at saturating conditions. B, Binding curve with increasing
concentrations of the scFv-6xHis fit to sigmoidal Hill equation. C, Competitive binding
assay of the scFv-6x with parent antibody. Increasing partent antibody are added after
saturating receptor with anti-VpreB scFv.
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For the production of pre-BCR specific CAR T cells, we modified published protocols for
lentivirus transduction using RetroNectin-coated 24-well plates. RetroNectin utilizes a
heparin-binding domain (H-domain), cell-binding domain (C-domain), and CS-1
sequence. Virus particles bind to the H-domain, while integrin receptors VLA-5 and VLA4 bind the C-domain and CS-1, respectively. The first round of transduction was attempted
with freshly-isolated PBMCs, without specific steps to enrich for CD8+ cytotoxic T cells.
As shown in Fig. 4B, this resulted in a marked uptake of the virus by non-CD8+ T cells.
Although these cells would be activated with PMA/ionomycin treatment (Fig. 4C), this
pool was not a productive source of cytotoxic CAR T cells and represented an apparent
sink for viral particles.

We next elected to add negative selection, using CD8+ enrichment kit (EasySep), to the
protocol prior to RetroNectin-mediated lentiviral transduction of peripheral blood T cells.
As shown in Fig. 4D, this resulted in successful CD8 enrichment. Results in Fig. 4E, we
achieved a higher transduction efficiency of CD8+ T cells (left panel, 4E), which also had
marked expression of the T cell activation marker, CD69+ (right panel, 4E).

CAR T Forms Synapse with BCP-ALL Blasts and Exhibits Cytotoxic Activity

When subjected to a single round of RetroNectin transduction, CAR T+ cells exhibited a
broad distribution of chimeric receptor expression, as shown in the typical example in Fig.
5A. Based upon calibration of these results using anti-HisTag antibodies and Simply
Cellular Bead standards (Fig. 5B), CAR expression levels ranged from 4600 to ~300,000
receptors/cell, with a median of ~71,000 receptors/cell. We found that a double
transduction protocol (see Methods) resulted in more consistent and increased receptor
expression in transduced CD8+ T cells (Fig. 5C) and adopted the two-transduction method
for all subsequent work.

We observed a strong correlation between the number of CAR expressed on the CD8 T
cell surface and the level of killing activity against target leukemia cells (Fig. 5D). Here,
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the HI category was defined to be as a count of >30,000 CAR per T cell, while the LO
category was defined to be cells displaying 10,000 receptors. The CAR T HI population
exhibited much more potent activity against 697-GFP and Nalm6-GFP BCP-ALL lines
(Fig 5E). Note that, while 697 cells express slightly higher pre-BCR binding sites than
Nalm6 cells (22,000 vs 18,000), there was no appreciable difference in leukemia cell
depletion after incubation with CAR T-Hi cells.

Figure 4. CAR T Detection and Activation status of T cells. A, Schematic of the antiVpreB scFv incorporated into the CAR T lentiviral cassette containing the CD28
(hinge/tm/cytosolic) and CD3ξ signaling subunit. B, Initial round of transduction of entire
population of PBMC. C, Activation of PBMC with PMA/ionomycin exhibits IFNγ
signaling. D, Negative selection enrichment of CD8+ T cells for new round of
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transductions. E, Increased transduction efficiency of CAR T lentiviral vector into CD8+
T cells, which exhibits expression of early activation marker CD69.

Figure 5. Confocal imaging of CAR T / preBCR synapse and in vitro cytotoxicity. A,
Anti-6xHis(AF555) antibody is used for calibrating the beads and for detection of receptor
on the surface of live CAR T cells. B, Calibration curve of the anti-6xHis(AF555) antibody
bound to the calibration beads with known number of binding sites. C, Transduction
efficiency of CAR T lentivival vector into CD8+ T cells. D, Cytotoxicity assay detects
decreasing numbers of target 697-GFP or Nalm6-GFP after 3-day co-incubation with
different ratios of the CART : Target. E, Quantification of receptors on surface of different
BCP-ALL cell lines.F, Confocal imaging of the CAR T (yellow) binding to 697 (GFP,
green) and accumulation of granzyme B (red) at the synapse (white arrow).
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We also evaluated the interactions of CAR T cells with leukemia target cells by
fluorescence microscopy. After co-incubation of CAR T cells with BCP-ALL cell line
(697), we observed the formation of a synapse between CARs on surface of T cells with
leukemic B cells labeled with cytosolic GFP (Fig 5F, white arrows). This engagement
resulted in relocalization of the CARs to the point of contact at the synapse (Fig 5F,
yellow). The T cell serine protease, granzyme B, accumulates at the synapse (Fig 5F, red).

Epitope Mapping for Structural Insight of the pre-BCR/CAR T Synapse

The antigen epitope is likely to have an important role in CAR T cell triggering. To gain a
more detailed understanding of the VpreB epitope in this study, we employed
protein/protein docking protocols and steered-molecular dynamics (SMD) to predict the
VpreB epitope. We first applied a soft, blind-docking approach of the scFv to the VpreB
region, given limited knowledge of the binding epitope. We utilized the ZDock algorithm
and set a restrictive criteria to limit the search area to solvent-exposed regions of the VpreB.
The top 10 poses from the soft-docking were output and we compared the relative
orientation of the CDR regions of the anti-VpreB scFv after superimposition of the
preBCR. Heat map analysis of CDR RMSD (Fig 6A, top) revealed the clustering of
receptor to four distinct binding poses (Fig 6A, bottom). Each of the top scoring subgroups
were then subject to the RosettaDock algorithm for further docking refinement. After
refinement, hundreds to thousands of different poses were generated and scored. We
selected the top poses based off the RosettaDock’s interface and total scores (Table 2).
Top scoring poses that were associated to groups identified from soft-docking protocol
were selected and moved into SMD simulations.

A linear correlation had been established between the SMD derived rupture force as a
function of pull constants and the derived ∆Gbind derived from umbrella sampling (US), so
we used this to rank our different poses. SMD simulations are comparable experimental
data derived from atomic force microscopy (AFM). In this case our scFv is attached to a
virtual spring whereby a constant force or velocity is applied to the center-of-mass to pull
the protein from the binding pocket (Fig 6B). As the COM distance increases between the
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scFv and the pre-BCR, a force builds up to a max point (rupture force) until critical
interactions are disrupted. By changing the pull force constant, we obtain different pull
force profiles (Fig. 6C). By plotting the rupture force versus the pull constant for the

Table 2. RosettaDock Refinement Output. Post-clustering refinement of scFv docked
to VpreB that determines outputs top performing scores based upon the interface and
total score. Grayed are the models used for input into SMD simulations for relative
affinity comparison.
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different poses, we arrive at a ranking between the different groups in the order of 3, 4, 2,
1 (Fig 6D). We selected pose 3 and performed longer simulations to identify critical
interactions between the CDR region and VpreB. Using a series of minimum distance , H
bond, and RMSF calculations we identified the top residues within the VpreB region. We
next performed screening alanine mutagenesis among several residues to determine
whether this would impact affinity in our SMD simulations. Mutation of several of the
identified residues showed a dramatic impact on apparent binding affinity, particularly
serine 11 (Fig 6E). The top five potential binding sites identified between scFv and VpreB
are shown (Fig 6F-G).
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Figure 6. Epitope mapping of the scFv binding site on surface of VpreB. A, Heat map
of that clusters different groups based off RMSD of the different CDR regions after
superimposition of the VpreB structure among the different models. B, Schematic showing
the basic premise of steered molecular dynamic simulations. C, Pull force curve at varying
pull force constants (kJ/mol/nm^2). Rupture force (kJ/mol/nm) is the max point of the pull
curve before key interactions are broken. D) Plot of rupture force (kJ/mol/nm) as a function
of the pull force constant (kJ/mol/nm^2) of the different model outputs. E) Plot of rupture
force (kJ/mol/nm) as function of the pull force constants (kJ/mol/nm^2) after performing
screening alanine mutagenesis of key residues within implicated in top predicted model.
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F-G) Best predicted model with top 5 key residues within the scFv (red) and VpreB
(yellow) highlighted.
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DISCUSSION
In contrast to the anti-CD19 CAR T therapy that has already been tested and validated in
clinical trials (15, 26, 44), we characterized a new target (28) that can utilize this therapy
in BCP-ALL. Recent evidence suggests that certain biophysical properties of the CAR
itself (epitope location (45-47), valency (48)) and/or upon the target cell (i.e. receptor
density (49, 50)) play an important role in dictating T cell efficacy. We speculate that the
bivalency of the pre-BCR with two equal binding sites (51) may impact CAR T signaling
efficiency. The pre-BCR, like the BCR (52), is already structurally optimized to form an
immunological synapse (52-54). The CD3ζ is a signaling subunit of the TCR that relies on
appropriate synapse formation to trigger activation (55, 56). Therefore we hypothesize that
the structural features of the pre-BCR, which have been shown to form synapses to
different cells (53, 54, 57), are well-suited to facilitate binding in a trans-fashion to the
CAR on surface of cytotoxic T lymphocytes, forming robust synapses that can trigger
activation. Recent literature provides ample evidence that suggest differentially engineered
CARs [see review (58)] with different structural features (46, 58), such as 4-1BB versus
CD28 co-stimulatory domains (59), exhibit changes in signaling that alter the T cell
efficacy when honing in on the same target (i.e.CD19). We are currently looking to
determine whether certain CAR T design principles still hold true when comparing CARs
that are made to target the pre-BCR with unique structural properties.

In this study, we observe that CAR T transduction generated a wide distribution of receptor
counts on the target cells (Fig. 5A). We showed that there were clear differences in efficacy
that depended upon the levels of expression on the surface of both CAR T and BCP-ALL
cells (Fig. 5D). Thus, it is not only important to understand how the threshold of signaling
for CARTs (50) with different signaling domains (i.e. 4-1BB versus CD28) (59) impacts
efficacy but also how the downstream signaling profile changes when we alter the antibody
binding specificity. Quantifying the receptor density, scFv/target affinity, synapse profiles,
downstream signaling and epitope mapping have been shown to be (50, 60, 61) important
to CAR T potentcy. We have already observed a clear polarization of the CAR T and
formation of granules at the synapse (Fig. 5F). It is well known that polarization of
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cytotoxic T cells leads to directed secretion of perforins and granzymes that is triggered by
cytoplasmic Ca2+ elevation (55). As a future direction, we will incorporate ratiometric
imaging to study the robustness of our CAR/pre-BCR synapse in activating signaling (62).
We are currently establishing whether synaptic exclusion of critical negative regulatory
receptors (PD-1, CD45, Tim-3) (63) might serve as a predictive measure for T cell
exhaustion (64). This will continue to be important in order to understand activation and
long-term duration of the CAR T cells when exposed to different targets. It has already
been established that the target epitope (65) and receptor density (66) are important
properties in fine-tuning the signaling threshold required for CAR T cell activation.

Incorporation of theoretical modeling (67), including MD simulations (41), advanced
docking protocols (40, 68), and rule-based modeling (69), can aid in our understanding of
these CAR T signaling thresholds and provide insight into the CAR T/target receptor
relationship. Our ability to utilize recent advances in antibody modeling coupled with
large-scale computational resources enables us to make better 3D predictions of our scFv
poses in binding to the target (Fig 6A-G). This structural input will allow us to apply these
substructure predictions to different spatial and temporal formats such as coarse grain
simulations (70). This can be used to make predictions about intermembrane spacing
distribution and/or how extracellular engagement might influence the interactions between
the cytoplasmic ITAM domain and the lipid bilayer (71). Further, predictions of the binding
pose can be compared to low-resolution TEM images (72), whereby we can establish how
different orientations influence the synapse. Use of computational methods in small
molecule therapy development has been accepted almost ubiquitously in the
pharmaceutical industry to optimize pharmacoketic profiles. Computational approaches
are applied to aid the experimental set-up whereby they can help generate testable
hypotheses and provide insight into experimental hurdles (73). The use of computational
design to guide experiments are just beginning to make headway in antibody-based
therapies. Improvements of algorithms and enlarging antibody databases are rapidly
improving our ability to predict 3D structure of antibody fragments (36). To this end we
have used computational modeling protocols to aid in the engineering of an anti-VpreB
scFv that retains pre-BCR specificity and exhibits high affinity (Fig 1-3).
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We propose that the pre-BCR is a unique target for subsets of BCP-ALL patients, since it
is expressed only at a specific stage during B cell development (74). Unlike CAR T and
antibody therapies that target the CD19 extracellular target (75-77), or TKI drugs for that
matter(78), treatment of pre-BCR+ leukemias with anti-preBCR CAR T should protect the
mature population of B cells that are essential to the adaptive immune response. The 5
and VpreB (79) are unique with no sequence homology to any other gene, which should
limit off-target effects. Further, we showed the pre-BCR is critical for survival in certain
subsets of leukemias (28). In plasma cell malignancies, groups showed that BCMA was
essential to the proliferation of these particular cells(80, 81).These data show the
importance of BCMA in the survival of plasma cells may prevent the outgrowth of a
resistant subpopulation. Also, in contrast to ROR1 (another proposed target in BCP-ALL),
which has been shown to be expressed on pancreatic and lung tissue in some models (82,
83), the pre-BCR’s restriction to B cells should minimize ‘on-target, off-tumor’ toxicity.
We still anticipate that our anti-VpreB CAR T will ablate both healthy and leukemic
precursor B cells alike, but anticipate, due to the narrow window that the pre-BCR is
expressed during B cell development, an large proportion of mature B cells should remain
intact. Other important things to consider include the loss of CAR T function via tumormediated immunosuppression (84) or chronic T cell activation that leads to the
upregulation of inhibitory ligands (85). These factor are worth considering and will be a
main point of focus in our studies to further characterize our anti-VpreB CAR T.

This upregulation of negative regulatory receptors is also known as T cell exhaustion (86).
Overstimulation of CAR T signaling receptor leads to increased expression of inhibitory
receptors (PD-1, TIM-3, LAG-3) reduced cytokine production and proliferative capacity,
and increased rates of apoptosis(59, 64). Different groups are employing alternative
strategies to minimize these deleterious aspect of overstimulated T cells. Incorporation of
the 4-1BB costimulatory domain showed reduced T cell exhaustion in anti-CD19 CAR T
constructs compared to the CD28 costimulatory domain (59). The 4-1BB signaling unit
corresponded with longer persistence beyond two years (24) which far exceeded the CD28
costimulatory domain, which exhibited a max persistence time of 68 days (44). These
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results show that the incorporation of certain costimulatory domains (4-1BB and CD28)
were important in regulating T cell activity when the CAR was honed in on a similar
epitope (i.e. CD19). However, a question still remains as to whether target specificity
(CD19 versus preBCR) might impact CAR T activation status and/or expression of
exhaustion markers when they have the same co-stimulatory domain (i.e. CD28). Many
groups have provided evidence to suggest that spatial organization of the epitope has an
important role in CAR T cell efficacy (45, 47, 65, 87, 88). Further, it was shown by (89)
that analogous receptors to anti-CD19 CARs engaged with their target on Raji B-cells and
exhibited a highly convoluted membrane surface that was remarkably different from those
interacting via TCR-pMHC. These data suggest that this engagement may impact CAR T
potency. Like the TCR-pMHC complex the structural properties of the pre-BCR(53, 54)
makes it optimally designed to engage antigen of a variety of forms to trigger the formation
of an immunological synapse. This might suggests that the pre-BCR may represent more
well-suited target in its capacity to form an appropriate signaling synapse compared to the
CD19 receptor in pre-BCR(+) leukemias.

This study points to the need to carefully optimize conditions for transduction and
expansion of CD8+ T Cells, and is an area that is of active attention (58). After cloning our
scFv into lentiviral vector, we showed robust activation and efficient surface expression
(Fig 4) of the CAR on the surface of CD8+ T cells. We determined it was advantageous to
remove non-CD8+ PBMCs to enable better transduction efficiency of the CAR T into the
CD8+ population. However, it will be important to further establish in vivo whether the
CD8+ is more optimal alone or when co-injected with CD4+ CAR T cells. It has recently
been shown that these CD4+/CD8+ ratios) may be important in for in vivo efficacy (90,
91).

Concluding Remarks

Approximately 13.5% (112 cases) exhibited tonic pre-BCR signaling that drove BCL6
expression, a positive feedback regulator of the pre-BCR pathway(35). In the majority of
leukemia subsets that did not contain a functional pre-BCR pathway there was active

126

repression of BCL6 expression (35). Interestingly, targeting Ph+ ALL with tyrosine kinase
inhibitors (TKIs) revealed a novel mechanism of drug resistance through increased BCL6
expression (92). This suggests that in ALL subsets that exhibit a pre-BCR(-) profile and
treated with TKIs targeting the cytokine receptor pathway should be monitored at later
stages to ensure there is no upregulation of pre-BCR signaling products. In the event that
the cells do express pre-BCR products, it may necessitate the use of therapies to target the
pre-BCR pathway. Targeting pre-BCR highly desirable, regardless if it is expressed early
on or at later stages of assessment.
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CHAPTER 5: DISCUSSION
This dissertation focuses on validating the pre-BCR self-oligomerization model on the
surface of leukemic blasts and the design of novel therapeutics against this target. While
there has been intense interest to understand the pre-BCR signal initiating mechanism (14), this work provided the first direct evidence for receptor homotypic interactions on live
cells. Further, to our knowledge no reports have explored the dimer interface of the preBCR as a putative target in BCP-ALL. Through the use of advanced imaging modalities
(5, 6) and theoretical modeling (7, 8) , we showed that oligomerization of the pre-BCR
occurs through both homotypic and galectin1-mediated mechanisms. We were the first to
show that we can directly target the dimer interface with inhibitory monovalent antibodies,
which demonstrably impacts the survival of leukemia blasts in vitro (9). Further, we make
a compelling case for the pre-BCR as a target for chimeric antigen receptor (CAR) T cell
therapy.

Validating the pre-BCR Oligomerization Model in Different BCP-ALL
Through the use of cutting-edge imaging techniques, we were able to capture brief,
repeated homodimerization on the surface of live leukemic B cells (Chapter 2, Fig. 1BD). Using SPT, we showed that pre-BCR dimer events were characterized by correlated
motion at short separation distances. Using the hidden Markov Model (HMM), we could
distinguish between tagged-preBCRs in the “dimer-state“ and the “free-state”. The dimer
state exhibited characteristic slower diffusion (Chapter 2, Fig. 1G-H). This is consistent
with slowed diffusion of dimers and their signaling partners, but may also be influenced
by transient residency of pre-BCR within protein islands that have been implicated in TCR
and BCR clustering (10, 11). Our observations of repeated interactions between pairs of
pre-BCRs is likely due to their transient co-confinement within these specialized
microdomains as well as corrals created by the dynamic cortical cytoskeleton (12, 13).
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We noted differences in dimer lifetimes and diffusion profiles of the pre-BCR on the
surface of two distinct BCP-ALL cell lines, 697 and Nalm6, which are characterized by
distinct genetic lesions (14, 15). Nalm6 cells showed slower diffusion rates that correlated
with a fivefold slower off-rate relative to 697 cells. These data suggest that the pre-BCR in
Nalm6 has a higher tendency to form slow-moving, higher-order oligomers. One possible
explanation is that this may be the result of specific VpreB single nucleotide
polymorphisms (SNPs) (9). We noted that a polymorphism in the VpreB was more
prevalent in Nalm6 cells, resulting in an asparagine introduction within the VpreB protein.
It is intriguing that this results in a putative N-glycosylation site, since prior work by others
linked N-glycosylation of the µHC (membrane heavy chain) to autonomous signals from
the pre-BCR (16). Further, addition of an N-glycosylation site into -HC receptors, which
does not contain this specific post-translational modification, was sufficient to activate
autonomous pre-BCR signaling (16). In contrast, a VpreB-UR SNP within the 697 cell
lines substituted lysine for glutamic acid. It has been suggested that acidic residues within
VpreB-UR are involved in salt bridge formations with positively charged 5-UR and may
affect the ability of the 5-tail to interact with specific ligands. Thus, a change in molecular
charge within the VpreB region might subsequently alter 5’s binding capacity. We also
showed that patient samples with unique cytogenetic profiles could be subdivided into one
of two diffusion patterns associated with either Nalm6 or 697 cells (Chapter 2, Fig. 6C).
Previous studies have shown that disruption of the actin cytoskeletal network with
latrunculin A (17) or through cofilin-mediated severing via Toll-like receptor ligands (18)
increased BCR diffusion. We do not rule out that the observed differences in diffusion
might also be associated with variations within the cortical actin cytoskeleton.

Galectin-1 Mediates Large Aggregation Through Different Binding Modes
In contrast to the frequent, serially engaging rebinding events characteristic of pre-BCR
dimerization, galectin-1 binds to pre-BCR to form larger, more stable aggregates. The
study of the glycan network and glycan-binding proteins adds an important feature to
membrane dynamics. Glycans are central to extracellular matrix and cell membrane due to
their ubiquitous presence on glycoproteins and glycolipids (19). Further, the multivalent
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nature of glycan-binding proteins have been shown to form higher-order oligomers
resulting in a glycan network (20, 21). While a large portion of studies have focused on the
functionality of lectins, many groups are now turning to advanced imaging techniques (9,
22) to study how these proteins influence membrane dynamics. We looked into how lectinbinding proteins and glycan networks might influence the pre-BCR interaction network.
Recent studies revealed that galectin-1 acts as an intermediary protein between the preBCR and glycoreceptors on both the pre-B cell surface and stromal cells (3, 4). It has been
postulated that galectin-1 is presented at the extracellular surface of stromal cells attached
to N-acetyllactosamines (LacNAc) on integrins at the stromal cell surface (23). In the
context of the bone marrow microenvironment, precursor B cells bearing a functional preBCR could bind to galectin-1 on stroma and induce a local conformational change in
galectin that alters its carbohydrate-binding preference (23). In one model, pre-BCRgalectin binding could mediate the release of trans-dominant pre-BCR/glycoreceptor
interactions between pre-B cells and stromal cells, in favor of cis- dominant interactions
between receptors on surface of pre-B cells. Introduction of galectin-1 in the absence of
stromal cells resulted in the formation of large clusters at the membrane surface (Chapter
2, Fig. 2A) and caused a dramatic slowdown of the pre-BCR (Chapter 2, Fig 3B). We
showed increased correlated motion of 2-color tagged pre-BCRs at greater separation
distances when galectin-1 was added (Chapter 2, Fig. 2B-C). When we blocked galectin1’s lectin-binding properties with saturating concentrations of lactose, we noted increased
pre-BCR mobility and correlated motion at shorter pre-BCR separation distances that were
similar to pre-BCR diffusion under tonic signaling conditions (Chapter 2, Fig 2B-D).
These results show that even in a cis- setting (absence of stromal cell binding) glycanmediated interactions influences the pre-BCR membrane dynamics. We anticipate that this
remodeling of pre-BCR from trans- to cis- hetero-interactions could drive differential preBCR signals as the pre-B cells escape the stromal-cell+ signaling niche (24). To understand
how pre-BCR dynamics in presence of galectin-1 influence downstream signaling we
turned to biochemical assays.

Galectin-1 +/- Lectin Binding Properties Influences Differential Signals
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Prior data revealed that formation of cell-cell contacts (“synapses”) between stromal and
precursor B cells leads to robust phosphorylation associated with pre-B cell activation (3,
25). Galectin-glycan lattices have been shown to be involved in a wide variety of cellular
processes from immune system and anti-tumor immunity responses (26, 27). We incubated
precursor B cells with soluble, dimeric galectin-1 in the absence of stromal cells, a
condition which would be more representative of cis- mediated galectin-1 interactions after
stromal cell release, and noted a significant reduction in pre-BCR proximal activation
profiles (Chapter 2, Figure 4A). These data suggest that galectin-1 mediated interactions,
either in the presence or absence of the stromal cells, may lead to drastically different
proximal activation profiles in pre-B cells. Interestingly, we noted that galectin-1 binding
in the presence of lactose led to increased Syk activity (pY352) above tonic signaling
conditions (Chapter 2, Fig 4A). This would suggest that, within these cis-dominant
conditions, the pre-BCR’s downstream signaling profile could be readily altered by
differential glycoreceptor aggregation. In one scenario (CBS exposed) galectin-1 binds the
pre-BCR through its protein-protein interaction and likely recruits other glycoreceptors
forming large heterocomplexes. Since galectin-1 has been shown to directly bind to
negative regulatory glycoreceptors such as CD45 (28), with intrinsic phosphatase activity,
this may explain the attenuated signal we observed (Chapter 2, Fig. 4A). In the other
scenario, (CBS blocked) galectin-1 enhances the ability for two pre-BCR to co-aggregate,
leading to enhanced proximal activation. Without the ability to bind glycoreceptors,
galectin-1 binding would be expected to stabilize homotypic interactions between diffusing
pre-BCRs, resulting in dimers, chains and complex aggregates. Galectin-1 with or without
carbohydrate leads to increased and decreased proximal activation, respectively. In both of
these cases, we noted a significant reduction of BCL6 expression. It would be interesting
to assess how the stromal cell signaling niche (24) may select for B cells that exhibit an
optimized signaling threshold, balanced through appropriate expression profiles that
balance critical feedforward and feedback loops.

Allosteric Control of Galectin-1 through Pre-BCR Binding Interactions
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Our theoretical work revealed that pre-BCR/galectin-1 interactions decrease galectin-1’s
affinity for N-acetyllactosamine residues (Chapter 3, Figure 6-7) by destabilizing the
sugar in the binding pocket (Chapter 3, Figure 4A-D). This work is another example of
how MD simulations can be used to study allosteric impacts in macromolecular structures
(29-31). These simulations corroborated the finding that pre-BCR binding alters critical
intermolecular interactions between Arg-73 and the carbohydrate (23). They also revealed
that the aromatic stacking interactions (32, 33) between the sugar and Trp-68 of galectin-1
(Chapter 3, Figure 4F-H) can be modified by pre-BCR binding.

Together, these

experimental and theoretical findings raise new questions that can be validated at the
bench. It would be interesting to test whether galectin-1/pre-BCR interactions alter
galectin-1’s binding preference for negative (i.e. CD45 or ITIM-containing) or positive
coregulatory receptors (i.e. CD19) at the plasma membrane. Further, principal component
analysis (34, 35) of our MD trajectories revealed that pre-BCR/galectin-1 interactions
increased root-mean-square fluctuations across several different eigenvectors at the Nterminal dimer interface region on adjacent monomer of the galectin-1 homodimer
Chapter 3, Figure 2D). This data may implicate that pre-BCR binding may destabilize the
dimer region and shift galectin-1’s monomer/dimer equilibrium in favor of monomers.
Allosteric control of dimerization has been reported before using MD simulations (36).
Further, experimental evidence suggests allostery to also be involved in galectin-1 binding
whereby it was shown through gel filtration studies that galectin-1 exists in a reversible
monomer-dimer equilibrium and carbohydrate binding shifted the equilibrium toward
dimer formation (37). This disruption in dimer/monomer stability would offer an alternate
explanation to the decreased phosphorylation of Syk at phospho-acceptor site 352
(Chapter 1, Fig 4A).

Targeting pre-BCR Dimerization Impacts Survival
We designed Fabs against the VpreB region of the surrogate light chain to address how
homotypic pre-BCR interactions support leukemia blast survival. We reasoned that a
monovalent antibody fragment against the VpreB component would sterically hinder 5mediated homodimers. Indeed, incubation of live BCP-ALL cells with this Fab for 10-
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15min inhibited pre-BCR homointeractions, seen as the significant loss of correlated
motion at short separation distances between distinctly labeled pre-BCRs (Chapter 2, Fig.
3C-D). Based on single particle tracking, we also observed that the inhibitory Fabs
decreased the incidence of slower diffusing pre-BCRs (Chapter 2, Fig. 3A-B) and
increased dimer off-rates (9). Using phosphorylated ITAMs and phospho-activation sites
on Syk as readouts; we showed that Fabs targeting the pre-BCR dimer blocked proximal
pre-BCR signaling (Chapter 2, Fig. 4A). Overnight Fab treatment abrogated BCL6
expression (Chapter 2, Fig. 3E), an important readout of constitutive pre-BCR signaling
(38). Just as inhibition of pre-BCR pathway kinases or BCL6 expression mitigated the
survival potential of leukemia cells (38), we showed that our Fab could also induce
apoptosis, especially in the presence of low-dose chemotherapy (Chapter 2, Fig. 5A &
7A). We expect that the likely mechanism that leads to apoptosis is regulated through
central B cell tolerance (39). Further, patient samples that were shown have different
diffusion patterns of the pre-BCR (Chapter 2, Fig. 6C) were more or less susceptible to
killing. Blasts that showed a significant disruption of pre-BCR mobility upon treatment
with the anti-VpreB Fab (Chapter 2, Fig. 6E) were more readily killed with lower doses
of chemotherapy (Chapter 2, Fig 7A). Although these observations suggest potential
biomarkers for classifying risk on leukemia, it is difficult to imagine that our methods could
be implemented in a clinical setting. The weak induction of killing of the anti-VpreB Fab
as a monoreagent had us speculate as to whether targeting the 5-UR (1) with
immunotherapy might display more robust and durable responses in leukemic B cells.

Small Molecule Inhibition Alters pre-BCR Dynamics and Survival
Evidence for pre-BCR+ signaling through tyrosine kinase and PI3 kinase pathways suggest
that subclasses of BCP-ALL patients may benefit from targeted therapy, including cellpermeable small molecule inhibitors (40-42). First, treatment of 697 cells for 10-15
minutes with Lyn (dasatinib) and Syk (BAY61-3606) caused a significant increase in preBCR diffusion (Chapter 2, Fig 6D). Due to the fact that treatment disrupted ITAM and
Syk phosphorylation (Chapter 2, Fig. 4D, we speculate that this increased diffusion is an
effect caused by a lower density of docking partners localized at the cell membrane, which
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might remove the population of slower diffusing pre-BCR particles. It has been suggested
that the docking of LAT to TCR clusters increases the number of interactions among TCRassociated kinases and an extensive LAT cytoplasmic domain, which may be important for
the compartmentalization of signaling (43). Extended treatment for 24 hours with these
Lyn and Syk inhibitors led to a significant reduction in BCL6 expression (Chapter 2, Fig.
4F) that correlated with a strong induction of cell death as monoreagants (Chapter 2, Fig
5B) or in conjunction with low-dose chemotherapy (Chapter 2, Fig. 5C). Just as precursor
B cells are eliminated if they lack autonomous pre-BCR signals (44), leukemic B cells are
also rejected if these critical signals are not received.

Small Molecule Hyperactivation Alters pre-BCR Dynamics and Survival
Most efforts to improve treatment options in leukemia are directed at development of
potent tyrosine kinase inhibitors aimed at keeping oncogenic signaling to a bare minimum
(45). At a first glance, this concept is pretty straightforward and appealing based upon
targeted suppression of pathways (i.e. Ras, Myc, BRAFV600E) that drive rapid cell
proliferation (46, 47). However, the situation is more complex since negative feedback
molecules can operate to keep the system in check (48). Leukemic B cells may be addicted
to negative regulation (49), which apparently counterbalances hyperactive pathways to
maintain a finely-tuned signaling threshold for survival. Further, leukemic B cells retain
many features that are characteristic of healthy lymphoid progenitors and are subject to the
controls that regulate central B cell tolerance. A series of important papers revealed that
hyperactivation of Erk (49) or Syk (50) pathways in pre-B leukemia cells offers a new
therapeutic strategy to combat acute leukemias. While most of these studies showed that
hyperactivation of select pathways lead to high rates of killing, these findings were only
conducted in Ph+ leukemias that have been classified as pre-BCR(-) (38). We recently
corroborated this finding (9) and showed that hyperactivation also rapidly killed pre-BCR+
leukemias (Chapter 2, Fig. 5B,D). One of the intriguing findings in this dissertation is that
modulation of the pre-BCR signal upward or downward in pre-BCR+ leukemia always led
to the downregulation of BCL6 expression. For instance, upon incubation of potent SHIP1 inhibitor (3AC) (51), we noted hyperactivation of Syk (Chapter 2, Fig4E) and
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significant downregulation of BCL6 (Chapter 2, Fig. 4F). This reduced BCL6 expression
was also shown with the introduction of exogenous galectin-1 (see above) whereby
proximal pre-BCR signals could be modulated up or down based upon the presence or
absence of lactose, respectively. Nonetheless, the downregulation of BCL6 with 3AC
treatment corresponding in a potent induction of apoptosis to a much greater extent than
seen with Syk-specific and SFK-specific inhibitors (Chapter 2, Fig. 5A).

Other Important Therapeutic Options in Leukemia
Biologic agents, such as therapeutic antibodies, are also options for targeted treatment in
BCP-ALL. These leukemic blasts have been shown to express a list of membrane antigens
on the surface with therapeutic potential (52). An idealistic target would be expressed in
all leukemic cells, exhibit little/no expression on healthy populations and should remain
stable (except those that internalize rapidly - see below) upon challenge with directed
therapy (53). Unfortunately, all of the targets currently proposed for use in BCP-ALL
treatment have a wide expression profile in both healthy and malignant cells (54).
Monoclonal antibody treatment toward these targets come in three predominant forms: 1)
naked antibodies, 2) T-cell engaging bispecific single-chain (BiTE®) antibodies, and 3)
toxin conjugated (54). Naked antibodies rely on their opsinizing capacity whereby the Fcregion of the IgG can recruit effector cells of the immune responses to trigger cell-mediated
phagocytosis (ADCP) and/or cytotoxicity (ADCC) (55, 56) or complement-dependent
killing (54). If the target of interest is known to internalize quickly, antibodies can be used
as delivery vehicles for toxic payloads (57). Each of these antibody forms have been or are
currently being tested in human trials, including B cell cancers such as Burkitt lymphoma
and Ph+/Ph- BCP-ALL (53). The most common targets studied for monoclonal antibody
use in BCP-ALL include CD19 (58), CD20 (59), CD22 (52), and CD52 (60). Therapeutic
antibodies directed at common B cell antigens have exhibited clinical responses in BCPALL (61-63) but rarely lead to durable responses or cures. Rituximab, an anti-CD20
antibody that induces killing by ADCC/ADCP or complement-activating pathways (64),
has been recently used to treat CD20+ BCP-ALL (61, 62). Rituximab was well tolerated
(61) with improved 5-year survival rates relative to standard induction and consolidated
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chemotherapy (62). Several therapy options have been used for CD19, with a bispecific Tcell engaging antibody, blinatumomab (63) showing promise in the clinic. This includes a
recent trial involving patients with active systemic ALL relapse (65, 66). The overall
response rate in this study approached 70% with median survival at 9.8 months for these
patients. Moxetumomab is an anti-CD22 immunotoxin that consists of a fragment variable
derived from the antibody fused to a 38-kDa fragment of Pseudomona aeruginosa exotoxin
A (67). In recent refractory ALL Phase I trial (68). Of the 17 patients that could be
evaluated, 24% achieved complete remission, 6% showed partial response and 47%
exhibited hematologic improvement. While most of these monoclonal antibody treatments
are being used for ALL salvage, it has been suggested that incorporation of these therapies
as frontline options may improve overall efficacy (54).

Rationalization of anti-VpreB CAR T cell Therapy for BCP-ALL
Above, we discussed the limitations of monovalent Fab’s directed at the pre-BCR dimer
interface, which weakly sensitized leukemic B cells to killing. Further we showed, that
while targeted therapy options through tyrosine kinase inhibitors and monoclonal
antibodies are good options, alternative approaches are necessary to more readily wipe out
the malignancy. An even more promising strategy is the use of CAR T cell therapy to target
BCP-ALL where many of the antigenic targets explored for monoclonal antibody treatment
are being tested (69, 70). Several different institutions are testing CD19-specific CAR Ts
in clinical trials [review (71)]. Results from these studies have been promising with
complete response (CR) rates from 70 to 91%, even in the relapsed or refractory B-ALL
setting (69). For instance, in the first published clinical trials (72) at Memorial Sloan
Kettering Cancer Center in New York, of the 32 patients receiving CAR T cell therapy, all
achieved minimum residual disease (MRD)-negative complete remission (73). In a recent
follow-up study the complete responses achieved 91% (74). Other malignancies apart from
BCP-ALL for CAR T therapy are being tested. These include CLL, multiple myeloma,
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, myeloid malignancies, and solid
tumors. For an extensive review of current targets that extend beyond BCP-ALL see (69).
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Though clinical data reveal the promising potential of CAR T cell therapy, especially in
the refractory/relapse BCP-ALL setting, there are still some inherent treatment concerns.
Similar to monoclonal antibody drugs, B cell specific CAR Ts target the same receptors
that are expressed (CD19, CD22, CD20) throughout the different developmental stages.
Thus, recent studies continue to report ‘on-target, off-tumor’ destruction of non-malignant
B cell leading to B cell aplasia (73, 75-78). However, B cell aplasia is not the only toxicity
associated with CAR T therapy. Other reports have described the onset of cytokine release
syndrome (CRS), acute anaphylaxis (77), cross-reaction to normal tissues (79, 80) and
neurological disorders (74). CRS is a byproduct of rapid and enhanced activation of the
transferred CAR T cells that results in a general disruption of the immune system including
release of proinflammatory cytokines such as TNF-alpha and IL-6 (70, 78). Incorporation
of IL-6 blockade with tocilizumab has been suggested to minimize effects caused by
“cytokine storms” (81). These factors are important to consider as groups continue to
advance the design of CAR T’s that can minimize these effects (82) or by being used in
conjunction with other therapeutic strategies (83).

CAR T Design: Minimizing Off-Target Effects
Another hindrance to CAR T cell therapy in clinical trials involving BCP-ALL is antigenic
escape (71, 84, 85). One particular mechanism of escape is through the loss of CD19
expression (86). Current strategies to overcome this limitation include the generation of
CAR+ T cells that can recognize multiple antigens (87, 88). However, the purported targets
for these multivalent CAR Ts include the CD20 (89) and CD22 (90), which would ablate
the B cell immune response. The non-polymorphic and high sequence similarity of splice
variants in VpreB may minimize the frequency of antigenic escape as has been observed
with anti-CD19 CAR T therapies (86). The unique regions found within 5 and VpreB (91)
do not exhibit sequence similarity within the proteome and should limit off-target effects.
It is also important to consider the importance of the this target to the survival of preBCR+ leukemias as we have shown previously (9). Similar to BCMA in plasma cell
malignancies (92, 93) and ROR1 in both ALL and CLL (94, 95), the pre-BCR is important
to survival of the leukemia blasts. This would entail that downregulation of the pre-BCR
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(a common escape mechanism when targeting CD19) would mitigate the survival capacity
of the blasts and minimize potential pathways of resistance. Unlike ROR1, with evidence
to suggest expression on pancreatic and lung tissue (96, 97) the pre-BCR specificity to B
cells should also minimize ‘on-target, off-tumor’ toxicity. While we would expect our antiVpreB CAR T to continue to target both healthy and leukemic precursor B cells alike, we
expect that this approach should sustain a higher proportion of mature B cells. Lastly, other
proposed mechanisms of escape are associated with the loss of efficacy of the CAR T either
through tumor-mediated immunosuppression (98) or chronic T cell activation leading to
induction of inhibitory ligands, called T cell exhaustion (99). These detrimental factors
may be alleviated through an understanding of CAR T signaling profiles and structural
constructions of the CAR itself.

CAR T Design: Threshold Considerations
CAR T cells, like T cells (100), must be optimally tuned for killing efficiency and longterm persistence (101). Several factors are important in modulating the CAR T cell
signaling threshold that includes epitope location (102), scFv affinity (103), target density
(104), and length of the spacer region (103, 105, 106). It has recently been shown that an
improved binding affinity does not always correlate with CAR T efficacy (103, 107-109).
A study involving a CAR against ROR1 in mantle cell lymphoma revealed improved
efficacy correlated with enhanced binding affinity (103). In contrast, several other studies
show that there was an avidity threshold for CARs whereby an improved binding constant
did not boost the CAR T’s therapeutic efficacy (107-109) and in some cases may even be
augment long-term survival (101). By tuning the affinity of a CAR, some groups showed
that CAR T’s could be made to discriminate between tumor cells and normal cells that
express lower or normal levels of the same antigen (110, 111). We have shown that
expression levels of the anti-VpreB CAR on the surface of effector T cells and/or relative
expression of the receptor on BCP-ALL impact the killing efficiency (Chapter 4, Fig 5D).
Quantitation of CAR numbers on surface of the T cells showed a broad distribution of
receptors (Chapter 4, Fig 5A) from few thousand to over 100,000. Understanding the
receptor density and affinity on CAR Ts may be an important consideration in order to
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optimize signaling thresholds that will maximize both T cell persistence and killing
capacity. In a recent study, an anti-CD20 CAR T showed that only about 200 CD20
molecules were required to induce killing; however, a 10-fold higher expression was
necessary for select cytokine production (104). It may be important to utilize the large
library of data describing TCR signaling thresholds. For instance, studies have revealed
that co-stimulatory receptors can lower the threshold for TCRs and inclusion of the
stimulatory CD28 domains into the TCR signaling complex lowered the total number of
TCR-pMHC interactions required to trigger activation (112). This information has been
used to enhance CAR T activity whereby most CAR designs include co-stimulatory
domains (i.e. CD28, 4-1BB) (102, 113, 114). In fact, it has been shown by Long et al that
addition of different co-stimulatory domains can augment or ameliorate T cell exhaustion
(113).

CAR T Design: Using Computational Modeling to Aid in CAR T Engineering
In Chapter 4, we described the first steps in developing an alternative chimeric antigen
receptor (CAR) therapy for pre-BCR+ cases of BCP-ALL.

This chapter outlined our

stepwise strategy to create and test scFv derived from an intact anti-VpreB IgG. When
expressed outside their typical context, recombinant antibody-based fragments can display
disappointing physicochemical and structural issues (115). Many reports have shown the
susceptibility of Ig domains to lose binding specificity or to be unstable due to structural
alterations such unfolding or aggregation (115). Loss of stability for small, recombinant
antibody fragments (i.e scFv versus Fabs) can be an additive effect. This may be due to the
loss of complementation or disulfide bonds along the quaternary structure (116). To
overcome a potential loss in structural integrity, scFv’s are typically designed to
incorporate a flexible peptide linker that is resistant to endopeptidases (117, 118). Even
with a flexible linker, scFv still have a tendency to unfold and a phenomenon called
“domain swapping” may occur. This effect, usually due to the length of the peptide linker,
results in the interaction of Ig domains of adjacent scFv causing them to oligomerize (119).
Further, another source of instability for the scFv are associated with the CDR loops (120).
To optimize our scFv design, we employed advances in antibody modeling tools (121) to
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construct several different 3D models. We then evaluated these structures using MD
simulations. Our homology models showed that the VL-linker-VH versus VH-linker-VL
orientation exhibited different intermolecular distances (Chapter4, Fig. 1A). Different
framework regions at the N- and C-terminal ends showed characteristic differences in the
root-mean-square deviations (Chapter4, Fig. 1B). These data suggest that upon
attachment of the inter-framework linker the VH-linker-VL orientation would minimize
both the intermolecular distance and residual fluctuations. This would help to minimize
allosteric impacts at the CDR region (Chapter 4, Fig. 1A-B). Our MD simulations
revealed that there was less of an impact at the CDR binding region with the VH-linkerVL orientation and 20mer linker model (Chapter 4, Fig. 1D-E). This information was then
applied to in engineering phase of our anti-VpreB Fab (Chapter 4, Fig. 2). We showed
that the soluble form of our 20mer scFv in the HC-linker-LC orientation retained specificity
and high affinity for the surrogate light chain on live leukemic B cells (Chapter 4, Fig. 23). This construct was then incorporated into a lentiviral vector, expressed on surface of
CD8+ T cells (Chapter 4, Fig. 5C) and displayed T cell activation markers (Chapter 4,
Fig. 4C,E). Importantly, these CAR Ts displayed in vitro cytotoxicity (Chapter 4, Fig.
5D) and synapse formation (Chapter 4, Fig. 5F) to BCP-ALL cell lines. With the
generation of a CAR T with in vitro efficacy, we could now turn to other important studies
to further characterize the anti-VpreB CAR T and its interaction with the novel BCP-ALL
target.

We employed protein/protein docking algorithms (122, 123) and molecular dynamics
simulations (124) to map out probable binding domains within the VpreB region (Chapter
4, Fig 6A-G). Computational approaches have been used to make in silico modifications
to the CDR region to engineer antibodies (125). These alterations can be incorporated into
the CAR’s scFv binding region in order to modify binding to oncogenic mutations that may
occur within the target and/or modulate the affinity threshold that would corresponds most
optimally with efficacy. Information about the binding site can also serve as the theoretical
framework to determine how intermembrane spacing, epitope proximity to membrane,
multivalency, interaction to different extracellular receptors, or synaptic exclusion may
influence CAR T signaling efficiency (76, 126). We can also use electron or confocal
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microscopy experiments to assess, synaptic size, recruitment of granzyme B, and synaptic
exclusion of negative regulatory receptors (PD-1, TIM-3, CD45). We showed that the
synapse formed between the anti-VpreB CAR T and BCP-ALL cell lines (Chapter 4, Fig
5F) results in polarization and accumulation of granzyme B at the contact zone (Chapter
4, Fig 5F). Data presented in (48) suggested that when anti-CD19 CARs engaged their
cognate receptor on Raji B-cells they exhibited a convoluted membrane that differed
markedly from the more “natural” TCR-pMHC synapse. We plan to assess whether antiVpreB CARTs exhibit a more optimal synapse formation due to the multivalent features
of the pre-BCR and its ability to form “development synapses” with other cells (24)
Further, it is known that accumulation of granules at the polarization zone derives from
elevated levels of Ca2+ levels (127). Through the use of ratiometric imaging we can
quantitatively measure differences of CAR T signaling to determine if anti-VpeB CARTs
display any signaling advantage relative to existing anti-CD19 CAR Ts. It is apparent that
a case-by-case testing will be required to optimize CAR T design.

The infusion of specific CAR T cell subsets at defined ratios may be important for
enhanced in vivo potency against tumors (128, 129). Due to the high uptake of our CAR T
into non-CD8+ (Chapter 4, Figure 4B) populations, we opted to enrich for CD8+
populations from PBMC populations to improve transduction efficiency of this particular
subset. We noted a significant improvement in the CD8+ transduction efficiency (Chapter
4, Fig. 4E), with high rates of in vitro efficacy (Chapter 4, Fig. 5D). However, early in
vivo testing in a BCP-ALL xenograft model exhibited a marked reduction of effector T
cells in the blood after 28 days (data not shown). We suspect this may be due in part to
lower proliferative capacity of CD8+ in vivo without signals received from PBMCs or TH
(CD4+) populations. Studies revealed that infusion of CD4+ and CD8+ T CAR+ T cell at
1:1 ratio exhibited a remarkable improvement in tumor reduction and long-term persistence
in the blood (128, 129) Thus, it might be important to selectively transduce both CD4+ and
CD8+ T cells with our CAR construct. We can then combine these two populations and
inject into the mice to compare how this combination fares relative to each population on
their own.
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CONCLUDING REMARKS
This dissertation set to improve our understanding of pre-BCR dynamics and their
corresponding signaling outcomes in the context of leukemia. As specific therapies
continue to be incorporated into BCP-ALL it is essential to understanding the complexities
of the pre-BCR signaling network. Our data revealed that similar to healthy B cell
populations, the pre-BCR continues to be a highly regulated process even in the context of
leukemia. Thus, as Mucshen and colleagues have suggested through a series of important
papers, hyperactivation or inhibition of the pre-BCR signaling network may confer novel
therapeutic benefits. While the pre-BCR+ leukemia subset represents a smaller population
of BCP-ALL patients (10-15%)(38), evidence suggests that tyrosine kinase inhibition of
the JAK/STAT pathway led to the upregulation of the feedforward pre-BCR pathway
regulator, BCL6 (130). It is worth considering how long-term treatment of the
IL7R/JAK/STAT pathway may influence expression profiles in BCP-ALL cases that are
initially diagnosed as pre-BCR(-). This factor may substantiate the need to target the preBCR pathway even in these pre-BCR(-) leukemic populations to reduce potential of all
possible escape routes.
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